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Abstract 
The number of women with low ovarian reserve seeking fertility treatment is 
increasing, due to advancing maternal age at conception. Women with low ovarian 
reserve have a low IVF success rate. This thesis aims to increase our understanding 
of women with low ovarian reserve, their reproductive outcomes and their 
reproductive physiology. The evidence is synthesised using two systematic reviews, 
a prospective cohort study, a retrospective analysis of data and two qualitative 
studies. The main findings are: 
 
1. Low ovarian reserve, quantified by AFC, AMH and FSH, is associated with low 
live birth rates and incidences of pregnancy loss after assisted reproduction.	
2. There is inter-cycle variation in AFC, AMH and FSH in women. In this cohort, 
FSH and AFC appear to have a higher magnitude of variation in comparison to 
AMH.	
3. There is inter-cycle variation in AFC, AMH and FSH in women with low ovarian 
reserve. 	
4. Clinicians find treating women with low ovarian reserve challenging. Women 
with low ovarian reserve are unaware of their low IVF success rates and there is 
cultural and religious stigma about the acceptance of egg donation. Both clinicians 
and women with low ovarian reserve express willingness to take part and support 
research studies. 
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Chapter one: introduction to thesis
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Chapter	one:	introduction	to	thesis	
Desire to reproduce is a primal human instinct. Symbols demonstrating the cultural 
importance of human fertility can be seen throughout most ancient civilisations, 
showing that  humans have been concerned about fertility from the onset of time 
(1).  In the United Kingdom, one in seven couples experience an inability to 
conceive (2). Women facing fertility problems have reported higher levels of stress, 
anxiety and low mood symptoms (3). Globally, it is estimated that around 50-70 
million couples experience difficulty with conceiving (4,5). This is likely to be an 
underestimate as there is poor access to fertility investigations and treatments in 
many developing countries (6). 
Natural human reproduction requires the male to be able to produce sperm, achieve 
erection and ejaculation. It requires the couple to be able to have coitus. It requires 
the woman to be able to ovulate, to have patent and functioning fallopian tubes, to 
have a uterus which is structurally normal and an endometrium which is suitable 
for implantation (7). A problem with any one of these aspects could result in 
difficulties with conception. In about 25% of couples, despite being fully 
investigated for infertility, no cause is identified (8). This is referred to as 
unexplained infertility.  
In vitro fertilisation 
In-Vitro Fertilisation (IVF) is one of the treatment options available for couples 
struggling to conceive. The first baby conceived by IVF was in 1978 and Robert 
Edwards was awarded a Nobel prize in 2019 for this achievement (9). In the past 
40 years, more than eight million babies have been conceived with the aid of IVF 
treatment worldwide (10). In 2014, in the UK alone, 52,288 women had IVF 
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treatment and 18,201 babies were born as a result (9). IVF is a suitable treatment 
option for couples with male factor infertility, damaged or blocked fallopian tubes, 
ovulation problems or unexplained infertility (11). IVF is a process by which a 
human egg is fertilised with a human sperm out of the woman's body. The fertilised 
egg is then placed inside the woman's uterus. Later in this chapter the IVF process 
is described in detail. 
The cost of IVF 
IVF treatment has cost implications. On average, an  IVF cycle in the UK costs 
between £3000 to £8000 (12). It is estimated that half of IVF cycles are funded by 
the National Health Service (NHS) (12). Thus an unsuccessful IVF treatment has 
financial implications to the individual couple as well as the state. IVF treatment is 
also an intensive process requiring a woman to attend the hospital or clinic on 
multiple days. Therefore other costs associated with IVF, including the time off 
work taken by the couple and the financial implications to the couple, wider society 
and the state is difficult to estimate.  
The cost of an unsuccessful IVF cycle cannot be quantified monetarily alone. Many 
studies have reported adverse mental health outcomes following unsuccessful IVF 
treatments (13–15). It has also been reported that the likelihood of a relationship 
break down is also significantly higher following unsuccessful IVF treatment (16).  
The IVF process is also associated with some potential short and long term 
complications (17). As the number of cycles a woman undergoes increases, so does 
the likelihood of her encountering a clinical complication, such as acquiring an 
infection or damage to surrounding structures during egg retrieval. 
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Additionally, the chance of any particular IVF cycle resulting in a live birth is low. 
The work by McLernon et al., shows the probability of a live birth based on the age 
of the woman and the number of IVF cycles (shown in the Figure 1 below). 
 
 
Figure 1: Probability of live birth per IVF cycle. (18) 
It can be noted that a significant proportion of women will require multiple IVF 
cycles before achieving pregnancy. Some women may never achieve pregnancy 
despite multiple cycles of IVF treatments. 
There is a clear benefit to the woman, the couple, society and the state in 
improving the success rate of each cycle.  
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The	IVF	process	
 
Figure 2: IVF key steps. 
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Significant disparity exists in the protocols used for IVF from one provider to 
another (19). The figure 2 above, summarises the key treatment steps in most IVF 
treatment regimes. In the following paragraphs I will explain the steps leading up 
to egg collection in more detail. 
Pituitary	down	regulation	
           The existence of unpredictability, introduced by the possibility of ovulation before 
egg collection, could result in an inability to retrieve eggs and therefore 
unsuccessful cycles (20). To avoid the unpredictability of ovulation, as well as to 
enable scheduling, most clinicians carry out pituitary down regulation. Pituitary 
down regulation is where the production of luteinising hormone (LH) and follicle 
stimulating hormone (FSH) by the anterior pituitary gland is halted (21).  This is 
achieved by either administering a gonadotrophin releasing hormone(GnRH 
)agonist, or a GnRH antagonist (21). A GnRH agonist acts by occupying all the 
GnRH receptors in the ovaries (22). A GnRH antagonist acts by blocking the GnRH 
receptors and thus blocking the release of gonadotrophins. 
Controlled	ovarian	hyperstimulation	
A fundamental objective of IVF treatment is to increase the yield of eggs produced. 
Multiple studies have demonstrated that the  higher the number of eggs retrieved, 
the better the chances of achieving a live birth (23,24). This is because there is a 
gradual attrition of eggs or embryos along the IVF process. For instance, a 
significant number of eggs retrieved would not have reached sufficient maturity for 
fertilisation (25). Amongst the eggs that are mature, only just over half are likely to 
be successfully fertilised (26). Even after fertilisation, many fertilised eggs may not 
develop into embryos. From the embryos that are developed, their maturation may 
be halted before the stage at which embryos are considered ready for transfer into 
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the patient. Having a large number of eggs can therefore mitigate against this 
gradual attrition and thus improve IVF outcomes. If multiple embryos are available, 
then those with the best quality can be chosen for implantation. There is evidence 
that embryos that had been graded highly by an embryologist, had a higher chance 
of achieving a live birth (27). 
 
 
Figure 3- Association between egg number and live birth rate.(23)  
The graph above (Figure 3), shows the work by Sunkara et al., demonstrating the 
relationship between the number of eggs extracted and the live birth rate. It can be 
seen that even a modest increase in the number of eggs extracted, for instance an 
increase from one to three, results in a higher than twofold increase in live birth 
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rate. Therefore increasing the number of eggs collected has the potential to improve 
reproductive outcomes significantly for women with low egg count. 
Maximising the number of eggs collected is achieved by controlled ovarian 
hyperstimulation. This is the process initiated by the administration of 
gonadotrophins. Gonadotrophins are administered and follicular maturation is 
monitored by transvaginal ultrasound scans. Once a critical threshold is reached, 
which is usually having at least two follicles size above 15-18mm in size, an egg 
collection is planned (28). 
Ovulation	trigger	
During physiological menstrual cycles, the rising level of oestrogens from the 
developing follicles results in the pituitary gland producing more LH. The LH surge 
results in the completion of the meiosis I in the oocytes and production of 
progesterone and prostaglandins within the follicle (29). The progesterone and the 
prostaglandins aid the breakdown of the follicle wall (30). This leads to the rupture 
of the follicle and release of egg. This event is known as ovulation. 
Pituitary down regulation results in the absence of the physiological LH surge. 
Therefore the  final egg maturation is achieved by an injection of human chorionic 
gonadotrophin (hCG), which mimics the action of the LH surge (31). Alternatively 
a gonadotrophin agonist injection (in those undergoing an antagonist protocol) can 
be administered, which leads to the production of the body's own LH surge (32). 
Subsequently eggs are harvested, inseminated and either embryos at cleavage stage 
or blastocysts are placed in the uterus. 
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The	problem	of	poor	response	
As described above, a crucial step for IVF is controlled ovarian hyperstimulation in 
order to retrieve eggs. When an inadequate number of follicles develop in response 
to controlled ovarian hyperstimulation or when at the point of egg collection, an 
inadequate number of eggs are obtained, this leads to cancellation of that IVF cycle. 
This is known as poor response to controlled ovarian hyperstimulation. Some 
studies quote that up to 15% of women undergoing IVF do not respond to controlled 
ovarian hyperstimulation (33). 
There are several risk factors associated with poor response, including increasing 
female age, history of previous poor response, low ovarian reserve and previous 
chemotherapy or radiotherapy (21). Low ovarian reserve is explained in subsequent 
paragraphs of this chapter.  
Internationally there has been significant disparity in what is defined as poor 
response to controlled ovarian hyperstimulation. Because of the varying definitions, 
the exact number of IVF cycles that are cancelled due to poor response is difficult 
to state with accuracy.  
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The Bologna consensus statement by European Society of Human 
Reproduction and Embryology (ESHRE). 
 For a woman to be defined as poor responder to controlled ovarian 
hyperstimulation, she must meet two of the following criteria: 
1. Advanced maternal age (defined as 40 years or more) or any other risk factor for 
poor ovarian response. 
2. A previous cycle where there has been a poor ovarian response, defined as 
resulting in three or less oocytes with a conventional stimulation protocol 
3.An abnormal ovarian reserve test (defined as an AFC of 5-7 or less, AMH of 0.5-
1.1 pmol/L )(34).  
Research also suggests that the percentage of women failing to respond to 
controlled ovarian hyperstimulation increases with advancing age (35). Given the 
fact that couples are choosing to delay conception and the mean age of patients 
undergoing IVF/ICSI is increasing, this problem is likely to increase in magnitude 
in the future (36). Hence there has been considerable interest in studying poor 
response, predicting poor response and studying the relationship between ovarian 
reserve and ovarian response (37,38). 
Ovarian	reserve	
Ovarian reserve is the reproductive potential of a woman’s ovary, thus refers to both 
the quantity and quality of the remaining oocytes (39). A woman has the highest 
number of oocytes as a fetus. This number steadily declines throughout life. Whilst 
age is a good predictor of the number of eggs, there can be significant difference in 
the number of eggs between two women of the same age (40). As a result, predictors 
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of ovarian reserve need to be utilised to estimate the ovarian reserve more 
accurately. 
Ovarian reserve versus ovarian response 
The terms ovarian reserve and ovarian response are often used interchangeably in 
literature, however they are different (41). Whilst ovarian reserve relates to the 
reproductive potential of a woman, ovarian response refers to how the ovaries 
respond to controlled ovarian hyperstimulation in a particular IVF cycle (42). It has 
been shown that there may be differing ovarian responses in the same woman who 
has multiple cycles of IVF treatment (43). Ovarian reserve tests are used by some 
to estimate the ovarian reserve as well as to predict the ovarian response (44). 
There are a number of ovarian reserve tests used, which include measuring serum 
levels of FSH, oestradiol, inhibin B, anti-mullerian hormone (AMH), the 
clomiphene challenge test and AFC. Of these investigations, FSH, AFC and AMH 
are considered to be the  most clinically useful investigations and are recommended 
for routine use by the NICE guidelines (8). 
Follicle	stimulating	hormone	
FSH is a glycoprotein polypeptide secreted by the anterior pituitary gland in 
response to gonadotrophin releasing hormone (GnRH), which is released by the 
hypothalamus. FSH production initiates follicle growth and maturation. Inhibin is 
produced by the granulosa cells and has a negative feedback on both the 
hypothalamus and the pituitary gland, inhibiting the production of FSH (45). 
Serum FSH levels are measured during the early follicular phase of the menstrual 
cycle, namely days one to four. FSH is a relatively cheap and easy blood test to 
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perform. However, there can be significant intra and inter-cycle variation in FSH 
values (46). Whilst FSH is a reasonable predictor of ovarian reserve, some 
clinicians consider it an unreliable predictor of ovarian response to controlled 
ovarian hyperstimulation (47). The diagnostic sensitivity of measuring serum FSH 
to predict poor response varies from 10-80%, with a specificity quoted between 64-
100% (39). 
Anti-mullerian	hormone	
AMH is a glycoprotein secreted by primary, pre antral and  antral  follicles (48).  
AMH is produced by the ovarian granulosa cells.  Studies have shown that AMH 
captures the decline in ovarian reserve better than FSH (49,50). There is also strong 
positive correlation between AMH and AFC (51). Studies have also shown that 
AMH can be a good marker for measuring ovarian responsiveness. AMH has been 
found to be lower in women who have had poor response to controlled ovarian 
hyperstimulation, in comparison to women with normal response (52). 
Serum AMH has been shown to be relatively constant throughout the menstrual 
cycle. This gives AMH a presumed advantage over FSH and AFC, as timing 
measurement with the correct part of the menstrual cycle is not strictly necessary 
(53). Measuring serum levels of AMH is however expensive in comparison to FSH, 
and is consequently not available in most UK NHS hospitals.  
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Antral	follicle	count		
 
Figure 4: Antral follicle (Modified from  Kristensen et al., with 
permission)(54) 
The primordial follicle is an oocyte (egg cell), surrounded by a layer of oestrogen 
secreting cells called the granulosa cells. All primordial follicles are cells which 
have been paused in a stage of cell division called meiotic prophase (54). 
At the beginning of each menstrual cycle, a number of primordial follicles get 
recruited to develop (55). The exact mechanism by which this occurs is poorly 
understood. It has been suggested that the number of follicles recruited correlates 
with the size of the total oocyte pool in the ovaries (56). It has been demonstrated 
that follicles are recruited in response to a rise in serum FSH levels (57). 
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The selected primordial follicles start to enlarge, and a layer called the zona 
pellucida, emerges. The granulosa cells in the follicle secrete oestrogen (58). At this 
stage the follicle is known as a pre antral follicle. The secreted oestrogen makes the 
wall of the egg cells increase the number of FSH receptors they have (59). The 
resulting increased FSH levels and the increased cell receptivity, lead to increased 
oestrogen production. The higher levels of oestrogens present, mature the pre-antral 
follicles to become antral follicles. Antral follicles measure between 2-10mm and 
can often be visualised by a transvaginal ultrasound scan (60). 
AFC shows the follicles that are available for recruitment during controlled ovarian 
hyperstimulation.  AFC is found to be a reliable reflection of the entire reserve of 
oocytes available (61). Studies have shown AFC to have a sensitivity of 9-73% and 
specificity of 73-100% for predicting ovarian response in an IVF cycle (39). 
Measuring and obtaining AFC is labour intensive, as it requires someone with 
expertise in ultrasonography. It also needs to be performed during the early 
follicular phase, making the timing of the test resource intensive. Some studies have 
also questioned the inter observer and intra observer variability of this test (62). 
Inter and intra observer variability of AFC will be explored further in chapter five. 
Factors	affecting	ovarian	reserve	and	reproductive	outcomes	
Advancing age is the biggest risk factor for diminished ovarian reserve and poor 
reproductive outcomes (63,64). This could be because of the decline of primordial 
follicles with age, which is described earlier in this chapter. It is also observed that 
with advancing of age, there is also a decline in the quality of oocytes(65). There 
have been limited human studies carried out studying the underlying mechanisms 
that result in poor quality of oocytes due to ethical and regulatory restrictions. 
Volarcik et al., studied donor oocytes and reported a greater proportion of meiotic 
14 
 
errors in oocytes obtained from older women(66). This study also found a greater 
degree of chromosomal segregation errors in oocytes obtained from women. Mice 
models have demonstrated an age related decline in the proteins cohesion and 
centromere specific histones, and as these proteins play an important role in 
chromosomal segregation, this may account for the greater degree of chromosomal 
segregation errors in older women(67). 
Body mass index (BMI) is associated with ovarian reserve tests, with women with 
a higher BMI showing lower AMH levels, lower FSH levels and higher AFC (68–
70). Lower FSH levels in obese women can be explained by the fact that adipose 
tissues produce oestrogens (70). Oestrogens have an inhibitory effect on FSH 
production through a negative feedback mechanism (71). Therefore women with 
high BMI who generally have more adipose cells are likely to have more circulating 
oestrogens, lowering the FSH levels. There are many mechanisms suggested for 
obesity’s effect on AMH and AFC, including some studies linking obesity with 
reduction in granulosa cell activity and suppression of Inhibin B (70). 
Other studies have suggested links between genes such as FMR1, ethnicity, 
smoking, vitamin D levels and caffeine intake on ovarian reserve tests (72–77). 
Ovarian	reserve	markers	and	ovarian	response	
Ovarian reserve markers are considered to be modest predictors of ovarian response 
(44). Some studies have shown that AFC, AMH and FSH can be predictors of live 
birth (78–80). However the ability of ovarian reserve markers to predict live birth 
has been questioned by a more recent study (81). Studies have also shown that 
ovarian reserve markers are predictive of the number of eggs retrieved (82–84). 
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AFC in particular has been shown to have a linear relationship with the number of 
eggs retrieved (82,84). 
Biological	mechanisms	
Numerous mechanisms have been postulated to explain the relationship between 
ovarian reserve tests and reproductive outcomes. Warburton et al had proposed the 
limited pool hypothesis(85). This theory suggests that when there is normal ovarian 
reserve, there are a number of follicles available at the beginning of each cycle to 
choose from. Therefore in natural conception the follicle containing the best quality 
egg becomes the dominant follicle by natural selection. In IVF, the ere are a number 
of embryos for the embryologists to choose from, and therefore the chances of a 
better quality embryo being chosen is higher. Conversely, in low ovarian reserve, 
there are fewer follicles and fewer eggs to compete to ovulate in natural conception, 
and there are fewer embryos to choose from in IVF. This could explain the lower 
rates of live birth and higher rates of pregnancy loss observed in women with low 
ovarian reserve. Ovarian reserve tests are also used by clinicians in determining the 
dose of FSH to administer to stimulate the ovaries, with women with low ovarian 
reserve getting higher doses of FSH(86). The work by Check et al., had 
demonstrated that higher doses of FSH adversely affects the quality of embryos in 
IVF cycles(87). This could also account for the relationship between ovarian 
reserve tests and reproductive outcomes. 
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Figure 5 AFC and the number of eggs collected- Moon et al.(84) 
The figure above is the work by Moon et al., demonstrating the linear relationship 
between AFC and the number of eggs collected (84). Even in women with a low 
AFC, it can be seen that a small increase in AFC leads to a corresponding increase 
in the number of eggs retrieved. 
Inter-cycle	variation	of	ovarian	reserve	markers	
Inter-cycle variation refers to the difference in ovarian reserve test values in the 
same woman, during different menstrual cycles. Studies have suggested that there 
is inter-cycle variation in ovarian reserve test values in women (62)(88). Scott el 
al., postulated that this variation could be due to the fluctuation in circulating 
gonadatrophins (89). Animal studies have shown a direct link between 
administration of corticotrophin releasing hormone, which is secreted in response 
to stress, and an immediate decrease in the circulating pulsatile GnRH release (90). 
Other animal experiments have shown similar responses elicited by other stress 
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induced hormones (91). It can be postulated that the periodic variation of physical 
and emotional stressors experienced by women, may have an impact on their 
gonadotrophins, and ultimately their ovarian reserve tests. 
 
Figure 6: An illustrated example of cycle to cycle variation 
I have explained in earlier paragraphs that there are fluctuations in ovarian response 
within the same woman. Some clinicians believe that the inter-cycle variation in 
ovarian reserve tests could be utilised to predict which monthly cycle was likely to 
result in the most favourable ovarian response. For example, in a particular month, 
there could be a low ovarian response, resulting in fewer eggs (for example four 
eggs), leading to fewer fertilised eggs (for example two eggs), further leading to 
only one embryo suitable for implantation. This could be contrasted with another 
month, in which the same patient has a better ovarian response, resulting in more 
eggs (for example seven eggs), leading to fewer fertilised eggs (for example four 
fertilised eggs) resulting in two or three embryos which are suitable for 
implantation. The question is firstly whether such variation in ovarian response 
exists from month to month, and secondly, how best to identify such variation.   
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Key messages from the introduction 
Subfertility is a global problem which causes significant distress to those involved. 
IVF is an effective option for many women with subfertility. 
Ovarian reserve refers to the reproductive potential of a woman in terms of her egg 
reserve. 
Ovarian response refers to how the ovaries respond to controlled ovarian 
hyperstimulation during IVF cycles. 
Poor ovarian response is when the ovaries fail to respond to controlled ovarian 
hyperstimulation and do not produce sufficient eggs. 
Poor ovarian response can have adverse consequences to the prospects of success 
with IVF treatments.                             
Ovarian reserve markers are tests used by clinicians to predict both the ovarian 
reserve and ovarian response. 
It is likely there may be menstrual cycle to menstrual cycle fluctuation in ovarian 
reserve tests- known as inter-cycle variation. 
It is the hypothesis of this thesis that inter-cycle variation in ovarian reserve tests 
could be used to identify the best month to start IVF treatment in women with low 
ovarian reserve, and potentially improve their IVF outcomes. 
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Aims	and	objectives	of	this	thesis	
In this thesis I set to understand if there is a menstrual cycle to menstrual cycle 
variation in ovarian reserve tests. The first step is to identify and collate the 
evidence that already exists. Currently there are no published systematic reviews 
on this topic. Therefore I carried out a systematic review on the intercycle variation 
in ovarian reserve tests, which I report in chapter two of this thesis. 
My second objective was to identify the relationship between ovarian reserve tests 
and reproductive outcomes. As outlined earlier in this chapter, the relationship 
between ovarian reserve tests and live birth rate has been established in published 
literature. However there is no consensus on ovarian reserve tests and pregnancy 
loss, with no published systematic reviews on this subject. Therefore I carried out 
a systematic review and meta-analysis on ovarian reserve tests and pregnancy loss 
and recurrent pregnancy loss. I test the hypothesis that ovarian reserve tests 
correlate with pregnancy outcomes, independent of confounding factors such as 
age, ethnicity and BMI, by carrying out a primary study of retrospective analysis of 
IVF data. 
My third objective was to identify if intercycle variation in ovarian reserve tests 
exist in women who have low ovarian reserve. I investigated this by carrying out a 
primary prospective cohort study in women with at least one risk factor for low 
ovarian reserve. I report these findings in chapter five of my thesis. 
My fourth objective was to understand the patient perspective. I explored their 
views on having a low ovarian reserve in general, and in particular their 
acceptability of having a treatment based on antral follicle count and their 
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acceptability of taking part in a clinical trial to test the efficacy of such treatment. I 
report my thematic analysis of the prospective qualitative study I carried out in 
chapter six of my thesis. 
My final objective was to gain insight into the clinician perspective of treating 
women with low ovarian reserve in general, as well as their their acceptability of a 
treatment protocol based on antral follicle count and their acceptability of testing 
the efficacy of such treatment protocol with a clinical trial. I report the thematic 
analysis of the qualitative study I carried out in chapter seven. 
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Chapter Objective Population studied Design Outcome of interest 
2 To ascertain if menstrual cycle to 
menstrual cycle variation in AFC, 
AMH and FSH exists in women 
Women of 
reproductive age 
Systematic review Inter-cycle variation 
3 To ascertain the relationship between 
ovarian reserve tests (AFC, AMH and 
FSH) and pregnancy loss as reported 
in existing literature 
Women having IVF 
treatment 
Systematic review and 
meta-analysis 
Pregnancy loss 
4 To ascertain the relationship between 
AFC and reproductive outcomes 
Women having IVF 
treatment 
Cohort study Live birth rate and pregnancy 
loss 
5 To establish the inter-cycle variation 
in AFC, AMH and FSH in women 
with low ovarian reserve 
Women with one or 
more risk factors for 
low ovarian reserve 
Cohort study Inter-cycle variation 
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Table 1: Outline of thesis 
6 To further understand the expectations 
of women with low ovarian reserve 
and to explore the acceptability of 
research and treatment based on inter-
cycle variation 
Women with a risk 
factor for low 
ovarian reserve 
Qualitative study with 
purposive sampling and 
thematic analysis 
Ideas, expectation and 
acceptability 
7 To further understand the challenges 
faced by IVF clinicians in treating 
women with low ovarian reserve and 
explore the acceptability of research 
and treatment based on inter-cycle 
variation 
IVF clinicians Qualitative study with 
purposive sampling and 
thematic analysis 
Ideas, expectation and 
acceptability 
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Chapter	two:	inter-cycle	variation	of	antral	
follicle	count,	anti-mullerian	hormone	and	
follicle	stimulating	hormone-	a	systematic	
review	
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Preamble	to	chapter	two	
In chapter one, I explained the burden of subfertility and the impact it has on 
women, couples and the wider society. I explained the problem of poor ovarian 
response and how ovarian reserve markers can predict poor response. I also referred 
to studies showing association between ovarian reserve tests, eggs retrieved and 
live birth rates in women who had assisted conception. I introduced the concept of 
menstrual cycle to menstrual cycle variability of ovarian reserve tests and the 
hypothesis of whether such inter-cycle variation could be used in the timing of IVF 
treatment and to improve outcomes for women with low ovarian reserve. 
The first step in testing this hypothesis is to establish whether menstrual cycle to 
menstrual cycle variation of ovarian reserve tests exists in women.  
Contributions 
Dr Bala Karunakaran- Conceived the idea, carried out the search, collected the data, 
carried out quality assessment, analysed the data and wrote this manuscript. 
Dr Abey Eapen was second reviewer for selecting included manuscripts and  was 
the second quality assessor. 
Mr Aurelio Tobias was consulted for his statistical expertise and advised that a 
meta-analysis was not possible. 
Mr Jon Andrews was consulted for his expertise on search strategies. 
Dr Ioannis Gallos and Prof Coomarasamy proof-read the manuscript and provided 
substantial edits. 
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Abstract	
STUDY QUESTION 
Is there variation in the ovarian reserve markers of AFC, AMH and FSH from one 
menstrual cycle to another, and if so what is the level of variation? 
 SUMMARY ANSWER 
There appears to be variation from one menstrual cycle to another, with AMH 
showing the lowest amount of variation and AFC and FSH showing a higher degree 
of variation. 
WHAT IS ALREADY KNOWN? 
Multiple studies had commented on the inter-cycle variation of ovarian reserve 
markers, though very few studies had made direct comparison with each other. This 
is the first systematic review on this topic.  
STUDY DESIGN, SIZE, AND DURATION 
A systematic search of the literature was undertaken, according to the preferred 
reporting items for systematic reviews and meta-analysis (PRISMA) guidelines.  
PARTICIPANTS/MATERIALS SETTING, METHOD 
The following online databases were systematically searched: PubMed, EMBASE, 
CINAHL and Cochrane library up to 20 January 2018, with no language or date 
restrictions. The search terms included inter-cycle, inter-cycle, inter-cycle, 
menstrual cycle, variation, difference, and serial, follicle stimulating hormone, 
FSH, anti-mullerian hormone, AMH, antral follicle count, and AFC. 
MAIN RESULTS AND THE ROLE OF CHANCE 
A total of 253 studies were identified through the literature search.  Eight studies 
met the inclusion criteria and data were extracted. A narrative synthesis was carried 
out. The trend was that AMH showed the least inter-cycle variability and FSH 
showed the most inter-cycle variability. 
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 LIMITATIONS AND REASONS FOR CAUTION 
Only one study had made direct comparison between AFC, AMH and FSH. Due to 
the heterogeneity of the way in which inter-cycle variation was reported, it was not 
possible to carry out a meta-analysis of pooled data. Therefore whilst trends can be 
observed, overall conclusions about inter-cycle variation cannot be made. 
WIDER IMPLICATIONS OF THE FINDINGS 
 The existence of inter-cycle variation means clinicians should be cautious in 
forming judgements about a patient’s ovarian reserve based on a single 
measurement of AFC, AMH or FSH. Further research is needed into inter-cycle 
variation in the poor responder and high responder cohorts and to see if this 
variation could be taken into consideration when planning individualised IVF 
protocols. 
TRIAL REGISTRATION:  Prospero CRD4201707442 
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Introduction	
In 2015, in the United Kingdom, 72,504 In vitro fertilisation (IVF) cycles were 
carried out (92). One of the crucial steps in in vitro fertilisation (IVF) is controlled 
ovarian hyperstimulation (93). This is usually achieved by stimulation of the 
ovaries by gonadotrophins (94). The success of the stimulation, and the subsequent 
number and quality of oocytes retrieved plays a significant role in determining the 
success of the IVF cycle (23). Hence, significant research has been carried out in 
improving controlled ovarian hyperstimulation protocols to maximise the yield of 
oocytes retrieved.  
Ovarian reserve tests such as follicle stimulating hormone (FSH), antral follicle 
count (AFC) and anti-mullerian hormone (AMH) tests have been proven to be 
surrogate markers for the success of IVF cycles (95). Ovarian reserve and ovarian 
reserve test values have been shown to decline with advancing age (96). The 
average age of a woman having IVF in the UK is 35, with the yearly trend showing 
an increase in the age at which women seek fertility treatment (92). Therefore there 
has been significant interest in optimising controlled ovarian hysterstimulation for 
women with low ovarian reserve. Many specialists also routinely use ovarian 
reserve tests to counsel women about their fertility potential, including commenting 
on their fertility potential outside the context of assisted reproduction (97). 
Therefore there is also a need to ascertain whether there is cyclical variability in 
ovarian reserve tests and whether a single result is sufficient for a clinician to 
confidently comment on a woman’s ovarian reserve. Some studies have suggested 
that there is inter-cycle variation between the ovarian reserve markers (98). This 
review sets out to look at the inter-cycle variation of the three most clinically used 
ovarian reserve markers, AMH, FSH and AFC. 
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Materials	and	methods	
The systematic review was conducted according to Preferred Reporting items for 
Systematic Review and Meta-Analysis (PRISMA) guidelines (99). 
Inclusion	and	exclusion	criteria	
Criteria for inclusion were established prior to the literature search. The decision 
was made to include any cohort studies in which participants had more than one 
measurement of AFC, AMH or FSH, during the early follicular phase of their 
menstrual cycle. Early follicular phase was chosen as it is established in literature 
as the optimal timeframe to measure both AFC and FSH (100).Both prospective 
and retrospective studies were included and no language restrictions were place. 
Women were included irrespective of their fertility status. 
	Literature	search	strategy	
A literature search was carried out on the following databases: MEDLINE, 
EMBASE, Cochrane central register of controlled trials and Web of science 
(inception - June 2017). A combination of Medical Subject Headings (MeSH) and 
text words were used to generate two subsets of citations. One subset included the 
following terms combined by the command OR: inter-cycle, inter-cycle, inter cycle, 
menstrual cycle, variation, difference, and serial. The second subset included the 
following terms combined by the command OR: follicle stimulating hormone, FSH, 
anti-mullerian hormone, AMH, antral follicle count, and AFC.  The two subsets 
were combined by the command AND to generate a list of abstracts to be screened. 
References of all included journal articles were examined to identify relevant 
articles not captured through the electronic searches. Primary authors were 
contacted for additional data and clarifications where possible. 
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Study	eligibility	and	selection	
 All titles and abstracts were screened by two reviewers [Bala Karunakaran (BK), 
PhD student and Abey Eapen (AE) , PhD student] independently. A third reviewer 
[Ioannis Gallos (IG), subspecialist trainee in reproductive medicine] arbitrated if 
there were disagreements. Full manuscripts were obtained for all selected abstracts. 
Full manuscripts were reviewed by both reviewers independently first, and then 
together, and agreement on which studies to be excluded was reached. The 
Newcastle- Ottawa scale was used to assess the quality of the included articles. 
Newcastle-Ottawa is a numerical scale, with a maximum of nine stars awarded 
(101,102). The Newcastle-Ottawa scale awards four stars for study selection, two 
stars for comparability and three stars for study outcome. Each study received a 
score from each of the reviewers (see table below). There was provision for a third 
arbitrator (IG) in instances of disagreement, which was not necessary. 
Data	extraction	and	analysis	
Data were extracted by the primary reviewer (BK) and tabulated. This was checked 
by a second reviewer (AE). The obtained information included study characteristics 
including - study design, study population, details of the tests, results and statistical 
analysis used. Data from the included articles of the systematic review are presented 
descriptively.  As there was significant heterogeneity in the study populations, test 
processes, and test thresholds, a numerical pooling (meta-analysis) was not 
considered appropriate.  
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Results	
Characteristics	of	included	studies	
Our literature search yielded 253 citations. 240 were identified through search of 
databases and 13 through screening of reference lists. The 253 titles and abstracts 
were screened by both reviewers (BK and AE). From that list 27 studies were 
chosen for full manuscript review.  After a comprehensive review of manuscripts 
by both reviewers (BK and AE), eight studies were deemed to meet the criteria for 
inclusion in the systematic review. The study screening and selection is expressed 
in the form of a flow diagram (see Figure 6)
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Figure 7 Study selection 
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Data extraction were performed on eight papers. Three of the studies assessed 
healthy women with no history of subfertility. The remaining five studies included 
women with subfertility. Seven of the studies were published in peer reviewed 
journals.  One of the studies was a conference abstract (103) . Due to heterogeneity 
of the reporting of inter-cycle variation and lack of uniformity in the statistical 
expressions made, a cumulative synthesis and meta-analysis was not possible. 
Therefore a decision was made to carry out a descriptive analysis.  
Quality	of	the	included	studies	
The table below shows the quality of included studies. The studies varied in quality, 
ranging between five and six stars in the Newcastle-Ottawa scale. Most studies 
studied women with difficulties conceiving. Two of the studies, Bancsi et al., and 
Brown et al., studied women with no reported fertility issues. All of the studies, 
apart from Bancsi et al., were published in peer reviewed journals. The studies 
spanned over a period starting from the year 1992 (Brown et al.,) and 2011 
(Rustamov et al.,). 
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Table 2: Quality of included studies 
 Selection    Comparability Outcome   Comments 
Study author, 
year of 
publication 
Representati
ve-ness of 
the exposed 
cohort 
Selection of 
the non-
exposed 
cohort 
Ascertainment 
of the 
exposure 
Demonstratio
n that 
outcome of 
interest was 
not present at 
start of study 
Comparability 
of cohorts on 
the basis of 
the design or 
analysis 
Assessment of 
outcome 
Was follow-up 
long enough 
for outcomes 
to occur? 
Adequacy of 
follow up of 
cohorts 
Total rating 
Bancsi et al., 
2004 
 
 NA  N/A     6 
Brown et al., 
1992 
Women 
without 
reported 
fertility 
problems 
N/A  N/A     5  
Elter et al.,  
2005 
 NA  N/A     6 
Escobar et al.,  
2010 
 N/A  N/A  Over a six year 
period. Age 
related decline 
could have 
significant 
bearing on 
results. 
 Retrospective 
analysis 
4 
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Fanchin et al., 
2005 
 N/A  N/A     6  
Jayaprakasan et 
al., 
2008 
 N/A  N/A     6 
Rustamov et al., 
2011 
 N/A  N/A     6 
Scheffer et al., 
1999 
 
 
Women 
without 
reported 
fertility 
problems 
N/A  N/A     5 
36 
 
Inter-cycle	variation	results	
Table 3: Inter-cycle variation results 
Author Population Study design Investigation Results Interpretation  
Brown JR et 
al., (104) 
48 healthy women 
with regular 
menstrual cycles,  
Prospective 
cohort  
FSH Blood samples 
obtained on day 3 
over multiple non-
consecutive cycles in 
one year period. 
Mean coefficient of variation (CV) 
was 25.6. The standard deviation 
of CV was 21.4-29.9. 
FSH showed a degree 
of inter-cycle 
variability, 
Elter et al., 
(105) 
52 healthy women 
with regular 
menstrual cycles 
and proven to be 
ovulatory with mid 
luteal phase 
progesterone. 
Prospective 
cohort, 
FSH, AFC taken in 
early follicular phase 
over two consecutive 
cycles, 
FSH  
Mean difference 0.27(+-1.83). 
Lower limit of agreement -3.2 (CI -
4.2 to -2.4). Upper limit of 
agreement 3.86 (CI 2.98 to 4.74). 
Multiples of Mean 0.99, 
 
AFC 
Mean  difference -0.17 (=-3.41) 
Lower limit of agreement -6.85 (CI 
-8.45 to -5.24) Upper limit of 
agreement 6.50 (CI 4.90 to 8.10) 
Multiples of Mean 13.35, 
Both AFC and FSH were 
shown to have 
variability. FSH had 
greater inter-cycle 
variability in 
comparison to AFC. 
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Escobar et 
al., (106) 
36 women having 
fertility treatment. 
Retrospective 
cohort over a 
6 year 
period. 
AMH taken during 
non-consecutive 
menstrual cycles. 
12/36 patients had at least one 
AMH value diverging by >50%. 
AMH showed degree pf 
variability. 
Fanchin et 
al., (51) 
46 women with 
regular menstrual 
cycles and a 
history of fertility 
problems. 
Prospective 
cohort. 
AMH, FSH, AFC taken 
over three 
consecutive menstrual 
cycles. 
AMH Intraclass correlation 0.89 
(CI 0.83 to 0.94) 
FSH Intraclass correlation0.55 (CI 
0.39 to 0.71). 
AFC Intraclass correlation 0.73 (CI 
0.62 to 0.84). 
The greatest inter-cycle 
variation is seen in FSH. 
The least amount of 
inter-cycle variation is 
seen in AMH. 
Jayaprakasan 
et al., (62) 
88 women with 
regular menstrual 
cycle having IVF 
treatment. 
Prospective 
cohort. 
AFC and FSH taken 
during the cycle 
before IVF treatment. 
Non-consecutive 
cycles. 
AFC 
Mean difference 0.16(SD1.98) 
Lower limit of agreement -3.71. 
Upper limit of agreement 4.03 
Multiples of Mean 0.48. 
FSH 
Mean difference -0.08 
Lower limit of agreement -4.52 
Upper limit of agreement 4.36 
Multiples of Mean 1.29. 
 
FSH is shown to have a 
greater inter-cycle 
variation in comparison 
to AFC. 
Rustamov et 
al., (103) 
186 women with 
regular menstrual 
cycles and a 
history of fertility 
problems. 
Retrospective 
cohort. 
AMH and FSH taken 
during non-
consecutive cycles. 
AMH 
Coefficient of variation 28% (SD 
3.6). 
 
FSH  
AFC and FSH are shown 
to have a similar inter-
cycle variation. 
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Coefficient of variation 27% 
(SD2.0). 
Bancsi et al., 
(107) 
120 women with 
regular menstrual 
cycle having IVF 
treatmen.t 
Prospective 
cohort. 
AFC On day 3 of two 
spontaneous 
menstrual cycles. 
Mean difference 0.05. A small inter-cycle 
variation is 
demonstrated. Smaller 
magnitude in 
comparison to other 
studies that studies 
AFC. 
Scheffer et 
al., (108) 
81 women  with 
regular menstrual 
cycles and  no 
history of fertility 
problems. 
Prospective 
cohort. 
AFC measured over 
three consecutive 
menstrual cycles. 
Mean difference -0.28 
Upper limits of agreement 8.37 (CI 
7.41 to 9.33). 
Lower limits of agreement -8.93 
(CI -7.41 to -9.89). 
Inter-cycle variation in 
AFC is demonstrated. 
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Brown et al., (104) included 48 female volunteers with no history of fertility problems and 
regular menstrual cycles, under the age of 40. It was prospective and serum FSH samples were 
obtained over multiple cycles over a year. Brown et al., also obtained multiple samples of serum 
FSH in the same cycle, on days two, three and four. The samples were not necessarily obtained 
during consecutive menstrual cycles. The inter-cycle variability was reported in the form of 
coefficient of variation (CV). CV is a measure that compares the standard deviation of a value 
in comparison to the mean (109). The greater the CV, greater the variability that exists. Brown 
et al., reported a CV of 25.6% [95% confidence interval (CI) 21.4-29.9%] from one menstrual 
cycle to another. This could be contrasted with the CV of day to day variability within the same 
menstrual cycle, where the CV was 14.9% (CI 11.5%-18.3%). The existence of greater CV 
between menstrual cycles in comparison to within the same menstrual cycle is indicative of the 
existence of inter-cycle variation in serum FSH measurements.  
Elter et al., evaluated 52 women with a history of subfertility with regular menstrual cycles. 
AFC and FSH were measured on day two of the menstrual cycle over two consecutive 
menstrual cycles (105). Inter-cycle variation was determined using a Bland Altman plot and by 
calculating limits of agreement (LOA). Bland Altman is a plot where difference between the 
two measurements is plotted against the average of the two measurements (110). The LOA is 
1.96 times the SD above and below the mean of differences and 95% of observed values should 
fall within the two LOAs. The study standardised the values, by dividing the range by its mean. 
The value derived is known as  multiples of mean (MoM) (111). Higher the MoM, greater the 
deviation from the mean and can be considered a surrogate marker for variation. Serum FSH 
had a MoM of 0.99 with an upper limit of agreement (ULA) of 3.86 and the lower limit of 
agreement (LLA) was -3.32. AFC had a MoM 1.45 and ULA of 6.50 and LLA of -6.85.  The 
authors of the study did further analysis on the clinical significance of the inter-cycle variability 
of AFC.  They defined an AFC of ten or above to correlate with a good ovarian response. The 
40 
 
cut-off of ten was determined by the authors based on the previous work by Fleming et al 
(112),. The study found that 58% of the subjects had less than ten follicles in one cycle and 
more than ten follicles in another cycle (33). The authors concluded that the inter-cycle 
variability of AFC was thus clinically significant. The authors did not carry out similar analysis 
on serum FSH values or commented on the clinical significance of inter-cycle variation of FSH. 
Escobar et al., was a retrospective study (published as a conference abstract), which evaluated 
36 women who had four or more fresh IVF cycles (106). AMH was measured at the beginning 
of each cycle. It was reported that at least a third of patients had an AMH value that varied by 
greater than 50%. However as these measurements were not consecutive and were measured 
over a six year period, the effect of decline of AMH over time could not be excluded. As this 
study is only a conference abstract, further information such as baseline characteristics was not 
available to critique. 
Fanchin et al,. was a prospective study which evaluated 47 women with a history of subfertility 
with normal menstrual cycles (51). AFC, AMH and FSH were measured during the early 
follicular phase in three consecutive menstrual cycles. Inter-cycle variation was expressed in 
the form of Intraclass correlation (ICC). ICC calculates the consistency of conformity between 
two variables (113). Therefore smaller the magnitude of ICC, greater the inter-cycle variability. 
AFC had an ICC of 0.73 [confidence interval (CI) 0.62 to 0.84], AMH values exhibited an ICC 
of 0.89 (CI of 0.83 to 0.94) and FSH exhibited an ICC of 0.55 (CI of 0.39 to 0.71). These results 
indicate that FSH showed the greatest inter-cycle variability and AMH showed the least inter-
cycle variability. 
Jayaprakasan et al., prospectively studied 100 women with normal menstrual cycles, with a 
history of subfertility undertaking fertility treatment (62). Measurements of AFC and FSH were 
taken in the early follicular phase on the cycle preceding the IVF treatment cycle.  The second 
41 
 
measurements were not taken on a consecutive menstrual cycle. However all measurements 
were taken in a period spanning a maximum of 12 months, thus limiting the impact of age 
related decline in ovarian reserve.  The inter-cycle variability was reported in the form of LOA 
and MoMs.  AFC results had a LLA of -3.71 and an ULA of 4.03 with a MoM of 0.48. FSH 
had a LLA of -4.52 and a ULA of 4.36 and a MoM of 1.29. These results indicate that FSH 
values have a greater inter-cycle variation in comparison to AFC. 
Rustamov et al., retrospectively studied 186 women with a history of subfertility, who had two 
samples of AMH and FSH taken during non-consecutive menstrual cycles, within an upper 
limit of one year interval between them (103). AMH had a CV of 28% and FSH had a CV of 
27%, showing consistent inter-cycle variation. However the study is limited by the fact that not 
all women included had normal menstrual cycles. 
Bancsi et al, prospectively studied 120 women with a history of subfertility with regular 
menstrual cycles (107). AFC measurements were taken during the early follicular phase of two 
consecutive menstrual cycles. The difference between the two values were calculated and 
expressed in the form of mean difference. As the differences of AFC between any two 
measurements could be either positive or negative in magnitude, when all the differences are 
added, they are likely to cancel each other. Therefore the mean difference, which averages all 
the values, is likely to be low. Bancsi et al found the mean difference to be 0.05. 
Scheffer et al, was a prospective cohort study which studied which looked at 81  women with 
regular menstrual cycles, no known fertility problems and history of proven fertility 
(demonstrated by a history of at least one pregnancy carried to term) (108). Early follicular 
phase AFC were measured during three consecutive menstrual cycles. The inter-cycle variation 
was reported as LOA. The mean difference between the measured AFC were -0.28. The LLA 
was -8.93 (95% confidence interval -7.41 to -9.33) and the ULA was 8.37 (95% confidence 
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interval was 7.41 to 9.33). This shows the existence of inter-cycle variation in AFC 
measurements, to a greater extent than expressed by both Elter et al and Jayaprakasan et al. 
Discussion	
In our systematic review we found a limited number of observational studies that found varying 
degrees of variation within and amongst the three tests of FSH, AMH and AFC. All three of 
these tests in the studies we found showed inter-cycle variation. The trend indicates FSH having 
the greatest inter-cycle variation and AMH having the least inter-cycle variation. 
Fanchin et al, was the only study which made direct comparison between AFC, AMH and FSH 
(51). The results of Fanchin et al., indicate that FSH had the greatest inter-cycle variability and 
AMH had the least inter-cycle variability. Rustamov et al., made direct comparison between 
AMH and FSH, with both demonstrating similar inter-cycle variation, with AMH having a CV 
of 28% and FSH having a CV of 27%. Jayaprakasan et al., compared the inter-cycle variation 
of AFC and FSH. It was demonstrated that FSH values showed greater inter-cycle variation in 
comparison to AFC. Analysing the results of all of the available results together, a trend of 
FSH having the most inter-cycle variability and AMH having the least inter-cycle variability 
can be noted. 
This study has many strengths. This systematic review is the first systematic review conducted, 
to our knowledge, examining inter-cycle variation of ovarian reserve markers.  The strengths 
of our methodology include agreeing on the research strategy a priori and registering the 
protocol, using a robust search strategy including individually searching all relevant databases, 
and placing no language restrictions on the studies.  All of the included studies were 
comprehensively assessed for quality using the Newcastle Ottawa scale. All apart from one 
study, Escobar et al, scored highly on the applicable domains of the scale.  
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The main weakness of this review comes from the degree of heterogeneity in which inter-cycle 
variation was reported: therefore pooling data and carrying out a meta-analysis was not 
possible. Another weakness of this review is the differences in study design of the included 
studies. Brown et al., and Scheffer et al., looked a population with no history of subfertility and 
therefore it is difficult to generalise their findings to women seeking fertility treatment. Four 
of the studies, Brown et al, Escobar et al, Jayaprakasan et al., and Rustamov et al., did not 
examine consecutive menstrual cycles. Escobar et al., had results spanning over a six year 
period. As ovarian reserve is known to decline with time, the impact of time elapsed between 
the measurements could not be eliminated (63,114). Escobar et al., and Jayaprakasan et al., had 
studied women who had pituitary down regulation and ovarian stimulation in between the 
measurements. There is limited published data available on the impact of ovarian reserve after 
IVF stimulation (115). The heterogeneity in the statistical tools used to express inter-cycle 
variation makes direct comparison between all studies not possible. 
A weakness of the analysis is the fact that different studies are likely to have used different 
assays to measure AMH. Studies carried out measuring AMH values on the same sample but 
using different assays have produced different results(116,117). Craciunas et al., had suggested 
that any measurements of AMH done prior to the introduction of the Gen IIm assays in 2013 
should be treated with caution(118). As all of the studies that reported on the intercycle 
variation of ovarian reserve markers were carried out prior to 2013, with varying sensitivity, 
specificity and comparability, our results should be treated with caution. 
The biological plausibility of inter-cycle variation has been explored by studies. Scott el al 
suggested that this variation could be due to the fluctuation in circulating gonadotrophins, 
which have been shown in many studies (89). Animal studies have shown direct link between 
administration of corticotrophin releasing hormone , which is secreted in response to stress, 
and an immediate decrease in the circulating pulsatile GnRH release (90). Other animal 
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experiments have shown similar responses elicited by other stress induced hormones (91). It 
can be postulated that the periodic variation of stressors experienced by women, may have an 
impact on their gonadotrophins, and ultimately the function of the pituitary gland and the 
ovaries.  
Only one study, Elter et al., explored the clinical significance of the inter-cycle variation and 
concluded that the inter-cycle variation in AFC was significant. This was achieved by broadly 
categorising all participants into two groups, those likely to have a normal response (AFC 
>/=10) and those likely to have a poor response (AFC < 10). Moving categories between 
menstrual cycles was deemed to be clinically significant. Caution is needed whilst interpreting 
this result, as a participant who had an AFC of ten in one menstrual cycle and an AFC of 11 in 
another, would have been classified as having a clinically significant result in this study. 
However in clinical practice, whether the addition of a single follicle would translate to an 
increase in live birth rate is questionable. 
The existence of inter-cycle variation in ORTs would suggest that clinicians should take 
caution when counselling women about their reproductive health based on a single 
measurement. AMH may be the most reliable test to look at a snapshot of the ovarian reserve, 
as it consistently showed the least inter-cycle variation. Therefore if a clinician needs to base 
their assessment on one test alone, AMH is the most suitable candidate. However both FSH 
and AFC, which showed higher degree of inter-cycle variation, which may reflect the dynamic 
state of ovarian function in a particular cycle. This could mean that values of FSH and AFC 
may prove more useful when deciding whether or not to commence an IVF cycle at that point 
in time. FSH and AFC values measured in a specific cycle could also be utilised when deciding 
the dose of gonadotrophin. 
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The clinical impact of inter-cycle variation is likely to be in those at risk of having a poor 
response to controlled ovarian stimulation, such as women with low ovarian reserve. For this 
group, a difference in a few follicles may translate to a significant difference in the oocytes 
retrieved.  
Further research, studying a population with risk factors for poor ovarian response, comparing 
the inter-cycle variation of AFC, AMH and FSH over multiple consecutive menstrual cycles is 
recommended.  Research correlating ovarian reserve test measurements with IVF outcome 
would also be beneficial in determining the clinical significance of inter-cycle variation. 
Further research in identifying any underlying biological mechanisms which can explain the 
intercycle variation is needed. Understanding such mechanism might provide therapeutic 
options to enhance a woman’s ovarian response and lead to better pregnancy outcomes. 
Conclusion	
There is evidence showing inter-cycle variation in FSH, AMH and AFC. There is insufficient 
evidence to determine which one of these ovarian reserve markers shows the greatest degree 
of inter-cycle variability. Available data indicates that AMH is likely to have the least amount 
of inter-cycle variability. However it must be noted that not all studies are in agreement with 
this. There is also limited evidence which suggests the existence of modest inter-cycle variation 
in both AFC and FSH. Further research is warranted to study ovarian reserve markers over 
multiple consecutive cycles for women with low ovarian reserve, to determine if significant 
inter-cycle variation exists. 
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Chapter	three:	ovarian	reserve	tests	(FSH,	AMH	
and	AFC)	and	pregnancy	loss:	a	systematic	
review	and	meta-analysis	
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Preamble	to	chapter	three	
In this thesis so far, I have explained the concepts of ovarian reserve and ovarian reserve tests. 
In chapter two of this thesis, I have shared the results of a systematic review I carried out 
demonstrating that inter-cycle variation exists in ovarian reserve tests within the same 
individual. In chapter one of this thesis I explore studies that had reported on the relationship 
between ovarian reserve tests and live birth in women having IVF. Pregnancy loss is an adverse 
outcome in women, with often significant consequences to the couple. The existing literature 
on ovarian reserve and pregnancy loss is conflicting. Therefore in this chapter I share the results 
of the first ever systematic review carried out exploring ovarian reserve tests and pregnancy 
loss. 
Contributions 
Dr Bala Karunakaran- conceived the idea, carried out the search, collected the data , carried 
out quality assessment, analysed the data and wrote this manuscript. 
Mr Derrick Yates was consulted on search strategy. 
Dr Rima Smith was second reviewer for selecting manuscripts and the second quality assessor. 
She also helped with checking the accuracy of the forest plots. 
Prof Coomarasamy proof-read the manuscript and provided substantial edits. 
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Abstract	
Study question 
Is there any association between reduced ovarian reserve and pregnancy loss? 
Summary answer 
Reduced ovarian reserve measured by AFC, AMH and FSH is associated with increased risk 
of pregnancy loss. Insufficient data is available on the relationship between ovarian reserve 
and recurrent pregnancy loss. 
What is known already? 
Ovarian reserve has been shown to be a good prognostic marker for the success of assisted 
conception treatments. However, the evidence from studies exploring the relationship between 
ovarian reserve and the risk of pregnancy loss is conflicting.  
Study size, design, and duration 
A systematic review and meta-analysis investigating the relationship between ovarian reserve 
and pregnancy loss in women undergoing assisted conception treatment and women with a 
history of recurrent pregnancy loss. 
Participants/materials, setting, methods 
The review protocol was registered with PROSPERO (CRD42018099041). Two groups of 
women were included in this review; women undergoing assisted conception treatment and 
women with a history of recurrent pregnancy loss. Literature searches were conducted to 
retrieve studies in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and 
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CINAHL, for observational studies from inception until 15th of December 2018. The 
Newcastle-Ottawa scale for observational studies was used to assess the quality of included 
studies. 
Main results and the role of chance 
Twenty-one studies involving 27, 249 participants matched the inclusion criteria for women 
undergoing assisted conception treatment and were included in the meta-analysis.  Data from 
eight studies reporting on the relationship between ovarian reserve and recurrent pregnancy 
loss were insufficient for meta-analysis. There was a significant association between reduced 
ovarian reserve and pregnancy loss for all three ovarian reserve markers: low AFC (RR 1.63 
[95% CI 1.42-1.87]), low AMH (RR 1.29 [95% CI 1.02-1.84]), high FSH (RR 1.24 [95% CI 
1.12-1.38]). 
Limitations, reasons for caution 
The present study evaluated couples undergoing assisted conception treatment. As such the 
results may not be applicable to women who conceive naturally. Data were insufficient for 
adjusting the analyses based on known confounding factors such as age and thrombophilia so 
their influence cannot be excluded. 
Wider implications of the findings 
Women with reduced ovarian reserve should be counselled about the higher risk of having a 
pregnancy loss following assisted conception treatment.  
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Introduction			
Ovarian reserve tests are widely used by clinicians to assess women, counsel women about 
their reproductive health and plan in-vitro fertilisation (IVF) treatment (100). National Institute 
for health and Care Excellence (NICE) guidelines recommend clinicians using antral follicle 
count (AFC), anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) to assess 
women seeking fertility treatment, as these tests are considered to be the most clinically useful 
(8). There are several studies which show that ovarian reserve tests are useful in assessing the 
ovarian response, yield of oocytes during egg collection and live birth rate (44,119,120). 
It is estimated that around 125, 000 women experience first trimester pregnancy loss in the 
United Kingdom, with over 40, 000 women requiring hospital admission (121). It has been 
shown that women who conceive with assisted conception have a higher incidence of 
pregnancy loss in comparison to women who conceive naturally (122,123). Pregnancy loss is 
associated with complications such as blood loss, sepsis, subfertility and sometimes results in 
maternal death (121). It has been reported that pregnancy loss can have lasting psychological 
consequences, affecting both the female and male partner (124,125). There is also evidence 
that women who conceive with assisted conception have a higher levels of psychological 
morbidity in comparison to women who conceive naturally (126). There is evidence that risk 
assessment and counselling prior to fertility treatment can help women who are more likely to 
experience adverse outcomes and can lead to a reduction in psychological symptoms (127). 
Previous studies have been conflicting and there are no published systematic reviews that 
explore the relationship between ovarian reserve tests and pregnancy loss. Providing women 
with information regarding their chances of experiencing pregnancy loss will better inform 
their decision on whether to undergo assisted conception. Furthermore, it will enhance pre-
treatment counselling by clinicians and also help to target further research to improve 
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outcomes. The aim of this review is study the relationship between AFC, AMH and FSH and 
pregnancy loss. 
Methods	
The protocol of our systematic review was published in Prospero (CRD42018099041) on sixth 
of June 2018 prior to commencing search. 
Data	sources	
MEDLINE, (from inception to December 2018) EMBASE (from inception to December 2018) 
and CINAHL (from inception to December 2018) databases were searched electronically and 
Web of Science was used to search for grey literature.  
The search of MEDLINE and EMBASE and CINAHL captured citations containing the 
relevant MeSH keywords and word variants were used to generate two subsets of citations. 
One subset was created combining the terms ‘ORT’, ‘ovarian reserve*’, ‘AFC’, ‘antral 
follicle’, ‘follicle’, ‘FSH’, ‘follicle stimulating hormone’, ‘folitropin’, ‘AMH’, ‘anti-mullerian 
hormone’ and ‘anti mullerian hormone’ using the command OR. A second subset was created 
combining the terms ‘miscarriage’, ‘misc*’, ‘abortion’, ‘spontaneous abortion’, ‘abort*’, 
‘pregnancy loss’, ‘live birth*’ and ‘pregnancy demise’ using the command OR. The two 
subsets were combined with the command AND to generate a list of citation to be screened. 
Bibliographies and reference lists of relevant articles were manually searched to identify papers 
not captured by the electronic searches. The ‘similar articles’ function in PubMed was used to 
identify further relevant publications. Authors were contacted where data were missing.  There 
were no language restrictions placed. 
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Eligibility	criteria	for	selecting	studies	
Primary observational studies which reported original data on association between ovarian 
reserve tests and pregnancy loss or recurrent pregnancy loss were included. Interventional 
studies, commentaries, narrative reviews, letters, case reports, conference abstracts and non-
human studies were excluded. Studies were included regardless of year of publication, 
language or country of study. 
Studies were selected in a two-stage process.  Initially, all abstracts and titles were screened by 
two reviewers (Bala Karunakaran [BK] and Rima Smith [RS]) and full manuscripts of 
potentially eligible citations were obtained.  A third reviewer (Arri Coomarasamy [AC]) was 
available to consult in instances of disagreement, which was not necessary. 
Two subsets of studies were selected. One subset included studies where participants had a 
measurement of AFC, AMH or FSH and pregnancy loss rates were available.  This included 
studies where pregnancy loss rates were reported, or where the reviewers were able to calculate 
the numbers of those who experienced pregnancy loss by subtracting the numbers of those who 
had a live birth from those with a positive pregnancy test. The second subset included studies 
examining any association between recurrent pregnancy loss and AFC, AMH and FSH.  
Data	extraction	and	synthesis	
Data were extracted by two reviewers (BK and RS) independent of each other and then verified 
together. The primary outcome was pregnancy loss (as defined by the constituent studies). 
Data were extracted from each paper for pregnancy loss rates and AFC, AMH or FSH 
categories. Where authors of the paper had classified a category as low ovarian reserve or 
normal ovarian reserve, we accepted their definitions. Where no such classification by the 
authors was available, we applied classifications of ovarian reserve as normal or low, trying to 
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closely match the reference ranges of other studies to make comparisons and meta-analysis 
possible.  
The meta-analysis was performed using Review Manager (version 5.0 for Windows) to 
combine and analyse the data; using the generic inverse variance method.   For the purpose of 
the meta-analysis, the ovarian reserve tests were grouped into three categories; AFC, AMH and 
FSH. In each category, the low ovarian reserve group was compared with the normal ovarian 
reserve group, against the outcome of pregnancy loss. Wherever possible, a subgroup analysis 
of the pregnancy loss rate in women with very low ovarian reserve was compared with women 
with normal ovarian reserve. Heterogeneity was assessed by examining the I2 statistics. A 
random-effects model was used when there was statistically significant heterogeneity.  
Heterogeneity was presented statistically and graphically using forest plot estimates with 95% 
confidence intervals. 
For studies investigating recurrent pregnancy losses, a narrative analysis was performed. 
Quality	assessment	
All articles selected for meta-analysis were assessed for quality using the Newcastle Ottawa 
Scale (102). The  Newcastle-Ottawa is a numerical scale, with a maximum of nine stars 
awarded (101,102). The Newcastle Ottawa scale awards four stars for study selection, two 
stars for comparability and three stars for study outcome. This tool was selected as it is 
designed to assess the quality of non-randomised studies; which is in-line with the study 
design of the included studies in this review.   
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Results	
The search yielded 2,779 citations. Of these, 251 were duplicates and were excluded. 98 full manuscripts were obtained 
and screened. Of these, 68 manuscripts were excluded (pregnancy loss data not available [67 studies], donor egg 
recipients [1]). 21 studies were included in the meta-analysis and seven studies were included in the narrative review. 
The study selection process is summarised in  
 
 
Figure 8.  
In total, 21 studies, consisting of 27, 249 participants, were included for the meta-analysis. 
Separate analyses were carried out for AFC, AMH and FSH. Two of the studies included for 
meta-analysis, Brodin et al., and Huyser et al., were prospective cohort studies (79,128). The 
rest of the 19 studies were retrospective cohort in nature. Tremellen et al., studied women 
having intra uterine insemination (IUI) treatment (129). The rest of the 20 studies were based 
on women who had IVF treatments. Included studies were conducted in nine different countries 
(United States [five studies], United Kingdom [four studies], Australia [four studies], Sweden 
[three studies], South Africa [one study], Taiwan [one study], Netherlands [one study], Brazil 
[one study] and Italy [one study]). The summary of study characteristics tables (Tables 8-10) 
below lists the definition of low ovarian reserve and normal ovarian reserve used in each paper. 
The quality assessment of included papers is summarised in Table 7. The overall quality of 
included study was moderate.
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Figure 8:  Selection process of included papers 
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Table 4: Characteristics of included FSH studies 
Author (year) Study design Population Definition of pregnancy loss Definition of ovarian reserve 
categories 
Number of 
women 
included 
Abdalla et al., 
(2006)(130) 
Retrospective 
cohort 
IVF Loss of pregnancy after a positive bHCG test 
and  before completion of 24 weeks of 
pregnancy 
Normal FSH 
 ≤10IU/ml 
High FSH 
 >10IU/ml 
9 
Bishop et al., 
(2017)(131) 
Retrospective 
cohort 
IVF All women with a positive bHCG test who did 
not achieve live birth 
Normal FSH 
≤10IU/ml 
HighFSH 
>10IU/ml 
8117 
Caroppo et al., 
(2006)(132) 
Retrospective 
cohort 
IVF All women with a positive bHCG test who did 
not achieve live birth 
Normal FSH 
 ≤10IU/ml 
High FSH  
>10IU/ml 
19 
Chuang et al., 
(2003)(133)  
Retrospective 
cohort 
IVF All women with a positive pregnancy test who 
experienced a loss before 20 weeks gestation 
Normal FSH 
 ≤10IU/ml 
High FSH 
395 
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 >10IU/ml 
Esposito et al., 
(2002)(47) 
Retrospective 
cohort 
IVF All women with a positive pregnancy test who 
experienced a loss before 20 weeks gestation 
Normal FSH 
 ≤10IU/ml 
High FSH 
 >10IU/ml 
104 
Huyser et al., 
(1995)(128) 
Prospective cohort IVF Definition of pregnancy loss not reported NormalFSH 
≤11.68IU/ml 
High FSH >11.68IU/ml 
40 
Luna et al., 
(2007) (134) 
Retrospective 
cohort 
IVF Pregnancy confirmed by ultrasound. No 
information on any gestational restrictions on 
the definition of loss provided 
Normal FSH ≤13.03IU/ml 
High FSH >13.03IU/ml 
2382 
Sabatini et al., 
(2008)(135) 
Retrospective 
cohort 
IVF Pregnancy confirmed by ultrasound and a loss 
before completion of 24 weeks. 
Normal FSH ≤10IU/ml 
High FSH >10IU/ml 
1589 
Thum et al., 
(2009)(136) 
Retrospective 
cohort 
IVF All pregnancies confirmed by ultrasound scan 
which did not result in live birth 
Normal FSH ≤10IU/ml  
High FSH >10IU/ml 
544 
Toner et al., 
(1993)(137) 
Retrospective 
cohort 
IVF Definition of pregnancy loss not reported Normal FSH ≤10IU/ml 
High FSH >10IU/ml 
48 
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Table 5: Characteristics of included AFC studies 
Author (year) Study design Population Definition of pregnancy 
loss 
Definition of 
ovarian reserve 
categories 
Number of women included 
Holte et al., 
(2011)(78) 
Prospective cohort IVF All pregnancies confirmed 
by ultrasound scan which did 
not result in live birth 
AFC<11 low 
AFC>11 normal 
804 
Hsu et al., 
(2011)(138) 
Retrospective 
cohort 
IVF All pregnancies confirmed 
by ultrasound scan which did 
not result in live birth 
AFC<11 low 
AFC>11 normal 
294 
Keane et al., 
(2017)(139) 
Retrospective 
cohort 
IVF All pregnancies confirmed 
by ultrasound but did not 
reach beyond 20 weeks 
gestation 
AFC<9 low 
 
423 
Mustafa et al., 
(2017)(140) 
Retrospective 
cohort 
IVF All pregnancies confirmed 
by bHCG but did not reach 
beyond 20 weeks gestation 
AFC<9 low 
 
534 
 
59 
 
Table 6: Characteristics of AMH studies 
Author (year) Study design Population Definition of pregnancy loss Definition of ovarian reserve 
categories 
Number of women 
included 
Brodin et al., 
(2013)(79) 
Prospective cohort IVF All pregnancies confirmed by 
ultrasound scan which did not 
result in live birth 
Normal AMH>0.84ng/L 
Low AMH<0.83ng/L 
337 
Friden et al., 
(2011)(141) 
Retrospective 
cohort 
IVF All women with a positive 
bHCG test who did not achieve 
live birth 
Normal AMH≥8.6pmol/L 
Low AMH<8.6pmol/L 
22 
Keane et al., 
(2017)(139) 
Retrospective 
cohort 
IVF All pregnancies confirmed by 
ultrasound but did not reach 
beyond 20 weeks gestation 
Normal AMH≥8.6pmol/L 
Low AMH<8.6pmol/L 
423 
Lekamge et al., 
(2007)(142) 
Retrospective 
cohort 
IVF All pregnancies confirmed by 
ultrasound. Any gestation limits 
for pregnancy loss not specified 
Normal AMH≥14pmol/L 
Low AMH<14pmol/L 
37 
Pereira et al., 
(2016)(143) 
Retrospective 
cohort 
IVF Pregnancy confirmed by 
ultrasound and a loss before 
completion of 24 weeks. 
Normal AMH≥1ng/L 
Low AMH<1ng/L 
500 
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Reijnders et al., 
(2016)(144) 
Retrospective 
cohort 
IVF All women with a positive 
bHCG test who did not achieve 
live birth 
Normal AMH≥1.05ng/L 
Low AMH<1.05ng/L 
268 
Tarasconi et al., 
(2017)(145) 
Retrospective 
cohort 
IVF All pregnancies confirmed by 
ultrasound and did not carry on 
beyond 12 weeks gestation 
Normal AMH≥1.60ng/L 
Low AMH<1.60ng/L 
551≥ 
Tremellen et al., 
(2010)(129) 
Retrospective 
cohort 
IUI All pregnancies confirmed by 
ultrasound and did not carry on 
beyond 12 weeks gestation 
Age related percentiles to define low and 
normal 
48 
61 
 
Table 7: Quality assessment of included studies (Newcastle-Ottawa Scale) 
 Selection    Comparability Outcome   Comments 
Study Author, 
Year of 
Publication 
Representative
ness of the 
exposed cohort 
Selection of the 
non-exposed 
cohort 
Ascertainment 
of the exposure 
Demonstration 
that outcome of 
interest was not 
present at start 
of study 
Comparability 
of cohorts on 
the basis of the 
design or 
analysis 
Assessment of 
outcome 
Was follow-up 
long enough 
for outcomes to 
occur 
Adequacy of 
follow up of 
cohorts 
Total rating 
Abdalla et al., 
(2006) 
    Not controlled 
for any 
confounders 
  Retrospective 
analysis 
6 
Bishop et al., 
(2017) 
    Not controlled 
for any 
confounders. 
However age 
grouping 
available. 
  N/A as 
retrospective 
analysis  
6 
Caroppo et 
al., (2006) 
    Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis  
6 
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Chuang et al., 
(2003) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Esposito et 
al., (2002) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Huyser et al., 
(1995) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Luna et al., 
(2007) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Sabatini et al., 
(2008) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Thum et al., 
(2009) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
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Toner et al., 
(1993) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Brodin et al., 
(2013) 
 
 
   Not controlled 
for any 
confounders 
 Loss to follow 
up not reported 
 6 
Friden et al., 
(2011) 
No description      Up to 20 weeks 
of gestation 
 6  
Keane et al., 
(2017) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Lekamge et 
al., 
(2007) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Pereira et al., 
(2016) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
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Reijnders et 
al., 
(2016) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Tarasconi et 
al., 
(2017) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Tremellen et 
al., 
(2010) 
Somewhat 
representative 
as this studied 
patients having 
IUI 
   Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
5          
Holte et al., 
(2011) 
 
 
   Not controlled 
for any 
confounders 
 Loss to follow 
up not reported 
 6 
Hsu et al., 
(2011) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
65 
 
Keane et al., 
(2017) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
Mustafa et al., 
(2017) 
  
 
  Not controlled 
for any 
confounders 
  N/A as 
retrospective 
analysis 
6 
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AFC	
The pooled meta-analysis for AFC is listed in Figure 9. In total, there were five included studies with 
3,413 participants. Results showed a statistically significant increased risk of having a pregnancy loss in 
women with low AFC compared to normal AFC; relative risk (RR) 1.63 (95% confidence interval [CI] 
1.42-1.87). Heterogeneity was relatively low (I2 = 16%).  
A subgroup analysis of very low AFC, defined as studies that had AFC of five or less as a category (Holte 
et al. [AFC ≤5], Hsu et al. [AFC ≤4], Keane et al. [AFC≤4] and Mustafa et al. [AFC≤4]) was carried out 
(78,138–140). 694 women were included in the subgroup analysis with low heterogeneity (I2 = 22%). 
Results showed a statistically significant increased risk of having a pregnancy loss in women with an 
AFC count of five or less compared to normal AFC; RR 1.62 (95% CI 1.23-2.14). 
AMH	
The results of the meta-analysis for AMH studies is listed in Figure 10. There were eight included studies, 
with the largest being Tarasconi et al., with 1,153 participants (145). 3,098 women were included in the 
meta-analysis and there was moderate heterogeneity (I2 = 44%). Results show a statistically significant 
increased risk of having a pregnancy loss in women with low AMH compared to normal AMH; RR 1.29 
(95% CI 1.02-1.84). There were insufficient data to allow for a further subgroup analysis of very low 
AMH. 
FSH	
The results pf the meta-analysis for FSH studies is displayed in Figure 14. The largest study is Bishop 
et al., with 8,117 participants (131). In total, there were 11, 492 women in the ten included studies. There 
was very low heterogeneity (I2 = 0%). Results show a statistically significant risk of having a pregnancy 
loss in women with high FSH compared to normal FSH; RR 1.24 (95% CI 1.12-1.38). 
A subgroup analysis of very high FSH, defined as studies that had FSH of 14 IU/ml or more as a category 
(Bishop et al. (FSH ³14 IU/ml), Caroppo et al. (FSH ³ 15IU/ml) and Toner et al. (FSH ³ 15IU/ml)) was 
carried out (131,132,137). In total, there were 7,264 participants in the three included studies.  There was 
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very low heterogeneity (I2 = 0%). Results show a statistically significant increased risk of having a 
pregnancy loss in women with FSH ³ 14 IU/ml compared to normal FSH; RR 2.28 (95% CI 1.87-2.79).
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Figure 9: Forest plot showing pregnancy loss by AFC categories 
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Figure 10: Forest plot showing pregnancy loss by AMH categories 
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Figure 11: Forest plots showing pregnancy loss by AFC categories 
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	Recurrent	pregnancy	loss		
The studies that investigated women with recurrent pregnancy loss were 
heterogeneous. They varied in methodology and in how they reported their 
outcomes, and were unsuitable for meta-analysis. 
Atasever et al., was a prospective cohort study carried out in Turkey over a five 
year period (146). The study compared women with a diagnosis of recurrent 
pregnancy loss, defined as three or more miscarriages, to a matched control group 
drawn from women seeking contraception. Atasever et al., measured AFC, AMH 
and FSH in the two groups and calculated mean values for each of the test and 
compared them. This study found that the mean levels of FSH were 8.6+-3.7UL 
(RPL group) and 7.1+-3.1U/L(control group), which was statistically significant 
(P=0.49). The levels of AMH were 2.9+-1.7ng/ml (RPL group) and 3.6+-1.6ng/L 
(control group), which was statistically significant (P=0.007). No significant 
differences were found in AFC measurements. 
Bussen et al., was a case control study carried out at the USA, which compared 
women with a history of unexplained recurrent pregnancy loss, defined as three or 
more pregnancy losses, with a control group consisting of multiparous women 
attending a fertility clinic seeking treatment for either tubal infertility or male factor 
infertility (147). This study found no significant difference in the FSH levels. 
Gurbuz et al., was a Turkish retrospective cohort study, which studied women with 
unexplained recurrent pregnancy loss (148). Recurrent pregnancy loss was defined 
as three or more consecutive losses. The control group of women included those 
with recurrent pregnancy losses, which were deemed as explained recurrent 
pregnancy losses by the investigators of the study. The mean FSH levels were 6.32 
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+-3.22 mIU/ml (explained RPL group) and 8.29+-2.99mIU/ml (unexplained RPL 
group   which was statistically significant (P=0.007). However, the investigators 
found that the number of women with elevated FSH levels, defined as 
FSH>10mIU/ml, were evenly distributed between the two groups. 
Hoffman et al., was a retrospective study based in the USA (149). It compared 
women with recurrent pregnancy loss and subfertility (pregnancy loss defined as 
three or more pregnancy losses), to women with subfertility who attended the same 
clinic. This study found no difference in the mean FSH concentrations of both 
cohorts. 
Pils et al., was an Austrian retrospective cohort study (150). It studied women with 
recurrent pregnancy losses, defined as three or more consecutive pregnancy losses 
with the same partner. It compared women with unexplained recurrent pregnancy 
loss, to women with recurrent pregnancy loss and at least one causative factor as 
determined by the investigators. The study found the median AMH levels to be 2.0 
ng/ml (explained RPL) and 1.2ng/ml (unexplained RPL), which was significant 
(p=0.037). No significant differences were found in FSH levels. 
Prakash et al., was a study carried out in Sheffield, United Kingdom (151). It 
compared women with recurrent pregnancy losses, defined as three or more 
consecutive first trimester pregnancy losses, to women with no history of pregnancy 
loss or female factor subfertility. The study found no significant differences in mean 
AMH and FSH levels between the cohorts. 
Trout et al., was a study carried out in the USA, studying women with recurrent 
pregnancy loss, defined as three or more first trimester pregnancy losses (152). 
Women with unexplained recurrent pregnancy los were compared to women with 
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recurrent pregnancy loss and at least one causative factor as determined by the 
investigators. The study compared the proportion of women who had elevated FSH 
levels, defined as ³11mIU/mL. The percentage of women with elevated FSH levels 
was 31% (unexplained RPL) and 5% (explained RPL), which was significant 
(P=0.02). 
Yuan et al., was a retrospective in design and it studied women in two different 
centres, one in China and one in the UK (153). It compared women with 
unexplained pregnancy loss with women who attended the fertility clinic in the 
same centres with no history of recurrent pregnancy loss. The investigators 
compared the proportion of women with high FSH levels, defined as ³10IU/l, in 
the two cohorts. No significant differences were found. 
The characteristics of the recurrent pregnancy loss studies are listed in Table 8.
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Table 8: Characteristics of recurrent pregnancy loss studies 
Author (year) Study design Population Ovarian 
reserve test 
studied 
Atasever et al., 
(2016) 
Prospective cohort Women with recurrent miscarriage defined as three or more losses, compared 
with age matched controls. 
AFC 
AMH 
FSH 
Bussen et al., 
(1999) 
Case-control study Women with unexplained recurrent pregnancy loss defined as three or more 
losses. Comparison group consisted of multiparous women who were 
seeking fertility treatment for known tubal or male factor infertility. 
 
FSH 
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Gurbuz et al., 
(2004) 
Retrospective 
cohort 
Women with unexplained recurrent pregnancy loss defined as three or more 
consecutive losses. The control group was women with recurrent pregnancy 
loss with what the investigators deemed a known causative factor, such as 
uterine septum 
FSH 
Hoffman et al., 
(2000) 
Retrospective 
cohort 
Women with recurrent pregnancy loss, defined as three or more losses, with 
subfertility, compared to women without recurrent pregnancy loss and 
subfertility. 
FSH 
Pils et al., (2016) Retrospective 
cohort 
Women with unknown recurrent pregnancy losses compared to with women 
with recurrent pregnancy loss with what was deemed by the investigators to 
be a causative factor. Recurrent pregnancy loss defined as three or more 
consecutive pregnancy losses, with the same partner. 
AMH 
FSH 
Prakash et al., 
(2006) 
Prospective case 
control 
Women with recurrent pregnancy losses, defined as three or more first 
trimester pregnancy losses. Compared to women with no history of 
pregnancy loss of female subfertility 
AMH 
FSH 
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Trout et al., (2000) Retrospective case 
control 
Women with unexplained recurrent pregnancy loss compared to women with 
explained recurrent pregnancy loss. 
Recurrent pregnancy loss was defined as three or more first trimester 
pregnancy losses. 
FSH 
Yuan et al., (2012) Retrospective 
cohort 
Women with unexplained pregnancy losses, defined as three or more 
consecutive pregnancy losses, compared to women with a history of 
subfertility without recurrent pregnancy losses. 
FSH 
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FSH	and	recurrent	pregnancy	loss	
Five studies found no association between FSH levels and recurrent pregnancy loss. 
Prakash et al. found no difference between women who have had recurrent 
pregnancy loss and control group (151). Bussen et al., found no difference between 
women with recurrent pregnancy loss and the control group (147). Yuan et al. , Pils 
et al, and Hoffman et al. studied women with unexplained recurrent pregnancy loss 
and compared them with women with subfertility as controls, and found no 
association between FSH and recurrent pregnancy loss (149,150,153).  
Three studies found an association between FSH levels and recurrent pregnancy 
loss. Atasever et al. compared women with recurrent pregnancy loss with matched 
controls and found that women with recurrent pregnancy loss have higher FSH 
levels (146). Trout et al. and Gurbuz et al. compared women with unexplained 
recurrent pregnancy loss with women with recurrent pregnancy loss with an 
identified causative factor, and found that women  with unexplained recurrent 
pregnancy loss had higher levels of FSH (148,152). 
AMH	and	recurrent	pregnancy	loss	
Two studies found an association between recurrent pregnancy loss and low AMH. 
Pils et al. found that women with unexplained recurrent pregnancy loss had lower 
AMH levels on average in comparison to women with recurrent pregnancy loss 
with an identified causative factor (150). Atasever et al. found that women with 
recurrent pregnancy loss had lower AMH levels in comparison to matched controls 
(146).  
We only found one study, Atasever et al., that explored recurrent pregnancy loss 
and AFC. No association was found. 
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Discussion	
This was a comprehensive review of current evidence of association between the 
ovarian reserve tests of AFC, AMH and FSH and pregnancy loss. The meta-analysis 
of 21 included studies, suggests there is a positive association between reduced 
ovarian reserve, and increased risk of pregnancy loss, in women having assisted 
conception treatment. The risk of a pregnancy loss is increased in those with very 
high FSH in comparison to high FSH, indicating that a biological gradient of the 
effect may exist. No conclusions can be drawn about the relationship between AFC, 
AMH and FSH and recurrent pregnancy loss. 
There are a number of possible theories to explain the relationship observed 
between reduced ovarian reserve and increased pregnancy loss. The limited pool 
hypothesis, suggested by many including Warbuton et al., explains that as those 
with low ovarian reserve are likely to have a lower number of follicles and yield 
less oocytes, the number of embryos available to pick for implantation is limited 
(85). Therefore, it is possible that clinicians are forced to use poorer quality 
embryos in those with low AFC.  
Work by Grande et al. has shown a strong association between low AFC and rates 
of aneuploidy(129). It is possible that low ovarian reserve test values are surrogate 
markers of DNA damage of the oocytes.  As the vast majority of early pregnancy 
losses are due to chromosomal errors, it is plausible that the higher incidence of 
pregnancy loss in those with low ovarian reserve could be attributed to the higher 
incidence of chromosomal errors (154). 
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Clinical	implications		
The findings of this study have clinical implications. When clinicians are 
counselling women with low ovarian reserve, they should not only counsel them 
about the anticipated lower IVF success chances, but also prepare them for the 
higher anticipated pregnancy loss rates. However, based on the current available 
evidence, we cannot recommend routinely testing for ovarian reserve in women 
experiencing recurrent pregnancy losses. We also cannot comment about the 
relationship between ovarian reserve tests and the chances of a natural conception 
resulting in pregnancy loss. 
Strengths	and	limitations	
This study has multiple strengths. To our knowledge this is the first systematic 
review on this subject. We followed a comprehensive search strategy, utilising 
multiple databases. The included studies scored moderately high on the Newcastle-
Ottawa scale, with most of the studies losing stars in the Newcastle-Ottawa scale  
for comparability, as they failed to adjust for confounders and for follow up. Despite 
this assessment by the Newcastle-Ottawa tool, due to not adjusting the results for 
known confounders such as age, ethnicity and BMI, we deem the included studies 
to be of significant risk of bias. 
Our study has many limitations. The main limitation is the heterogeneity among the 
studies in this review. The reference ranges applied to define low ovarian reserve 
were not consistent across the studies. Most of the studies were based on women 
with subfertility, thus limiting the generalisability of findings. None of the studies 
used standardised IVF protocols across all participants, thus making it difficult to 
rule out that differences in pregnancy loss, observed between the cohorts, cannot be 
accounted by treatment differences. Most studies did not measure the ovarian 
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reserve immediately before commencing the IVF protocol. As such, we cannot 
exclude the temporal effects on the recorded ovarian reserve test result and the 
actual ovarian reserve on the cycle of commencing treatment. The results are also 
not adjusted for known confounding factors, such as the woman’s age and body-
mass index. Not all studies used the same AMH assay. Liss et al., have 
demonstrated  that the same serum sample could produce differing results based on 
the assay used (155). The impact of inter assay differences on AMH results cannot 
be excluded. Additionally, many of the studies had small sample sizes (Abdalla et 
al., n=9, Caroppo et al., n=19) (130,132).  
Future	research	
A large prospective cohort study, exploring the relationship between ovarian 
reserve tests and pregnancy loss, with results adjusted for confounding factors such 
as age and BMI is recommended. Further research into whether donor oocytes, or 
starting the IVF treatment on a cycle with an optimum ovarian reserve test value 
may yield future treatment options for these women.  
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Preamble	to	chapter	four	
In this thesis I have explained what poor ovarian response is and the consequences it can have for affected 
women. I have explained the concepts of ovarian reserve and ovarian reserve tests. I have also shared 
studies showing that the higher the number of eggs retrieved, the better the chances of achieving a live 
birth. In chapter two of this thesis, I have shared the results of a systematic review I carried out, 
demonstrating that variation in ovarian reserve tests exists between one menstrual cycle to another. 
As explained in chapter one, whilst there are some studies which show an association between ovarian 
reserve tests and live birth, there have been recent studies disputing the value of ovarian reserve tests in 
predicting that. Pregnancy loss is an adverse IVF outcome with sometimes devastating consequences. In 
chapter three I shared the results of a systematic review and meta-analysis I carried out- which showed 
an association between ovarian reserve tests and pregnancy loss. However the studies included in the 
systematic review had failed to adjust the data for known confounders. 
In this chapter I describe a cohort study I carried out, studying the association between AFC and live 
birth rate and pregnancy loss, after adjusting for confounding factors such as age, ethnicity and BMI. 
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Abstract	
Study Question 
What is the relationship between antral follicle count (AFC) and a) livebirth and b) pregnancy loss? 
Summary Answer 
Our study shows that AFC correlates with livebirth and pregnancy loss, independent of age, body mass 
index (BMI) and ethnicity. 
What is known already? 
Ovarian reserve tests (ORT), including AFC, have been shown to be good prognostic markers of the 
success of assisted conception treatments. However, studies evaluating the relationship between AFC 
and livebirth are limited, and studies exploring AFC and pregnancy loss have shown inconsistent 
findings. 
Study size, design, and duration 
The study included 25,767 cycles of in-vitro fertilisation (IVF) or intra-cytoplasmic sperm injections 
(ICSI). Data was collected prospectively from 2008 to 2016. 
Participants, materials, setting, and methods 
This was a study of women receiving IVF or ICSI treatment at any CARE (Centres for Assisted 
Reproduction and Embryology, UK) Fertility clinics in the UK and Ireland. Analysis was restricted to 
fresh embryo transfers following controlled ovarian stimulation. Frozen embryo transfers or transfers 
using donated oocytes were excluded. The primary outcomes were live birth rate (LBR) and pregnancy 
loss. 
Main results and the role of chance 
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We included data from 25,767 cycles. AFC was available in 10,023 cycles. The live birth rate per embryo 
transfer was 33% (6,927/21,003). There was a significant increase in the live birth rate from 20% with 
an antral follicle count of 5 or less, rising to 41.1% with an antral follicle count of 25 or more (Figure 1). 
Pregnancy loss rate, combining biochemical and clinical pregnancy losses, was 27.3% (2,656/9,719). 
AFC negatively correlated with pregnancy loss. Pregnancy loss was up to 41.7% with an antral follicle 
count of 5 or less and gradually decreased down to 23.2% with an antral follicle count of 25 or more. 
The association remained strong even when adjustments were made for age, body mass index and 
ethnicity for both live births and pregnancy loss. 
Limitations, reasons for caution 
This study evaluated couples with subfertility and studied women undergoing fertility treatment. 
Therefore, the results may not be applicable to women who conceive naturally. 
Wider implications of the findings 
AFC is a widely used test as part of investigating women who are struggling to conceive. This study 
shows that AFC can be an important aid for clinicians in counselling women about their likelihood of 
live birth and pregnancy loss and aid their decision making. 
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Introduction	
The aim of fertility treatment is to enable the couple to conceive and raise a child. Therefore, live birth 
rate is considered to be the most important clinical outcome in assisted conception (156). Several studies 
have explored the relationship between AFC and livebirth in assisted conception. However, these studies 
were generally small, and were of variable methodological quality (78,157,158).  
Pregnancy loss is a common complication, often with devastating consequences. Studies show that early 
pregnancy loss affects one in five pregnancies (159). Pregnancy loss is associated with significant 
psychological morbidity; it has been found that women may suffer with Post Traumatic Stress Disorder 
(PTSD) after experiencing the loss of their pregnancy (160), Amongst women who experience pregnancy 
loss, those who experienced a loss following IVF treatment are shown to have higher incidence of 
psychological symptoms in comparison to those who conceived naturally (126). Assisted reproduction 
is often self-funded by patients; as a result, there are often financial consequences following pregnancy 
loss post IVF treatment.  
There is a clear need for clinicians to be able to counsel couples on their personalised chance of livebirth 
and risk of pregnancy loss before commencing IVF treatment. Being able to stratify the chance of 
livebirth and the risk of pregnancy loss according to AFC can ultimately help patients make informed 
choices about their treatment. There is evidence showing that in the IVF setting, when women with poor 
prognosis are adequately counselled and informed of the higher chances of adverse outcomes prior to 
commencing treatment, they coped better (161). 
Antral follicles are the recruitable pool of follicles available in the follicular phase of the menstrual cycle. 
AFC is usually measured during the early follicular phase of the menstrual cycle (35).. AFC is commonly 
used as part of routine fertility investigations. Low AFC is established as a good predictor for poor 
response to ovarian stimulation in IVF (119). 
There are conflicting results from studies which analysed AFC and live birth rate. Holt et al., 
demonstrated that AFC strongly correlated with live birth rate (78). Leijdekkers et al., demonstrated that 
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the addition of AFC to existing prediction models increased the ability for researchers to be able to 
successfully predict the chances of achieving live birth (158). However, the work by Hsu et al., showed 
that whilst AFC was useful in predicting the number of eggs retrieved in an IVF cycle, it was not useful 
in predicting live birth rates (162). 
Few conflicting studies have been published exploring the relationship between AFC and pregnancy loss.  
Two cohort studies, Bishop et al., (131) and Haadsma et al., (163), found no association between AFC 
and first trimester pregnancy loss. However, Keane et al., another cohort study, reported an association 
between AFC and first trimester pregnancy loss. Thus, there is a clear need for further research to 
establish the relationship between AFC and pregnancy loss conclusively. 
Material	and	methods	
Study	design	
This study was an analysis of all cycles of IVF or ICSI treatment at any CARE fertility clinic in the UK 
and Ireland, from 2008 to 2016. CARE is a fertility provider which treats patients who self-fund their 
fertility treatment. The choice of treatment protocol and dose of medicines used at CARE is 
individualised to each woman and is left to clinicians’ discretion. CARE database consisted of 
anonymised data extracted from prospectively collected clinical information as part of the routine care 
women received. Data were analysed from six fertility centres within the CARE consortium 
(Nottingham, Manchester, Northampton, Sheffield, Dublin and London) and a further seven satellite IVF 
units (Bolton, Boston, Derby, Leicester, Mansfield, Milton Keynes and Peterborough). This study 
protocol was developed based on the methodology described by Gallos et al., who had carried out 
analysis on a similar dataset (164). Analysis was restricted to fresh embryo transfer cycles following 
controlled ovarian stimulation. Frozen embryo transfer cycles were excluded from the analysis as there 
is a lack of consensus on the comparability of reproductive outcomes between fresh and frozen cycles. 
There is currently a large RCT being carried out to answer this question(165,166). Cycles using donated 
oocytes were also excluded. A separate sensitivity analysis based on women who had frozen embryo 
transfers or had oocyte donation could not be performed due to the small number of participants 
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Antral follicle count was measured during the early follicular phase (days 2-6) of the menstrual cycle 
before the IVF/ICSI treatment. The ultrasound scans were performed by sonographers, trained nurse 
sonographers or reproductive medicine specialists. IVF/ICSI treatment protocols were based on clinician 
discretion. Embryos transfers were performed by experienced clinicians using Wallace® Sure View® 
Catheter under ultrasound guidance.  
Live birth was defined as the delivery of a live baby after 24 weeks gestation. As cycles that did not reach 
the stage of embryo transfer were excluded, the live birth rate was calculated per embryo transfer instead 
of per cycle started. 
A pregnancy test was performed 18 days after oocyte recovery.  Biochemical pregnancy loss was defined 
as a failure of pregnancy after a positive urinary pregnancy test, with or without visualisation of a 
pregnancy at first ultrasound examination (at 7 ± 1 week gestation) (167). Clinical pregnancy loss was 
defined as pregnancy loss after detection of fetal heart activity before 24 weeks of gestation. The outcome 
of pregnancy loss includes the combination of biochemical and clinical pregnancy losses.  
Statistical	analysis	
Baseline patient characteristics, cycle characteristics and outcome data were described as frequencies 
with percentages, or means with standard deviations, as appropriate.  The rates of the reproductive 
outcomes were plotted graphically using mean proportions and 95% confidence intervals.  
A multiple-imputation analysis was adopted for any missing data for AFC, or covariates such as age and 
body mass index (29). The multiple imputation method imputed 10 values to fill in each of the missing 
values for antral follicle count or covariates. After that, statistical analysis was performed on the 10 
imputed datasets separately and the results combined.  The goal was to obtain better estimates of 
parameters and their standard errors (29). Dependant variable/ outcomes of livebirth follow a binomial 
distribution. However, as the sample size is large, it is possible to use Poisson regression as an 
approximation for binomial distribution. Advantage of such approach is that Poisson regression can be 
used to express the results as relative risk(RR), in oppose to odds ratio (OR). RR is a preferred measure 
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by many clinicians and is found to be more intuitive(168). A Poisson regression model was fitted to 
estimate crude and adjusted risk ratios for confounding variables such as age, body mass index and 
ethnicity. The assumption that the results produced by Poisson regression were valid was verified by 
comparing OR for all the values and RR for unadjusted early and late pregnancy loss, which were  
calculated using a binomial regression and a generalised linear model. This is included in Appendix 5. 
The work by Dhillon et al., had shown that IVF outcomes could be confounded by factors such as age, 
ethnicity, BMI, parity and duration of infertility(169). In the subset of women with AFC results available, 
there were very few women with parity and duration of fertility accurately recorded. Therefore we 
adjusted the data for age, ethnicity and BMI which were reliably recorded in most women. We carried 
out a sensitivity analysis taking into account the within patient variability for women with more than 1 
IVF/ICSI cycle in the database and adjusted for clustering. Further sensitivity analyses were performed 
to evaluate the impact of imputed values. All statistical analyses were done using Stata statistical 
software, release 14. 
Ethical	approval	
Permission for use of the database was granted by CARE. Analysis of the database was anonymised. 
Such analysis of existing routine data supplied under license/agreement involving interventions in use 
only do not require formal IRB approval. However, each clinic is licensed by the Human Fertilisation 
and Embryology Authority (HFEA) and all activity is regularly inspected. The dataset was anonymized 
according to the ICO's (Information Commissioner's Office) guide on non-identifiable data. Furthermore, 
the CARE data protection certificate allows for the data to be used for survey and research purposes. 
Results	
There were 45,279 cycles performed at the CARE centres during the study period. We included data 
from 25,767 cycles after excluding cycles using donated oocytes, frozen embryo cycles, and cycles that 
were cancelled prior to embryo transfer. We chose to present the outcomes per embryo transfer rather 
than per cycle initiated, as the database did not contain sufficient information on the clinical indication 
for cancelling cycles. AFC was available in 10,023 cycles (46.1%) and these were included in the 
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regression model.  All cycles were followed up to the point of the clinical pregnancy scan. The live birth 
outcome was not available for 752 cycles (3.5%) and they were excluded from the analysis for this 
outcome.  The baseline characteristics are displayed in the table below. The mean AFC was 17.9 
(Standard Deviation (SD) 12.8). 
Table 9: Baseline characteristics 
 
 
 
 
 
 
Characteristics n (%) or mean (SD) Whole dataset (n = 21,755) 
Age 34.8 ± 4.7 
Duration of subfertility (years) 3 ± 2.2 
Body Mass Index 24.7 ± 4 
Ethnic background  
White 
Asian 
Black 
Chinese 
Other/Mixed 
 
16,478 (83.1) 
1,886 (9.5) 
242 (1.2) 
164 (0.8) 
1,060 (5.4) 
Antral follicle count 17.9 ± 12.8 
Previous live birth 4,336 (19.9) 
Previous miscarriage 4,790 (22) 
Oocytes retrieved 9.6 ± 4.9 
Ovarian stimulation protocols 
Long agonist 
Short flare agonist 
Antagonist 
 
11,704 (54.1) 
1,459 (6.7) 
8,484 (39.2) 
Cause of infertility 
Unexplained 
Tubal 
Ovulatory 
Male 
Uterine/peritoneal 
Mixed or other cause 
 
5,173 (23.8) 
2,004 (9.2) 
1,139 (5.2) 
6,734 (30) 
935 (4.3) 
5,770 (26.5) 
Treatment type 
IVF 
ICSI 
 
5,920 (27.2) 
15,835 (72.8) 
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Table 10: Baseline characteristics of women with available AFC data 
 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
AFC was split into categories in increment of five follicles to see if a gradual increase in AFC will result 
in a gradual increase in live birth rate and a gradual decrease in pregnancy loss rate. The live birth rate 
per embryo transfer was 33%. A decision was made to not analyse AFC based on clinical thresholds of 
low, normal and high as there is no clear clinical consensus on the cut offs for these labels. There was a 
significant increase in the live birth rate from 20% with an antral follicle count of 5 or less, rising to 
41.1% with an AFC of 25 or more (see Table 11).  
Characteristics 
n (%) or mean (SD) 
Women with  AFC data available (n = 10, 023) 
Age 34.8 ± 4.6 
Duration of subfertility (years) 2.7 ± 2.0 
Body Mass Index 24.5 ± 3.9 
Ethnic background  
- White                                                                                                                      
- Asian                                                                                                                                  
- Black 
- Chinese 
- Other/Mixed 
 
8,133 (83.2)    
877 (8.9)                                
138 (1.4) 
82 (0.8) 
542 (5.5) 
Antral follicle count 17.9 ± 12.8 
Previous live birth 1,945 (19.4) 
Previous miscarriage 2,465 (24.6) 
Oocytes retrieved 9.5± 4.7 
Ovarian stimulation protocols 
- Long agonist 
- Short flare agonist 
- Antagonist 
 
6,859 (68.9) 
517 (5.19) 
2,584 (25.9) 
Cause of infertility 
- Unexplained 
- Tubal 
- Ovulatory 
- Male 
- Uterine/peritoneal 
- Mixed or other cause 
 
1,796 (17.9) 
857 (8.5) 
432 (4.3) 
3,371 (33.6) 
391 (3.9) 
3,176 (33.7) 
Treatment type 
- IVF 
- ICSI 
 
2,823 (28.2) 
7,200 (71.8) 
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Table 11: Live birth and pregnancy loss per AFC category 
        
Thres
hold 
Live birth rate 
(95% CI) 
Unadjusted 
RR  
(95% CI) 
Adjusted RR 
 (95% CI) 
Pregnancy 
loss rate 
(95% CI) 
Unadjusted 
RR (95% 
CI) 
Adjusted RR 
(95% CI) 
≤5  
20.0 (16.92 to 
23.43) 
0.52(0.44 to 
0.62) 
0.47 (0.37 to 
0.60) 
41.7 (35.0 to 
48.7) 
1.85(1.57to 
2.27) 
1.90(1.50 to 
2.39) 
6-10 
25.0 (23.00 to 
27.0)) 
0.65 (0.59 to 
0.72) 
0.75 (0.67to 
0.84) 
32.6 (29.1to 
36.2) 
1.44 (1.22 to 
1.70) 
1.32( 1.09 to 
1.59) 
11-15 
31.2 (29.23 to 
33.12) 
0.81(0.74 to 
0.89) 
0.86 (0.78 to 
0.96) 
28.9 (26.0 to 
31.8) 
1.23(1.09 to 
1.50) 
1.22(1.02 to 
1.47) 
16-20 
38.4 (36.01 to 
40.90) 
Reference Reference 
22.6 (19.7 to 
25.6) 
Reference Reference 
21-25 
37.45(34.64 to 
40.31) 
0.97(0.88 to 
1.07( 
0.94(0.94 to 
1.01) 
26.9(23.4-30.7) 
1.19 (0.99 to 
1.43) 
1.27(1.03 to 
1.56) 
>/25 
41.12 (39.03 to 
43.23) 
1.07 (0.99 to 
1.15) 
1.04 (0.92to 
1.10 
23.2 (20.8-25.7) 
1.03 (0.87 to 
1.21) 
1.11 (0.92 to 
1.34) 
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Table 12: Early and late pregnancy loss per AFC category 
        
Thres
hold 
Early 
pregnancy loss 
rate (95% CI) 
Unadjusted 
RR  
(95% CI) 
Adjusted RR 
 (95% CI) 
Late 
pregnancy 
loss 
(95% CI) 
Unadjusted 
late 
pregnancy 
loss RR (95% 
CI) 
Adjusted 
late 
pregnancy 
loss RR 
(95% CI) 
≤5  
29.38 (23.33 to 
36.03) 
1.75(1.35 to 
2.27) 
1.84 (1.34 to 
2.52) 
12.32 (1.35 to 
3.37) 
2.13(1.57to 
2.27) 
2.02 (1.23 to 
3.33) 
6-10 
19.39 (16.51 to 
22.54)) 
1.15 (0.93 to 
1.43) 
1.14 (0.89to 
1.46) 
13.17 (10.74 to 
15.92) 
2.28 (1.62 to 
3.20) 
1.72( 1.19 to 
2.50) 
11-15 
19.33 (16.92 to 
21.93) 
1.15(0.94 to 
1.40) 
1.15 (0.91 to 
1.45) 
9.57 (7.81 to 
11.57) 
1.65(1.18 to 
2.33) 
1.39(0.96 to 
2.02) 
16-20 
16.81 (14.28 to 
19.59) 
Reference Reference 9.57(7.81-11.57) Reference Reference 
21-25 
19.36(16.25 to 
22.77) 
1.15(0.92 to 
1.44) 
1.25(0.97 to 
1.63) 
5.77 (4.26-7.62) 
1.31 (0.88 to 
1.95) 
1.29(0.84 to 
1.99) 
>/25 
15.72 (13.69 to 
17.92) 
0.94 (0.76 to 
1.15) 
1.05 (0.83to 
1.33) 
7.44(6.01 t 9.08) 
1.28 (0.91 to 
1.82) 
1.24 (0.85to 
1.82) 
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The overall pregnancy loss rate, combining biochemical and clinical pregnancy losses, was 27.3% (3308 
/10 073). Pregnancy loss was up to 41.7% with an AFC of 5 or less and gradually decreased down to 
23.2% with an antral follicle count of 25 or more (see Table 11). 
 
Figure 12: Pregnancy loss per AFC category (X axis shows AFC categories in increments of five 
follicles and Y axis shows the probability of pregnancy loss) 
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Figure 13: Live birth per AFC category (X axis shows AFC categories in increments of five follicles 
and Y axis shows the probability of live birth) 
 
 
This association was independent of age, body mass index and ethnicity for both live births (crude RR 
0.83; 95% CI 0.77—0.89 and adjusted RR 0.863; 95% CI 0.85—0.92) and pregnancy losses (crude RR 
0.83; 95% CI 0.77—0.89 and adjusted RR 0.86; 95% CI 0.85—0.92).  
When split into clinical and biochemical pregnancy loss, AFC categories were shown to have a stronger 
association with biochemical pregnancy loss in comparison to clinical pregnancy loss (Figure 14). 
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Figure 14: Biochemical, clinical and total pregnancy loss by AFC categories. (X axis shows AFC 
categories in increments of five follicles and Y axis shows the probability of pregnancy loss) 
 
When we examined the impact of a low AFC (0-5 follicles) for young women of 20-30 years, where the 
pregnancy loss rate is expected to be low, it was found that the risk of pregnancy loss was almost double 
compared to women with a normal AFC (16-20) (RR 1.99; 95% CI 1.19-3.35; p=0.009).  
Discussion	
This study establishes an association between AFC and live birth rate and pregnancy loss, independent 
of age, ethnicity and BMI in patients having IVF/ICSI treatment. This is one of the largest studies carried 
out evaluating the association between AFC and pregnancy loss to our knowledge. As all IVF cycles that 
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were included within this study were of patients receiving treatment from the same provider, the extent 
of inter provider treatment variation is minimised. 
However, this study does have a number of limitations. All women included in this study self funded 
their treatment. In UK, there are strict eligibility rules on access to state funded treatment, with older, 
multiparous and women with higher BMI being excluded. Therefore it is conceivable that there could be 
differences in the baseline characteristics and socio-economic status between women who were treated 
at CARE and women who receive state funded IVF, which could limit the generalisability of our study. 
As all data is from IVF cycles, it is difficult to draw conclusions about the relationship between AFC and 
pregnancy loss in women who conceive naturally. As frozen cycles and intra uterine inseminations were 
excluded from the analysis, these results are not applicable to all women having assisted conception. At 
CARE, AFC was not always measured in every patient, and is carried out at the clinician’s discretion. 
Furthermore, there were no guidelines on how clinicians use AFC in determining the most appropriate 
treatment option. It is likely that AFC would have been taken into consideration by the clinicians when 
determining the IVF protocol and dose of stimulation medication, therefore the impact of this on the 
outcomes cannot be excluded. A future survey of clinicians based at CARE, establishing how AFC results 
affects their decision of which treatment protocol and medication dosage to use could enable us to make 
some assumptions in this area.   
 
Inherent errors associated with the measurement of AFC, including inter observer variability, are also 
not accounted for. It is also plausible that some factors may have an impact on both the ovarian reserve 
(170) and the endometrium (171) independently. For example, smoking is shown to impact on the ovarian 
reserve as well as the endometrium. Therefore, the association between AFC and pregnancy loss may be 
accounted for in other ways. 
We used Poisson regression to estimate the RR. This model enables one to calculate adjusted RR, which 
is deemed intuitive and preferred by many clinicians(168)(172). However for count data, such as ours, 
97 
 
poisson may not always be the most appropriate model as it is based on the assumption that the mean is 
identical to the variance(173). However the impact of any such errors on large datasets is limited. We 
were able to demonstrate the reproducibility of our results by carrying out binomial regression using 
generalised linear model to calculate ORs and RR for unadjusted live birth and early and late pregnancy 
loss. This has been listed in appendix 5. The similarity of results produced by both models gives 
confidence of the existence of the relationship between AFC and live birth and pregnancy loss, 
independent of the regression model used. 
This study’s finding showing association between AFC and live birth rate supports the findings of other 
studies, including Holte et al., and Fisch et al (78,174). Holte et al., is a large prospective cohort study, 
where IVF outcomes were adjusted to both the woman’s age and the number of previous treatment. Holte 
et al., demonstrated a linear relationship between AFC and live birth rate up to an AFC of 30. Fisch et 
al., showed that those with an AFC >20 had a statistically significant higher live birth rate in comparison 
to those with an AFC<10. Interestingly, there was little difference in the live birth rate between the AFC 
categories of <10 and 10-19 follicles. 
However our study’s finding showing an association between AFC and live birth rate is in contrast to the 
findings of Hsu et al., and Li et al (157,162). Hsu et al., found that whilst AFC was predictive of ovarian 
response, it did not correlate with pregnancy rates, implantation rates or live birth rates. Whilst the 
investigators of this study had adjusted their results for age, they had not adjusted for ethnicity and BMI, 
despite the presence of statistically significant uneven distribution of these characteristics between AFC 
categories. It is difficult to ascertain if the differences between our study and this study could be 
accounted by this. Li et al., demonstrated that there was a trend indicating women who achieved live 
birth had higher AFC. However Li et al., did not find a statistically significant association between AFC 
and live birth rate. Li et al., did not adjust the analysis of AFC and live birth rate to possible confounding 
factors such as age, ethnicity and BMI. Further comment on whether the differences between Li et al., 
and our study could be accounted by this lack of factoring confounding variables cannot be made.  
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This study’s finding of an association between AFC and pregnancy loss supports the findings of Keane 
et a (139)l, Mustafa et al (140)and Sahu et al (175). However this does contradict the findings of Bishop 
et al (131) and Haadsma et al (163). Bishop et al (131), studied the association between AFC and 
pregnancy loss by allocating patients into categories of low, normal and high AFC. Low was determined 
as an AFC count of 10 or below.  However many clinical guidelines, including the NICE guidelines (8) 
set the threshold for a patient to be deemed to be having a low ovarian reserve to be at a value of four or 
below. Therefore by setting the bar of AFC to be at 10, Bishop et al., might have diluted the reporting of 
any relationship between AFC and miscarriage. Haadsma et al., was a prospective cohort study, which 
looked at both spontaneous conception as well as assisted reproduction. Therefore the study population 
was not comparable to our study. 
There are a number of possible explanations for the relationship between AFC and live birth and 
pregnancy loss. The limited pool hypothesis explains that as those with low AFC are likely to have a 
lower number of follicles and yield less oocytes, the number of embryos available to pick for implantation 
is limited. Therefore it is possible that clinicians are forced to use poorer quality embryos in those with 
low AFC.  
Work by Grande et al (176), has shown strong association between low AFC and rates of aneuploidy. It 
is possible AFC is a good surrogate marker of DNA damage of the oocytes.  As vast majority of early 
pregnancy losses are due to chromosomal errors (Jacobs PA, 1987), it is plausible that the higher 
incidence of pregnancy loss in those with low AFC could be attributed to the higher incidence of 
chromosomal errors. 
The implications of this study are numerous. Firstly, in an IVF setting, when encountering patients with 
a low AFC, clinicians should not restrict their discussion to the probability of IVF success, but also 
counsel them about the higher pregnancy loss rate. This is particularly important in younger women, who 
may not be expecting a high chance of having a pregnancy loss after implantation. Most literature 
currently focuses on age as the key predictor of the chances of IVF success and pregnancy loss. AFC is 
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an independent predictor of live birth and pregnancy loss, and should be used in addition to age to 
accurately counsel women on their individualised risk. 
 Further research is needed to determine whether a relationship between AFC and pregnancy loss 
following natural conception exists. 
Conclusion	
A relationship between low AFC and live birth and pregnancy loss, independent of age, ethnicity and 
BMI, in patients having IVF treatment exists. Further research is needed to explore if such relationship 
exists for women who have spontaneous conception. 
 
 
 
 
 
 
 
100 
 
Chapter	five:	inter-cycle	variation	in	antral	follicle	
count,	anti-mullerian	hormone	and	follicle	
stimulating	hormone	in	women	with	risk	factors	for	
poor	ovarian	response-	a	prospective	cohort	study	
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Preamble	to	chapter	five	
Thus far in the thesis, I have established: 
1. There is some month-to-month variability in ovarian reserve tests as measured by FSH, AMH 
and AFC. The variation appeared to be greater for FSH and AFC when compared with AMH, but the 
available data were limited and heterogenous in nature, preventing a meta-analysis. 
2. There is an association between AFC and egg count. There is published evidence that egg count 
closely relates to live birth outcome. 
3. There is some association between AFC, AMH, FSH and pregnancy loss. 
However, due to the heterogenous nature of the existing studies, I could not draw firm conclusions about 
the degree of menstrual cycle to menstrual cycle variability, necessitating a primary study. Furthermore, 
existing studies did not specifically examine women with low ovarian reserve. As explained in chapter 
one, this is the group for which a small increase or decrease in the number of eggs collected is likely to 
have the greatest clinical impact. 
To establish whether a menstrual cycle to menstrual cycle variation exists in ovarian reserve tests in 
women with low ovarian reserve, I carried out a primary study. This study and its results are described 
in this chapter. 
 
 
 
 
 
 
102 
 
Contributions 
Dr Bala Karunakaran- Conceived the idea, carried out AFC and blood tests, data collection, data analysis 
and wrote this manuscript. 
Dr Abey Eapen carried out some of the AFC measurements and blood tests and helped with quality 
assurance. 
Mr Aurelio Tobias and Dr Adam Deval helped analysis using STATA and PRISM packages respectively. 
Prof Coomarasamy proof-read the manuscript and provided substantial edits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
Abstract	
STUDY QUESTION: Is there variation in the ovarian reserve markers of AFC, AMH and FSH from 
one menstrual cycle to another, often referred to as inter-cycle variation, in women with low ovarian 
reserve? 
 SUMMARY ANSWER: This study proves a menstrual cycle to menstrual cycle variation exists for 
AFC, AMH and FSH in women with low ovarian reserve.  
WHAT IS ALREADY KNOWN: Multiple studies had commented on the inter-cycle variation of ovarian 
reserve markers, though very few studies had made direct comparison with each other. There are no 
studies that have studied this variation in women with low ovarian reserve. 
STUDY DESIGN, SIZE, AND DURATION: A prospective cohort study of 47 women over three 
consecutive menstrual cycles  
PARTICIPANTS/MATERIALS, SETTING, METHOD: 47 women with an identified risk factor for 
low ovarian reserve, recruited from a large tertiary fertility clinic (Birmingham women and children’s 
NHS Trust) in United Kingdom. 
MAIN RESULTS AND THE ROLE OF CHANCE: The mean of AFC Max variation, AMH Max 
variation and FSH Max variation were 3.87, 9.61pmol/L and 6.48 respectively. When analysis was 
restricted to women who we deemed to have low ovarian reserve(AFC of 10 or less, AMH of 5.5pmol/L 
or less or FSH of 8.9IU/ml or more for one or more measurements), the mean of AFC Max variation, 
AMH Max variation and FSH Max variation were  2.4, 1.2pmol/L and 3.8IU respectively. 
 LIMITATIONS AND REASONS FOR CAUTION: Whilst every effort was made to reduce 
measurement errors, inter and intra operator variability and its potential impact on the results cannot be 
entirely eliminated. The clinical impact of this observed inter-cycle variability is also unknown. 
WIDER IMPLICATIONS OF THE FINDINGS:  The existence of inter-cycle variation means 
clinicians should be cautious in forming judgements about a patient’s ovarian reserve or whether a patient 
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should be treated or not based on a single measurement Further research is needed into the clinical 
implications of this inter-cycle variation, including whether starting IVF treatment on a month with a test 
showing high ovarian reserve would result in better reproductive outcomes. 
TRIAL REGISTRATION:  researchregistry3201 
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Introduction	
Ovarian reserve tests are routinely carried out by clinicians prior to starting assisted conception 
treatments (100). Clinicians use these tests as aids to determine the suitability for IVF or ICSI, the best 
treatment protocol, the dose of medication used for ovarian stimulation and in counselling the couple 
about IVF success (177). 
There are a plethora of ovarian reserve tests available. NICE guidelines recommend that clinicians restrict 
their investigations to testing for antral follicle count (AFC), anti-mullerian hormone (AMH) levels and 
follicle stimulating hormone (FSH) levels, as these tests have the strongest evidence supporting them (8).  
The relationship between ovarian reserve tests and IVF outcomes have been demonstrated in multiple 
studies (44). The analysis carried out in chapter three showed a positive relationship between AFC and 
live birth rate (LBR). The analysis in chapter three also demonstrated a decrease in pregnancy loss rates 
as the AFC increased. Therefore it can be expected that higher the ovarian reserve, the more likely a 
woman is to have a successful IVF outcome. There are multiple reasons why low ovarian reserve may 
have such impact. Firstly, those with poor ovarian reserve are more likely to have a poor response to 
controlled ovarian hyperstimulation (178). The consequence of this could either be cancelling the IVF 
cycle or having a lower number of oocytes extracted, with less chance of fertilisation or development of 
a good quality embryo (179). The increased pregnancy loss associated with low ovarian reserve has two 
potential explanations. The limited pool hypothesis, as outlined in chapter three, suggests that as the 
number of oocytes is limited, the number of embryos that are available to choose from also becomes 
limited, resulting in poorer quality embryos being used and therefore higher rates of pregnancy loss. 
Some academics have suggested that ovarian reserve test values may reflect the ageing process of the 
ovary and that low values may indicate  ovaries which have undergone accelerated ageing, non-
concordant with the actual age of the woman (180). As older women  have higher rates of miscarriage 
and embryos with chromosomal abnormalities, women with abnormally aged ovaries could also have 
higher rates of pregnancy loss (181)(172). 
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The systematic review in chapter two suggests that there is month to month variation in ovarian reserve 
tests within the same individual. However as also described in chapter two, included studies looked at 
either healthy volunteers or women with subfertility, and did not specifically focus on women with low 
ovarian reserve. Cycle to cycle variation in a woman with normal or high ovarian reserve is unlikely to 
be clinically important. The work by Sunkara et al., showed a positive correlation between the number 
of eggs retrieved, from one to 15 eggs and live birth rate (23). Beyond 15 eggs, no correlation was found. 
The work by Hsu et al., has shown strong correlation between AFC and the number of oocytes retrieved 
(162). For women with a high AFC, month to month variation is unlikely to have an impact as they would 
have a high yield of oocytes resulting in a high quality of embryos to choose irrespective of the month. 
However, for a woman with an AFC of two in one month and six in another month, this difference could 
be clinically important.  
There is a need to investigate whether menstrual cycle to menstrual cycle variation exists within 
individuals who have a low ovarian reserve and thus likely to have a poor ovarian response. The aim of 
this prospective cohort study was to establish the inter-cycle variation in AFC, AMH and FSH in women 
who were at risk of having a low ovarian reserve. 
Measuring	inter-cycle	variation	
There is little consensus on how to measure variation of a test result within the same individual. Studies 
looking at inter-cycle variation have deployed various statistical tools to study this. Some authors have 
calculated inter-cycle variation as mean difference (104,105,107,108). Mean difference is derived by 
calculating the difference between two observed values and subsequently calculating the average of all 
the differences (182). This approach has considerable limitations. As the difference between the first and 
second observation could be either in positive or negative magnitude, when the differences are added 
together they are likely to cancel each other. Therefore mean difference which is an average of the values 
will be small and underestimate the true variation.  
107 
 
Fanchin et al., calculated the inter-cycle variation as intra-class coefficient (ICC) (51). Intra-class 
coefficient was first described by Shrout and Fleiss, and is now a widely used tool to assess the 
reproducibility of an investigation (183,184). McGraw defined intra-class coefficient as the proportion 
of variance as attributable to the measurement (185). However intra-class coefficient is limited by 
studying the overall agreement between the two cohort measurements; therefore it is not best placed to 
study the agreement between multiple measures from the same individual.  
Some studies, including Brown et al., and Rastamov et al., used coefficient of variation to measure inter-
cycle variation (103,104). Coefficient of variation is the difference between the values in relation to the 
mean of the values (109). As coefficient of variation takes into account the mean, the resultant value is 
skewed by the value of the mean and thus limited in its generalisability. 
Due to these limitations, many authors, including Jayaprakasan et al., have used Bland Altman plots and 
limits of agreement to express variation (62). A Bland Altman plot graphically displays the difference 
between two observations plotted against the average of the two measurements (186). Limits of 
agreement are calculated as the mean plus and minus 1.96 times the standard deviation (92). Limits of 
agreement are drawn as a line on the graph.  This method has the advantage of studying the difference 
between the values specifically. It also allows values of positive and negative magnitude to be plotted on 
the same graph. As the mean and standard deviation is calculated based on every value that has been 
entered, the limits of agreement represent the entire dataset and have limited value in assessing an 
individuals’ inter-cycle variation.  Despite this, a graphical representation is useful for identifying outliers 
with the greatest inter-cycle variation. 
Methods	
Study	Design	
Before beginning the cohort study, the aim was to recruit 47 women who were being investigated for 
subfertility. The assumption of 10% drop out after commencing investigation was anticipated. The 
sample size was determined as previous studies had been able to establish inter-cycle variation for AFC, 
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AMH and FSH with between 40-50 paired measurements (a summary of previous studies can be found 
in Chapter two of this thesis (Table 3). The sample size was also limited for pragmatic reasons based on 
the funding available to carry out AMH and FSH tests  and the number of scan slots available to perform 
AFC. 
The study was approved by the North of Scotland Research Ethics Service (16/NS/0104 IRAS 204528). 
Women were recruited from secondary care fertility outpatient clinics at the Birmingham Women’s and 
Children’s Hospital (BWCH).  
The inclusion criteria were designed to identify women at risk of having low ovarian reserve. According 
to the Human Fertilisation and Embryology Authority (HFEA) October 2007 data, which were also 
featured in the 2013 NICE Guidelines (shown in appendix), live birth rate per embryo transfer starts to 
decline steeply after the age of 35. Therefore women aged over the age of 35 were included in the study. 
The NICE guideline designates an FSH level of greater than 8.9 IU/ml or an AMH of less than 5.4 pmol/L 
as abnormal (8). Hence, these values were adopted for AMH and FSH. As AFC was not measured at the 
outpatient clinic, no inclusion criteria based on AFC was adopted. Any woman with a previous history 
of poor response to controlled ovarian hyperstimulation was also included in this study. We included 
women with one of the risk factors for low ovarian reserve in this study. 
Prospective participants were identified by the secondary care clinicians and introduced to the researcher. 
A participant information sheet was provided(appendix 2), and prospective participants were invited to 
discuss this further with the researcher. In instances where the prospective participant was not fluent in 
English, an interpreter was provided. At the end of the discussion, if the prospective participant was 
willing to proceed, written consent was obtained(appendix 3). Participants were given the contact details 
for a dedicated telephone number for this study, and instructed to make contact as soon as their next 
menstrual cycle commenced. 
Participants were invited to attend during their early follicular phase, (defined for the purpose of this 
study as days two to six of their menstrual cycle) for three consecutive menstrual cycles. The decision 
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for three consecutive menstrual cycles was taken as this time period fell within the average time women 
waited between their initial and follow up visit at this hospital. Therefore our research was designed not 
to delay the commence meant of IVF treatment. The participants’ understanding of the study and their 
consent to proceed was then reconfirmed by the researcher before taking the first measurements. A 
venepuncture was performed and blood was collected using an Eclipse® needle and vacutainer system 
with Serum Selective II Tubes (SSTII). SST II tubes have been shown to be superior to the alternative 
Serum Selective Plus (SST) tubes in studies, with less volume dependent variation in results (187). Each 
of the participants was tested for AMH and FSH levels. The analysis of serum  was carried out using 
electrochemicaluminescence on a Roche Cobas e801™ platform (188). All serum samples were carried 
out by an accredited laboratory (TDL laboratories London). 
All participants had a transvaginal ultrasound scan performed with consent and a chaperone. All scans 
were performed by one of two investigators to keep inter-observer variability to a minimum. 20 scans 
had both investigators scanning each participant together to ensure agreement and quality assurance. 
Participants were asked to empty their bladders and then subsequently placed in a modified Lloyd Davies 
position. All scans were performed using a Voluson S8, GE Healthcare ™ Scanner with a 3.8-9.3MHz 
endocavity volume probe. A baseline pelvic anatomy scan was carried out to assess for any pelvic 
pathology prior to performing an antral follicle count. 
For this study, follicles measuring 2-10mm were recorded as antral follicles (153). Real-time two 
dimensional ultrasound scan (2D US) was used. Participants were scanned in two planes (longitudinal 
and transverse) to identify the optimal plane for identifying and counting the antral follicles. Each ovary 
was scanned from one ovarian margin to another, using the technique described in the consensus opinion 
published by Coelto Neto et al. (189). Ultrasound scan was performed on each ovary and antral follicles 
measured and recorded separately. 
Statistical	analysis	
To establish the greatest variation within one individual, for each ovarian reserve test, the lowest obtained 
value (trough result) of the three visits was subtracted from the highest value (peak result) of the three 
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visits, to produce the maximum variation. The mean of the maximum variation and its standard deviation 
was calculated. Further descriptive statistical analysis, such as bland-altman plots, limits of agreements, 
medians, inter-quartile ranges were calculated. 
Most statistical calculations were done using STATA version 14 (Stata corp, College station, TX, USA). 
Bland-altman plots were produced using PRISM version 7 (Graphpad, San Diego, USA). 
Results	
Baseline	characteristics	
The baseline characteristics of participants are displayed in Table 13. The majority of the women were 
aged over 35 (88.9%), non-smokers (93.2%) with high FSH levels (55.6%), primary infertility (75.5%) 
and no previous fertility treatment history (93.3%).  
Table 13 Baseline characteristics 
Average age in years(SD) 39.2(2.9) 
Ethnicity  
White(%) 18(40.0) 
Black(%) 2(4.4) 
Chinese(%) 3(7.0) 
South Asian(%) 15(33.3) 
Other(%) 7(15.5) 
Smoking status  
Yes(%) 2(4.4) 
No(%) 30(66.6) 
Previous smoker(%) 12(26.6) 
Fertility status  
Primary infertility(%) 34(75.5) 
Secondary infertility(%) 11(24.4) 
Previous IVF(%) 3(6.7) 
No Previous IVF(%) 42(93.3) 
Ovarian reserve status  
Age >35(%) 40(88.9) 
Low AFC(%) 8(17.8) 
Average of AFC (SD) 8.3(5.7) 
Low AMH(%) 18(4.0) 
Average of AMH 9.2(10.0) 
High FSH(%) 25(55.6) 
Average of FSH(SD) 10.9(7.2) 
Previous poor response (%) 1(2.2) 
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Pattern	observed	over	three	visits	
Graphical displays of the results of all visits by participants, and results for those with low AFC, low 
AMH and high FSH are shown in the figures below. 
 
Figure 15: AFC value obtained plotted against each visit 
 
Figure 16: AMH value obtained plotted against each visit 
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Figure 17: FSH value obtained plotted against each visit 
Table 14 shows the summary characteristics of the observations from the three ovarian reserve tests 
amongst the women studied. For each study the mean difference between month one and month two and 
month two and month three were calculated. The largest magnitude of observed difference within each 
participant was labelled AFC max variation, AMH max variation and FSH max variation respectively. 
This was calculated by subtracting the highest value obtained in all measurements from the lowest value 
obtained from all measurements. Means, standard deviation and interquartile range of the maximum 
variation values are displayed in Table 15. 
Maximum variation in women with lower ovarian reserve, defined as an AFC of 10 or less, an AMH of 
5.5pmol/L or less and an FSH of 8.9IU or higher, in one or more measurements, were analysed separately. 
Means, standard deviation and interquartile range of the maximum variation values are displayed in Table 
15. 
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Table 14 Mean of differences, standard deviation, upper limits of agreement and lower limits of 
agreement 
ORT Mean of 
differences 
Standard 
deviation (SD) 
Upper limits of 
agreement (ULA) 
Lower limits of 
agreement (LLA) 
AFC     
Month1-Month2 0.95 4.07 8.93 -7.03 
Month2-Month3 0 2.92 5.72 -5.72 
Difference 
between highest 
AFC measurement 
obtained and the 
lowest AFC 
measurement 
obtained 
(AFC Max 
Variation) 
3.87 2.75 1.51- 9.25 
AMH     
Month1-Month2 -1.89 4.58 7.79 -10.16 
Month2-Month3 0.58 5.29 10.9 9.79 
Difference 
between highest 
AMH 
measurement 
obtained and the 
lowest AMH 
measurement 
(AMH Max 
variation) 
9.61 8.06 6.18 -25.40 
FSH     
Month1-Month2 -9.61 8.06 6.18 -25.40 
Month2-Month3 -0.79 9.47 17.78 -19.36 
Difference 
between highest 
FSH measurement 
obtained  and the 
lowest AFC 
measurement 
obtained 
(FSH Max 
variation) 
6.48 9.74 12.61 -25.57 
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Table 15 Maximum variation of AFC, AMH and FSH 
 Median Quartile 
one 
Quartile 
three 
Interquartile 
Range 
AFC Max 3.0 2.0 5.0 3.0 
AMH Max 7.8 2.2 15.0 12.8 
FSH Max 3.8 1.6 8.0 6.4 
 
 
 
 
Table 16 Maximum variation in women with low AFC, low AMH and low FSH 
 Mean  Standard 
deviation 
Median Quartile 
onw 
Quartile 
three 
Interquartile 
Range 
AFC Max in 
low AFC 
2.4      1.5 2.0 2.0 3.0 1.0 
AMH Max 
in low AMH 
1.2 1.0 1.1 0.5 1.6 1.1 
FSH Max 
in low FSH 
3.8 6.1 1.8 1.1 4.1 3.0 
 
Bland-Altman plots were created for the difference between visit one and visit two, visit two and visit 
three, visit three and visit one, as well as for the maximum difference (the difference between the highest 
and lowest measurement). 
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Figure 18: AFC bland-altman plots- difference between the values (y axis) plotted against the 
average of the two values (x axis). 
116 
 
 
 
Figure 19: AMH bland-altman plots- difference between the values (y axis) plotted against the 
average of the two values (x axis). 
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Figure 20: FSH bland-altman plot- difference between the values (y axis) plotted against the 
average of the two values (x axis). 
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Discussion	
This study proves a menstrual cycle to menstrual cycle variation exists for AFC, AMH and FSH in 
women with low ovarian reserve. AFC Max variation, AMH Max variation and FSH Max variation, 
which were calculated by subtracting the lowest obtained value from the highest obtained value within 
each individual, is the measurement of most importance. This is because as this value reflects the highest 
variation between the three visits, it describes the biggest potential menstrual cycle to menstrual cycle 
variation within any individual. The mean of AFC Max variation, AMH Max variation and FSH Max 
variation was 3.87, 9.61pmol/L and 6.48IU/ml respectively. When analysis was restricted to women who 
we deemed to have low ovarian reserve (AFC of 10 or less, AMH of 5.5pmol/L or less or FSH of 
8.9IU/ml or more for one or more measurements), the mean of AFC Max variation, AMH Max variation 
and FSH Max variation was 2.4, 1.2pmol/L and 3.8IU/ml respectively. 
Study	strengths	
There are several strengths to this study. This is one of the few studies which looked at inter-cycle 
variation of ovarian reserve tests as the primary outcome. This is the only study to our knowledge which 
has specifically focused on women with an identified risk factor for poor ovarian response to controlled 
ovarian hyperstimulation. Therefore the findings of this study are generalisable to the population at risk 
of poor ovarian response to controlled ovarian hyperstimulation. Birmingham is an ethnically diverse, 
multicultural city and its residents comprise of a wide range of socio-economic backgrounds. 
Consequently, this study is likely to capture the diversity of the UK population. Unlike some of the other 
studies which have analysed data retrospectively or used data collected for routine clinical use, this study 
collected data prospectively. The ultrasound machine and settings were standardised and the same 
laboratory assays were used for all participants, reducing any systematic errors in measurements. All 
scans were performed by one of two investigators, keeping variation between operators to a minimum 
and reducing inter observer variation. As the three scans and blood tests were carried out in three 
consecutive menstrual cycles, the resultant variation due to age related decline in ovarian reserve is 
minimised. 
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Study	limitations	
There is some debate as to whether other techniques, such as cine-loop ultrasound scan, three dimensional 
ultrasound scan or sono AVC may be more accurate in measuring AFC (189). Sono AVC uses computer 
automation to measure and count the follicles and can reduce the uncertainty posed by human judgement 
(98). However it has been shown that automatic evaluation of follicles can  often count para-ovarian 
structures as follicles (189).  Cine-loop ultrasound scan has the benefit of allowing the scan to be recorded 
and played back and therefore to have an independent verification by a second person (190). Three 
dimensional mode allows the investigator to look at the ovaries in multiple planes. Advanced functions 
such as rendering mode which enhances the contrast, and inversion mode which allows complete 
visualisation of all follicles within the required volume are also available in three dimensional mode— 
these can make the AFC more accurate (191). However the consensus opinion by the International 
Society of Ultrasound in Obstetrics & Gynecology (ISUOG), stated that there is no clear evidence that 
one technique was superior to another (189). Furthermore, these techniques require advanced training, 
expensive equipment and software, and are not routinely performed by care providers. As one of the aims 
of this study is to lead to results that could be clinically relevant and reproducible, a decision was made 
to use conventional two dimensional real-time scanning. 
There were some limitations due to study design. A similar study with a bigger sample size and one that 
was multi-centred could provide greater confidence in generalisability. For pragmatic reasons the number 
of cycles were limited to three in this study. Continuing to observe women over a greater number of 
consecutive cycles could be informative.  
Investigators were not blinded to results of previous month’s scans. It was decided that due to the small 
number of participants in the study at any given timeframe, an investigator recollecting the scan 
performed the previous month could not be avoided. Therefore the bias introduced by the knowledge of 
the previous results cannot be eliminated. As all ultrasound scans had to be performed during the early 
follicular phase of the menstrual cycle, there was a need for an investigator to be on standby throughout 
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the month. Therefore a pragmatic decision was taken to have all ultrasound scans performed by one of 
two investigators. Therefore the impact of inter-operator variability cannot be excluded. 
Another weakness of this study was that whilst participants were chosen for having a risk factor present 
for reduced ovarian reserve, not all participants had truly reduced ovarian reserve. This has been partially 
accounted for in analysis, where calculations were restricted to those with proven reduced ovarian reserve 
tests.  
Mechanisms	of	action	
Chapter one of this thesis describes the hypothalomo-pituitary-ovarian axis and the interaction between 
AFC, AMH and FSH. FSH is produced by the pituitary gland.  Studies have shown that environmental 
stress, nutritional state and body mass index have direct impact on the pituitary gland and subsequent 
FSH levels, therefore levels are transient (192,193). It has been reported that very small fluctuations 
weight can result in disruption to pituitary function (194). This could account for the inter-cycle variation 
observed in FSH in this study. FSH plays a crucial role in recruiting pre-antral follicles and in the process 
of pre-antral follicles developing into antral follicles (55). Hence AFC can reflect both the ovarian reserve 
of the woman as well as the levels of FSH in the preceding weeks. It could be argued that the same 
external factors which affect the FSH levels, could also affect the AFC. It could be suggested that external 
factors like prolonged stress or prolonged poor nutritional state may have a greater influence on AFC 
than transient changes. AMH is predominantly produced by preantral and small antral follicles, and not 
by large antral follicles (162). As the influence of external factors and FSH levels on pre-antral and small 
follicles is minimal, the influence of such factors on inter-cycle variation of AMH may be limited (195). 
Comparison	to	existing	studies	
The results of this study are in agreement with many other studies that looked at inter-cycle variation, 
including Bancsi et al., Elter et al., and Hansen et al.,(107)(105)(196). It should be noted that Elter et al., 
also looked at all three ovarian reserve tests that were investigated in this study. None of the studies listed 
above investigated women particularly at risk of poor response to controlled ovarian hyperstimulation. 
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The results of this study are in contrast to the findings of Jayaprakasan et al., (62). Jayaprakasan et al., 
found that AFC had the least inter-cycle variation. Jayaprakasan et al., was a prospective cohort study 
which had the inter-cycle variation of ovarian reserve tests as the primary outcome. Jayaprakasan et al., 
also investigated AFC, AMH and FSH, however there were variations in the study design, which may 
account for some of the differences in findings. Jayaprakasan et al., investigated women with subfertility, 
but did not specifically analyse women with a risk factor for poor response to controlled ovarian 
hyperstimulation. Jayaprakasan et al., also took the measurements at consecutive IVF cycles, and not 
consecutive menstrual cycles. The study protocol specified that there had to be a minimum of two 
menstrual cycles between one IVF cycle and another, therefore there was a time delay between the two 
measurements. There are many studies which document the age related decline in ovarian reserve tests 
and the effect of time on the measurements cannot be excluded (63,114,197). Jayaprakasan et al. also 
restricted the investigation to two IVF cycles, unlike this study which studied three consecutive menstrual 
cycles. Therefore the likelihood of discovering inter-cycle variability is increased in this study. 
Clinical	implications	
The establishment of inter-cycle variation in women with low ovarian reserve has clinical implications. 
The study by Moon et al., demonstrated that AFC positively correlated with the number of eggs collected, 
even in women with low AFC count (84). Sunkara et al., have demonstrated that eggs collected positively 
correlate with live birth rate, with a linear relationship as eggs collected increase from one to 15(23). 
Therefore it is likely that this menstrual cycle to menstrual cycle variation that we observed in women is 
of clinical importance. 
Clinicians must also exercise caution in making clinical decisions or counselling women based on a 
single measurement of an ovarian reserve test. It is important that clinicians do not make important 
clinical decisions such as deciding not to proceed with IVF treatment based on a single result. In women 
with low ovarian reserve, AMH showed less Max variation in comparison to AFC and FSH. Therefore 
when interpreting results in women with low ovarian reserve, clinicians could interpret the AMH to be a 
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stable predictor of the woman’s ovarian reserve, whilst using AFC and FSH as dynamic tests to assess 
the functional state of the ovary in that particular menstrual cycle. 
Implications	for	future	research	
Women with poor ovarian reserve are known to have adverse IVF outcomes (44,177). As inter-cycle 
variation in ovarian reserve tests has been established in women with low ovarian reserve in this chapter, 
it poses the possibility of timing IVF treatment with optimal ovarian reserve test values. AFC is likely to 
be the most useful test, as this study has shown that it is likely to have clinically significant inter-cycle 
variation, even in women with low ovarian reserve. Further research, in the form of a clinical trial where 
IVF is started in the optimal cycle for the individual woman, may yield a new approach to IVF in women 
with low ovarian reserve. 
We did not correlate the relationship between each ovarian reserve test value, taken at the same visit, 
within the same individual. Further research with a larger sample size, studying paired ovarian reserve 
tests and the relationship between them could help to identify the underlying biological mechanisms and 
better inform clinicians in interpreting them. 
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Chapter	six:	perception	of	diminished	ovarian	
reserve:	a	qualitative	study	
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Preamble	to	chapter	six	
So far in my thesis, I have shown that women with low ovarian reserve have poor reproductive outcomes. 
I have shown that ovarian reserve tests showed association with reproductive outcomes such as 
pregnancy loss and live birth rate. I have also demonstrated that AFC positively correlates with live birth 
and negatively correlates with pregnancy loss. A systematic review conducted as part of this thesis 
showed that there was menstrual cycle to menstrual cycle variation in ovarian reserve tests. The 
prospective cohort study I carried out showed that there is menstrual cycle to menstrual cycle variation 
in ovarian reserve tests in women with low ovarian reserve. There was a cycle to cycle maximum 
variation of 2.4 noted with AFC. The next step in this research journey would be to test the hypothesis 
that identifying a month with a high AFC in a particular woman, and starting treatment on that particular 
month, could lead to an improved reproductive outcome. 
In this chapter, I describe the prospective qualitative study I carried out to understand the needs of women 
with low ovarian reserve and explore their ideas and expectations. I explore their attitude towards 
research and their level of acceptability in taking part in a research study as proposed above. 
 
Contributions 
Dr Bala Karunakaran- Conceived the idea, carried out interviews, transcribed, carried out analysis and 
wrote this manuscript. 
Dr James Cheshire was the second coder and helped with analysis. 
Prof Coomarasamy proof-read the manuscript and provided substantial edits. 
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Abstract	
Study Question 
What are the views of women with low ovarian reserve with regards to their fertility? How acceptable 
taking part in research is to women with low ovarian reserve? 
Summary Answer 
There is a lack of awareness of their ovarian reserve and potential for age related decline. This lack of 
awareness was more prevalent in certain cultural and social groupings. Women with low ovarian reserve 
wished that there had been more education on this topic at an earlier stage in their life, either at school or 
opportunistically by GPs. There is a strong desire to contribute to research amongst this population. 
Women were happy to accept a short delay in treatment if such delay could result in better IVF outcomes. 
Whilst the concept of a randomised controlled trial was not intuitively appealing, women were willing to 
participate in such trials if there was an overall compelling case made. 
What is known already? 
It is known that women are choosing to delay conception worldwide. There are published studies showing 
that the general population has poor awareness of the age related decline in fertility and overestimate the 
success of IVF treatments. There is little published about women with low ovarian reserve and their ideas 
and expectations, as well as their acceptability of clinical research. 
Study size, design, and duration 
This prospective qualitative study included 21 women over a six month period. 
Participants/materials, setting, methods 
This was a qualitative study which prospectively recruited women attending the fertility clinics of 
Birmingham women and children’s hospital and had a risk factor for low ovarian reserve present. 
Purposive sampling with maximum variation was carried out to select participants. Semi-structured 
interviews were conducted and thematic analysis using framework method was carried out. 
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Main results and the role of chance 
Results were presented in four areas; women’s perception of ovarian reserve and their reasons for 
delaying starting family, need for further awareness of ovarian reserve, acceptability of an antral follicle 
count based IVF treatment protocol and women’s attitude to research and acceptability of delaying 
treatment to identify the optimal cycle. Summary of the themes is presented above. 
 Limitations, reasons for caution 
This study only recruited women from one fertility clinics. Therefore even with the use of maximum 
variation sampling, caution is needed about generalisability. 
Wider implications of the findings 
This research highlights the need for strategies to increase age related decline in ovarian reserve amongst 
women. Further research is needed to identify strategies to improve understanding in ethnic minority 
groups. When designing research for women with low ovarian reserve, considerations need to be made 
to ensure that any delay in starting treatment is kept to a minimum. If a randomised control trial design 
is used, investigators should be mindful of the reservation about this form of research amongst this 
population and should ensure that the rationale for such design is clearly communicated to potential 
participants. 
Study funding/competing interest(s) 
None 
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Introduction	
Most women have an expectation that they will have children at some stage in their lives (198). It has 
been  shown that women’s perception of their chances of conception tend to be more optimistic than their 
actual chances of conception (199).The general understanding of fertility and factors affecting chances 
of fertility is poor, even amongst those who are seeking help to conceive (200). 
Ovarian reserve is a term used to describe the number and quality of primordial follicles left in a woman’s 
ovaries (201). Primordial follicles contain all the eggs that can be fertilised in a woman’s lifespan (202). 
Ovarian reserve, low ovarian reserve and risk factors for low ovarian reserve are explored in detail in 
Chapter One of this thesis. Increasing age is one of the most common contributors to a woman having 
low ovarian reserve (203). Many couples are delaying having children, with the mean age of child bearing 
rising in the western countries (204). Given this trend, the number of women experiencing fertility issues 
due to diminished ovarian reserve is likely to rise. Studies show that women’s awareness of age related 
fertility decline is low (205,206). In addition many women who were aware of the age related decline 
were under the impression that IVF would be able to reverse this entirely (207). One study showed that 
less than quarter of women had realistic perceptions of the chances of a successful IVF cycle (208). 
There is a dearth of published studies exploring women’s views about diminished ovarian reserve and 
ovarian reserve testing. One study showed that there is an appetite for ovarian reserve testing amongst 
women (209). There are also studies indicating that greater awareness of ovarian reserve will change 
family planning and reproductive behaviours amongst the population, despite an acknowledgement that 
this might not always be within every person’s control (206,210,211). In order for health providers to 
tailor the care provided and meet the needs of women with low ovarian reserve, a greater understanding 
of their views and motivating factors is essential. 
There is also little published evidence on women with low ovarian reserve and their acceptability of 
research, clinical trials and new treatments. There are some studies indicating that women of childbearing 
age are motivated to take part in research (212,213). However, the generalisability of these results to 
women seeking fertility treatment and especially women with diminished ovarian reserve is unclear. To 
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be able to successfully carry out research to improve outcomes for women with diminished ovarian 
reserve, researchers need to be able to design a research protocol which would be acceptable and 
appealing to this target population. In order to achieve that, a clear understanding of what drives these 
women to take part in research and what would be within the limits of their acceptability is needed. 
Furthermore, clinical trials that have engaged patients prior to the conception of the study, have been 
shown to have better recruitment, lower dropout and overall improved outcomes (214–216). 
This study sets out to explore the views of women with diminished ovarian reserve and what they expect 
from a clinical trial aimed to improve their reproductive outcomes. 
Methods	
Ethical	approval	
A qualitative study was designed to explore the ideas and expectations of women with diminished ovarian 
reserve. Ethical approval to conduct this study was granted as part of the original ethical approval 
application by the North of Scotland Research Ethics Service (16/NS/0104 IRAS 204528). 
Participant	Selection	
Purposive sampling with maximum variation sampling was carried out. Purposive sampling is a non-
random sampling method where participants are chosen because of the qualities they possess (217). 
Purposive sampling is known to be ideal to get rich data from a limited number of participants (218). 
Maximum variation sampling is a subtype of purposive sampling, and describes the process by which 
participants are chosen because of their heterogeneity to ensure the widest variation is captured (219). 
This technique of sampling allows important shared patterns to emerge out of the heterogeneity and 
enables the capturing of both similarities and differences amongst participants (220). 
Women attending a secondary care Fertility clinic at an NHS hospital (Birmingham Women’s and 
Children’s NHS Trust) were recruited. Participants were purposively chosen from women with a risk 
factor for diminished ovarian reserve. The risk factors for diminished ovarian reserve included participant 
age of 35 or above, serum follicle stimulating hormone (FSH) levels of 8.9IU/ml or above, serum anti-
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mullerian hormone (AMH) levels of 5.4pmol/L or less, or a previous history of poor response to 
controlled ovarian hyperstimulation. There is a detailed justification of the choice of risk factors for low 
ovarian reserve in Chapter Five of this thesis. A detailed description of controlled ovarian 
hyperstimulation and poor response can be found in Chapter One of this thesis. Participants were chosen 
in such a way to ensure a wide range of ages, ethnicities, religions and socioeconomic factors were 
included. Verbal and written informed consent was obtained from each participant as part of a wider 
study and the full description can be read in Chapter Five.  
Sampling was continued until saturation was reached and no further themes were identified (221). In 
total, 21 women were included. 
Interview	structure	
Interviews were carried out at Birmingham Women and Children’s Hospital. The decision to carry out 
interviews at this setting was made to minimise the inconvenience for participants and to avoid intrusion. 
All interviews were carried out by Dr Bala Karunakaran MBBS, BSc, DPMSA, MRCOG (male specialist 
registrar and PhD candidate). The interviewer had undergone prior training in qualitative methodology 
(having undertaken a course by Nuffield department of primary care and health sciences, University of 
Oxford).  
Semi-structured interviews were used to collect data. This method was chosen as it allowed the utilisation 
of the investigator’s a priori knowledge of women with low ovarian reserve as well as allowing flexibility 
to explore themes pertinent to the individual participant in detail. Semi-structured interview is considered 
the optimal method of interviewing when only a single sitting is possible to obtain data (222).An 
interview guide was produced prior to the study (attached in appendix 3). A mixture of open, probing 
and closed questions was used and participants were given an opportunity to express anything they 
considered important at the end of the interview. The interviews were conducted with either just the 
interviewer and the participant or if the participant elected to, the participant’s partner present. Interviews 
were recorded and stored on a password protected computer in a secure locked room. Interviews were 
transcribed verbatim at a later stage. Transcripts were anonymised and analysed using NVivo 11 
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organisational software (NVivo qualitative data analysis Software; QSR International Pty Ltd. Version 
11).  
Analysis	
Thematic analysis was chosen as it is considered a suitable approach which bridges the gap between 
qualitative and quantitative methodologies (223). A framework analytical approach was adopted. 
Framework analysis was first described by Ritchie and Spencer, and is a method by which clear steps are 
followed to produce a structured output of summarised data (224). Framework approach is used 
extensively in analysing semi-structured interviews (225), and has been validated in healthcare research 
(226). 
The seven steps of thematic analysis as described by Gale was followed and an analytical matrix 
developed (224). The data was coded to identify overarching themes, following the principles outlined 
by Braun and Clarke (227). Some a priori labels were deductively identified prior to analysis, based on 
the investigator’s prior clinical experience (228). Subsequent themes were captured inductively, using 
open coding, a process described by Struss, where new labels are assigned by the investigator (229). 
Similar labels were grouped together into themes. First ten percent of all transcripts were analysed and 
coded independently by a second researcher (James Cheshire, PhD student) to increase reliability and to 
compare and validate initially identified themes (230). An analytical framework was developed and 
applied to transcripts. A framework matrix was created on NVivo to chart the data. The framework matrix 
was analysed to interpret the underlying themes. The resultant themes and the relationship between the 
themes were noted by the investigators with quotes selected to best illustrate each theme and subtheme.  
Results	
We followed the Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist in 
reporting our methodology and findings (231). This is presented in Table 17. 
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Table 17: Consolidated criteria for reporting qualitative studies (COREQ). Modified from Tong 
et al., (231),. 
No.  Item  
 
Guide questions/description Reported section 
Domain 1: Research team 
and reflexivity  
  
Personal Characteristics    
1. Interviewer/facilitator Which author/s conducted the interview or 
focus group?  
 
Methods 
2. Credentials What were the researcher’s credentials?  
 
Methods 
3. Occupation What was their occupation at the time of the 
study?  
Methods 
4. Gender Was the researcher male or female?  Methods 
5. Experience and training What experience or training did the 
researcher have?  
Methods 
Relationship with 
participants  
  
6. Relationship established Was a relationship established prior to study 
commencement?  
No 
7. Participant knowledge of 
the interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons 
for doing the research  
Methods 
8. Interviewer 
characteristics 
What characteristics were reported about 
the inter viewer/facilitator? e.g. Bias, 
assumptions, reasons and interests in the 
Methods 
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research topic  
Domain 2: study design    
Theoretical framework    
9.Methodological 
orientation and Theory  
What methodological orientation was stated 
to underpin the study?  
Methods 
Participant selection    
10. Sampling How were participants selected?  Methods 
11. Method of approach How were participants approached?  Methods 
12. Sample size How many participants were in the study?  Results 
13. Non-participation How many people refused to participate or 
dropped out? Reasons?  
Results 
Setting   
14. Setting of data collection Where was the data collected?  Methods 
15.Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
Methods 
16. Description of sample What are the important characteristics of the 
sample? e.g. demographic data, date  
Results 
Data collection    
17. Interview guide Were questions, prompts, guides provided 
by the authors? Was it pilot tested?  
Appendix 
18. Repeat interviews Were repeat inter views carried out? If yes, 
how many?  
No 
19. Audio/visual recording Did the research use audio or visual 
recording to collect the data?  
Methods 
20. Field notes Were field notes made during and/or after 
the inter view or focus group? 
Methods 
21. Duration What was the duration of the inter views or 
focus group?  
Methods 
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22. Data saturation Was data saturation discussed?  Methods 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction?  
No 
Domain 3: analysis and 
findings  
  
Data analysis    
24. Number of data coders How many data coders coded the data?  Methods 
25. Description of the coding 
tree 
Did authors provide a description of the 
coding tree?  
N/A 
26. Derivation of themes Were themes identified in advance or 
derived from the data?  
Methods 
27. Software What software, if applicable, was used to 
manage the data?  
NVivo 
28. Participant checking Did participants provide feedback on the 
findings?  
Discussion 
Reporting    
29. Quotations presented Were participant quotations presented to 
illustrate the themes/findings? Was each 
quotation identified? e.g. participant number  
Results 
30. Data and findings 
consistent 
Was there consistency between the data 
presented and the findings?  
Discussion 
31. Clarity of major themes Were major themes clearly presented in the 
findings?  
Results 
32. Clarity of minor themes Is there a description of diverse cases or 
discussion of minor themes?       
Results 
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In total 30 women were approached and invited to be interviewed. Of these, 21 women agreed to be 
interviewed. (Five stated that they did not have time, three were unwilling to be recorded and one gave 
no reason). Baseline characteristics of participants are listed in Table 18. 
Table 18: Baseline characteristics of interview participants 
Average Age (SD) 38.1(2.0) 
Ethnicity  
White(%) 10(47.6) 
Black(%) 2(9.5) 
Chinese(%) 3(14.3) 
South Asian(%) 5(23.8) 
Other(%) 1(4.8) 
Fertility status  
Primary infertility(%) 15(71.4) 
Secondary infertility(%) 6(28.6) 
Previous IVF(%) 2(9.5) 
No Previous IVF(%) 19(90.5) 
Ovarian reserve status  
Age>35(%) 16(76.2) 
Low AFC(%) 8(38.1) 
Low AMH(%) 9(42.9) 
High FSH(%) 15(71.4) 
 
Results are presented in four main themes: 
1. Women’s perception of ovarian reserve and their reasons for delaying starting a family. 
2. Need for further awareness of ovarian reserve. 
3. Acceptability of an antral follicle count based IVF treatment protocol. 
4. Women’s attitude to research and acceptability of delaying treatment to identify the optimal cycle. 
Perception	of	ovarian	reserve	and	reasons	for	delaying	fertility	
Most women interviewed had a good understanding of ovarian reserve and how it related to age. One 
participant stated: 
“My understanding is that it deteriorates after 35 but it’s not necessarily like 
falling off a cliff”. [Participant 06] 
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However, many women reported that their lack of awareness of ovarian reserve and age-related decline 
of fertility in the earlier part of their life led to a delay in starting a family. Many felt that fertility is a 
taboo subject which is not talked about in social circles. 
“I certainly didn’t hear that in my teens or in my 20s and as such I made a 
conscious decision to wait until 30” [Participant 04] 
“I knew about the ageing process but I don’t think I realised it was as young as 
you are 35, 40. I don’t think people talk about it do they” [Participant 20] 
Another participant reported that even when family members and friends want to talk about fertility, it is 
often considered socially unacceptable to do so.  
“I think they did the honourable thing and not mention it to me”. [Participant 16] 
There was a trend noted among women from certain cultural and religious backgrounds reporting that it 
was their social norm not to discuss fertility at school or at home. One woman who grew up in Nigeria 
reported that discussing fertility was unacceptable when she was growing up. Another woman from an 
Irish background stated: 
“I went to a catholic school and the teaching was very much 
about how not have sex or get pregnant (laughs)”.  
[Participant 15] 
The second most common reason reported for delaying starting a family was not having met the right 
person. These group of women generally reported that though they had regrets that they had not met the 
right partner earlier in their lives, they would prefer to wait for the right person instead of “getting 
pregnant with anybody because my clock is ticking” [Participant 03]. 
Women also reported having different priorities earlier in their life and that leading to delay of fertility. 
“Priority was to study and enjoy life and travel the world” [Participant 17]. Career also had a big bearing 
on the decision to delay treatment for multiple women who were interviewed.  
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“I chose not to have children because it was so damaging to career”          
[Participant 04] 
Women who claimed to work in a male dominated profession believed that once the hierarchy becomes 
aware that she is trying to conceive, barriers to progression will arrive. 
“Opportunities would most certainly have been closed to me had I disclosed 
pregnancy and actually, I had to hide a number of miscarriages because of 
the environment, I knew the promotions wouldn’t then come because it 
would be, “Oh, you’ve been trying,” and the investment would stop.” 
[Participant 18] 
Need	for	awareness	
Most participants felt that there was a need for greater awareness about the decline in fertility with age. 
Some felt strongly that there should be a national education campaign. The majority felt that this 
education should begin at secondary school to enable women to factor this in their life aspirations. 
“I perhaps would have rather been told as a teenager or something to 
consider my fertility in line with my biological clock”. [Participant 08] 
The majority of women also considered that GPs should also have an active role to play. Many felt that 
during their regular consultations or contraceptive checks, GPs could have initiated discussions. 
However, when this idea was presented to other women, some felt that this would be inappropriate. 
“It’s assuming that someone wants a family. Not everyone does”. [Participants 17]. 
Acceptability	of	an	antral	follicle	count	based	IVF	treatment	
Women were asked about the concept of having additional scans and blood tests to aid clinicians to start 
their treatment on their optimal month. In general, participants were very enthusiastic about the concept. 
The idea of having multiple tests to gather information rather than relying on one test intuitively appealed 
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to many women. Many described the thought of “not just one number, one test” [Participant 01] as being 
“holistically better” [Participant 21].  
The participants seemed not to consider the additional burden of investigations, including additional 
transvaginal ultrasound scans, bothersome. Even women who had considerable distance to travel to the 
hospital were prepared to face the additional visits. 
“It obviously is an inconvenience because you’re not on my doorstep, and obviously 
I’ve got a child so we’ve got childcare to sort out, but that’s fine. As I say, we’ve 
got supportive people around us. I would happily do it” [Participant 05]. 
The main concern about the treatment expressed was about the potential delay to starting treatment, with 
concerns about the time related decline in their fertility. 
“the more you wait longer, you get older as well, the chances are getting lower and 
lower.” [Participant 11] 
Two of the participants categorically stated that they would not accept any form of delay in starting their 
IVF treatment. Most women accepted that there might be a trade-off between delay in treatment and 
potential better outcomes. 
“If it made me wait a little bit longer to get hopefully a better result, then yes, or a 
bit more of a high percentage of it working, then definitely”. [Participant 13] 
When pressed about the maximum delay in treatment they would be prepared to accept, most stated that 
this would be between four to six months. They emphasised on the distress caused by uncertainty and 
wanted a clear plan as to how many cycles they might be scanned for. One woman stated, “[I] wouldn’t 
mind being under treatment knowing that I had an end date” [Participant 20].  
Attitude	to	research	
The cohort of women interviewed were very supportive of research participation. Most of them were 
positive about altruistic fertility research, even if it will not directly benefit them. 
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“If I can help someone that, you know, might not have any children at all ... I know 
how that feels and I’ve got one ... then yeah, I think it’s acceptable to do that”. 
[Participant 07] 
Many reported that it was heartening to know that there was a high volume of research being carried out 
in reproductive medicine. Participants showed a great understanding of the need for research to evaluate 
and improve treatment options. 
“I absolutely would because obviously you want to move towards a situation where 
people don’t continue to have treatments that are less effective” [Participant 07]. 
When asked about taking part in a clinical trial about an antral follicle count based IVF protocol, most 
women were positive about it. One of the participants expressed her concern about being one of the first 
participants. 
“Err, of course you don’t want to be the first one”. [Participant 20] 
Others expressed concerns about the design of a randomised controlled study, with a particular dislike of 
the chances of ending up in the control arm of the trial. 
“The problem you’ve got with that is if you’ve got people that know each other. 
They’re both going for the same thing, and then someone says, ‘Well, I’ve been 
selected for this. You should speak to the hospital. They might be able to do you’”. 
[Participant 09] 
The lack of choice and the uncertainty about which treatment arm one might end up in was concerning 
for some. However, those with concerns stated that this alone will not deter them partaking in research. 
Some of the participants felt that if there were additional benefits of participating in the study, such as an 
additional free or subsidised IVF cycle, that might motivate them to participate in the clinical trial. 
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Discussion	
Multiple conclusions can be drawn from this study. Firstly, there are several reasons why women delay 
starting a family, perhaps the most significant is the lack of patient awareness of their ovarian reserve 
and potential for age-related decline. This lack of awareness was more prevalent in certain cultural and 
social groupings. Women with low ovarian reserve wished that there had been more education on this 
topic at an earlier stage in their life, either at school or opportunistically by GPs, although a small minority 
felt that such intervention was inappropriate. There is a strong desire to contribute to research amongst 
women with low ovarian reserve. With regards to their participation in further research, women were 
happy to accept a short delay in treatment if it could result in better IVF outcomes. Whilst the concept of 
a randomised controlled trial was not intuitively appealing, women were willing to participate in such 
trials if there was an overall compelling case made. 
This study has multiple strengths. This study followed a validated qualitative research methodology and 
with its purposive sampling with maximum variation design, it successfully captured a wide range of 
patient voices. Sampling was continued until saturation of data was achieved. The researcher was not 
part of the routine care provider for patients, eliminating potential coercion. All interviews were recorded 
and transcribed, with 10% of the interviews being coded by two researchers independently, ensuring 
reproducibility. 
The main weakness of this research was that it was set at a single centre. Therefore, even with maximum 
variation sampling and Birmingham being one of the most ethnically diverse centres in the UK, the 
generalisability is limited. The high acceptability of research amongst those interviewed should be read 
caution, as by default women who were willing to participate in an interview are likely to be positive 
about taking part in other forms of research. The interviews were also conducted by a researcher who 
was involved in wider research into antral follicle count and improving outcomes. This was deemed 
necessary to be able to give the participants sufficient explanation so that an informed discussion could 
take place. However, inherent bias of the interviewer could not be entirely eliminated. 
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The venue of the interview and the role of the interviewer are known to impact the responses in qualitative 
interviews(232,233). The interviewer was also a doctor specialising in fertility. Even though he was not 
part of the team providing routine care for these women, the influence of his role on the answers provided 
cannot be eliminated. Interviews were conducted in hospital setting rather than at participants’ homes. 
This environment may not have put women at ease and may have influenced the flow of interviews.  
Results were not fed back to participants post-analysis so as to reduce patient burden. This meant that 
refining of themes by participants was not pursued. 
Women reported poor awareness of age-related decline in fertility, especially when they were in their 
20s and early 30s. These findings are similar to the findings of other studies based on the wider population 
(205,206). The reasons that emerged from this study as to why women are delaying starting a family, 
such as changes in life priorities, focus on career and a family-unfriendly workforce environment, is 
comparable to the findings of Mills et al (234). The general high level motivation amongst the participants 
to take part in research for altruistic reasons support finding of Newington et al., who interviewed patients 
in other medical specialities (235). The concern expressed by many of the participants towards 
randomisation also reflects the findings of other studies such as Jenkins et al (236). However Jenkins et 
al found that once additional information about the trial and the fact that participation is entirely voluntary 
and could be withdrawn at any time is explained to participants, the majority were willing to partake in 
a randomised controlled trial.(236). This also resonates with the participants of our study who stated that 
they would be happy to participate in randomised controlled trials despite their initial reservations, if they 
agree with the overall rationale for the study.  
This study has identified patients’ lack of awareness of their ovarian reserve and its decline. Further 
strategies are needed to improve the education and reduce the number of women requiring treatment with 
low ovarian reserve. Further research by primary care researchers to determine the best time for GPs to 
engage with women in discussion about fertility and ovarian reserve could be of benefit. There are 
multiple barriers to starting family early, including workplace discrimination and the gender pay gap, 
and research into strategies to overcome them are needed. 
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This study shows a positive attitude of patients towards being involved in research for women with low 
ovarian reserve. Any study designed to improve outcomes for this population should be mindful of the 
time pressure these women are under. When designing studies, researchers would be prudent to look at 
the patient’s entire treatment pathway, and identify how it could be streamlined, in order to minimise any 
delay to starting treatment. Given the high levels of concern expressed about randomised controlled trial 
design, if this is chosen, then significant resources need to be allocated to explain the rationale behind 
the choice of design to patients to ensure high levels of participation. 
Conclusion	
There is a reported lack of awareness of ovarian reserve and its decline. Targeted strategies to improve 
education will be welcome amongst women. There is a great appetite for participating in research in 
women with low ovarian reserve. 
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Chapter	seven:	clinicians’	perspective	of	low	ovarian	
reserve	and	acceptability	of	research-	a	qualitative	
study	
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Preamable	to	chapter	seven	
So far in my thesis, I have shown that women with low ovarian reserve have poor reproductive outcomes. 
I have shown that ovarian reserve tests showed association with reproductive outcomes such as 
pregnancy loss and live birth rate. I have also demonstrated that AFC positively correlates with live birth 
and negatively correlates with pregnancy loss. A systematic review conducted as part of this thesis 
showed that there was menstrual cycle to menstrual cycle variation in ovarian reserve tests. The 
prospective cohort study I carried out showed that there is menstrual cycle to menstrual cycle variation 
in ovarian reserve tests in women with low ovarian reserve.  
The next step in this research journey would be to test the hypothesis that identifying a month with a high 
AFC in a woman with low ovarian reserve, and starting treatment in that particular month, could lead to 
improved reproductive outcome. 
In chapter six, I shared the results of a qualitative study I carried out on women with low ovarian reserve, 
which provided further insight into their views, and their desire to take part in clinical research. It also 
provided further insights into factors researchers should take into consideration when designing a clinical 
trial. 
A successful clinical trial also needs buy in from clinicians. In this chapter, I share the results of a 
qualitative study I carried out exploring the views of clinicians involved in treating women with low 
ovarian reserve. I aim to identify their views on taking part in research. I also aim to gain further insights 
and experiential data on treating women with low ovarian reserve. 
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Abstract	
Study Question 
What are the views of clinicians who treat women with low ovarian reserve with regards to the current 
treatment options that are available, the current gaps in care and their appetite to support research? 
How acceptable is a research trial based on serial ultrasound scanning of women with low ovarian 
reserve to identify the optimal month to start IVF treatment? 
Summary Answer 
Clinicians find consultations with women with low ovarian reserve challenging. There is a keen interest 
to contribute to research amongst IVF clinicians. Most clinicians find a research study based on serial 
ultrasound scans to identify the optimal month to start IVF treatment acceptable. 
What is known already? 
There is a high level of anxiety amongst IVF providers, especially related to poor outcomes in patient. 
There is research showing collaborative priority setting with the involvement of all stakeholders lead to 
better clinical outcomes. 
Study size, design, and duration 
Qualitative study over a period of three months. 
Participants/materials, setting, methods 
Purposive sampling with maximum variation amongst experts. 10 doctors, six embryologists and three 
nurses from locations across England. Semi-structured interviews recorded and transcribed verbatim. 
Thematic analysis carried out using the framework methodology. 
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Main results and the role of chance 
Clinicians found these consultations particularly challenging because of the perceived high expectations 
of the women. Unexpectedly low ovarian reserve test results often cause distress to women and clinicians. 
There is a lack of acceptable alternative treatment options, as women often find using donor eggs 
unpalatable. There are cultural and religious factors which affect the acceptability of donor eggs. 
 There is strong support for facilitating research amongst reproductive clinicians. The ideal research 
project designed to with  a clinically relevant research question, simple in its design, not be resource 
intensive, be multi-centred and have the potential to make changes to clinical practice. It was felt that 
clinicians with an established prior relationship with the participant were better placed to recruit to 
studies. 
Clinicians found the concept of a research study based on scanning for consecutive months and 
identifying the optimum cycle for women with low ovarian reserve appealing and most were positive 
about wanting to be part of such study if offered. Practical issues for consideration included additional 
psychological, physical and logistical burden posed by delaying the onset of treatment and need for the 
availability of sonographers with the expertise. 
Limitations, reasons for caution 
Study carried out in England only so generalisability is limited 
Wider implications of the findings 
Fertility care providers should ensure that there is provision for longer consultations supported by staff 
trained in counselling to better support women with low ovarian reserve. There is a need for a public 
health campaign to reduce the stigma of donor eggs, especially amongst some ethnic and religious 
communities. This chapter also sets out a criteria which is useful to have in consideration when 
designing research projects. 
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Introduction	
There are very few qualitative studies that have been published in the field of reproductive medicine that 
study the perspectives of clinicians. This is despite the fact that there is evidence showing that in the IVF 
setting, when the needs of the healthcare staff are taken into consideration, patient outcome improves 
(237). There is evidence that anxiety levels are higher in doctors practising reproductive medicine in 
comparison to other doctors and that unsuccessful outcomes of IVF treatment is one of the main stressors 
(238). It has been shown that women with low ovarian reserve have lower chances of success with IVF 
treatment (44,239,240). Therefore it is likely that treating women with low ovarian reserve can be 
technically as well as emotionally challenging to clinicians. Research into clinicians treating women with 
low ovarian reserve has focused on establishing clinical consensus on definition and treatment options, 
and has failed to delve deeper into understanding their experiences and views (34,241). 
There is a need for further research to improve reproductive outcomes for women with low ovarian 
reserve. Boaz et al., argued that involvement of stakeholders in research is crucial in bridging the gap 
between research production and the research usage, resulting in greater impact (242,243). There is 
evidence that involving healthcare professionals in the design, conduct and interpretation of clinical trials 
yields better clinical outcomes (244,245). Esmail et al., make the case that stakeholder involvement 
should be included in setting the priorities for research and should be embedded into all research projects 
(246). Cook et al., have made the case that collaborative priority setting is applicable for research 
conducted within the NHS (247). 
This study aims to investigate healthcare providers’ understanding of women with low ovarian reserve, 
and what they perceive their patients expect from treatment and research. This study will examine/assess 
clinicians’ attitudes towards collaborating in fertility research and the feasibility of conducting a research 
to improve reproductive outcomes in women with low ovarian reserve. 
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Methods	
Participant	Selection	
Purposive sampling of experts was carried out. Purposive sampling is a non-random sampling method 
where participants are chosen because of the qualities they possess (217).Purposive sampling is known 
to be ideal to get rich data from limited number of participants (218). Expert sampling is carried out when 
a group of participants are approached because of their expertise in a particular field (217,248). Within 
the group of experts, maximum variation sampling was used. Maximum variation sampling is a subtype 
of purposive sampling, and describes the process by which participants are chosen because of their 
heterogeneity to ensure the widest variation is captured (219). This technique of sampling allows 
important shared patterns to emerge out of the heterogeneity and enables the capturing of both similarities 
and differences amongst participants (220). 
Doctors, fertility nurses and embryologists practising in both state funded institutions and private sector 
were approached for interview. Participants were also selected amongst attendees at fertility conferences 
as well as by contacting IVF units. Sampling was continued until saturation was reached and no further 
themes were identified (221).  
Interview	structure	
All interviews were carried out by Dr Bala Karunakaran (specialist registrar and PhD candidate, Male, 
Qualifications MBBS, BSc, DPMSA, MRCOG). The interviewer had undergone prior training in 
qualitative methodology (Attended course by Nuffield department of primary care and health sciences, 
University of Oxford).  
Semi structured interviews were used to collect data. This method was chosen as it allowed the utilisation 
of the investigator’s a priori knowledge of women with low ovarian reserve as well as allowing flexibility 
to explore themes pertinent to the individual participant in detail. Semi structured interview is considered 
the optimal method of interviewing when only a single sitting is possible to obtain data (154). An 
interview guide was produced prior to the interviews. Mixtures of open, probing and closed questions 
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were used and participants were given opportunity to express anything they considered important at the 
end of the interview. The interviews were conducted at a location of convenience for the participant. 
Interviews were recorded and stored in a password protected computer in a secure locked room. 
Interviews were transcribed verbatim at a later stage. Transcripts were anonymised and analysed using 
NVivo 11 organisational software. 
Analysis	
Thematic analysis with framework approach was chosen, as this a validated qualitative research method 
which has been used in many settings to analyse semi-structured interviews, including in the healthcare 
setting (223,224). The justification for using this method of analysis in qualitative interviews is outlined 
in Chapter Six of this thesis. 
 We followed an identical methodology as described in chapter six of this thesis. 
Results	
We followed the Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist in 
reporting our methodology and findings(231). This is presented in Table 19. 
Table 19 Consolidated criteria for reporting qualitative studies (COREQ). Modified from Tong et al., 
(199) 
No.  Item  
 
Guide questions/description Reported section 
Domain 1: Research team 
and reflexivity  
  
Personal Characteristics    
1. Inter viewer/facilitator Which author/s conducted the interview or 
focus group?  
 
Methods 
2. Credentials What were the researcher’s credentials?  
MBBS, BSc, DPMSA, MRCOG 
Methods 
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3. Occupation What was their occupation at the time of the 
study?  
Methods 
4. Gender Was the researcher male or female?  Methods 
5. Experience and training What experience or training did the 
researcher have?  
Methods 
Relationship with 
participants  
  
6. Relationship established Was a relationship established prior to study 
commencement?  
No  
7. Participant knowledge of 
the interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons 
for doing the research  
Methods 
8. Interviewer 
characteristics 
What characteristics were reported about 
the inter viewer/facilitator? e.g. Bias, 
assumptions, reasons and interests in the 
research topic  
Methods 
Domain 2: study design    
Theoretical framework    
9.Methodological 
orientation and Theory  
What methodological orientation was stated 
to underpin the study?  
Methods 
Participant selection    
10. Sampling How were participants selected?  Methods 
11. Method of approach How were participants approached?  Methods 
12. Sample size How many participants were in the study?  Results 
13. Non-participation How many people refused to participate or 
dropped out? Reasons?  
Results 
Setting   
14. Setting of data collection Where was the data collected?  Methods 
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15.Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
Methods 
16. Description of sample What are the important characteristics of the 
sample? e.g. demographic data, date  
Results 
Data collection    
17. Interview guide Were questions, prompts, guides provided 
by the authors? Was it pilot tested?  
Appendix 
18. Repeat interviews Were repeat inter views carried out? If yes, 
how many?  
No 
19. Audio/visual recording Did the research use audio or visual 
recording to collect the data?  
Methods 
20. Field notes Were field notes made during and/or after 
the interview or focus group? 
Methods 
21. Duration What was the duration of the inter views or 
focus group?  
Methods 
22. Data saturation Was data saturation discussed?  Methods 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction?  
No 
Domain 3: analysis and 
findings  
  
Data analysis    
24. Number of data coders How many data coders coded the data?  Methods 
25. Description of the coding 
tree 
Did authors provide a description of the 
coding tree?  
N/A 
26. Derivation of themes Were themes identified in advance or 
derived from the data?  
Methods 
27. Software What software, if applicable, was used to 
manage the data?  
NVivo 
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28. Participant checking Did participants provide feedback on the 
findings?  
Discussion 
Reporting    
29. Quotations presented Were participant quotations presented to 
illustrate the themes/findings? Was each 
quotation identified? e.g. participant number  
Results 
30. Data and findings 
consistent 
Was there consistency between the data 
presented and the findings?  
Discussion 
31. Clarity of major themes Were major themes clearly presented in the 
findings?  
Results 
32. Clarity of minor themes Is there a description of diverse cases or 
discussion of minor themes?       
Results 
 
In total, 25 clinicians were approached for interview, of which 19 agreed to be interviewed. The six who 
declined to be interviewed gave their current busy schedule as the reason. The baseline characteristics of 
the interviewees is given in the table below. 
Table 20: Baseline characteristics 
Profession Number  Percentage 
Doctor 10 47.4% 
Nurse 6 31.6% 
Embryologist 3 15.8% 
Sector   
Private 2 10.5% 
State 12 63.2% 
Both 3 15.8% 
Gender   
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Male 12 63.2% 
Female 7 36.8% 
Ethnicity   
White 10 52.6% 
Black 3 15,8% 
Asian 4 21% 
Other 0 0% 
 
We present the results of our qualitative study under three headings: Treating women with low ovarian 
reserve, qualities of an ideal research study and the acceptability of an antral follicle count based research 
study. 
Treating	women	with	low	ovarian	reserve		
The	consultations	
Clinicians universally felt that consultations with women with low ovarian reserve were difficult and 
often provoked anxiety about how the patient might receive the news and how best to deliver the 
consultation with least amount of distress caused to the patient as possible. 
“Erm, I’m anxious in terms of how the patient’s going to receive the news of 
low ovarian reserve. Erm, and I’m also thinking about, you know, what sort 
of success rate should I quote either with natural conception or with IVF.” 
(Doctor 03). 
Many doctors compared their consultations with women with low ovarian reserve to consultations they 
previously had with patients who were being informed of a newly diagnosed cancer. 
“It’s a difficult ... first of all it’s a difficult consultation if without warning you are 
telling a young patient your reserves are low, ….. it’s like breaking the bad news of 
cancer to young women” (Doctor 05). 
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Many clinicians, particularly those who worked in government funded IVF clinics, identified multiple 
aspects of these consultations as particularly troublesome. Firstly, by the time ovarian reserve tests are 
done, a patient is often committed in their fertility journey. This is because AMH is self-funded by 
patients and therefore often only done just prior to embarking on IVF treatment. AFC is not routinely 
done and often only performed at the beginning of fertility treatment. Many clinicians reported that 
women found the news of low ovarian reserve and its implications difficult to receive at this stage of 
their treatment. 
“Sadly, sometimes by the time they get to us it’s not been mentioned that they’ve 
got a low, erm, a low ovarian reserve and it can be quite a shock when they get to 
the fertility services and find out actually you’re gonna have to be on the top dose 
of medication because you’ve got low ovarian reserve, the likelihood of you 
responding well is quite slim, you know and, and they’re hearing this information 
for the first time which is not ideal.” (IVF Nurse 03). 
“You know, it’s very challenging because patients have a very high set of 
expectations when  
they come to see anyone in the fertility service. And even when we find out that they 
have got low ovarian reserve those expectations still stay quite  high. So, I always 
find it quite a challenging consultation in general” (Doctor 09). 
It was also felt that younger women struggled with the notion of having low ovarian reserve in 
comparison to older women. A senior fertility nurse also remarked that people’s perception of what is 
considered as older in terms of fertility has been shifting, with increasing expectations, making 
consultations about low ovarian reserve harder. 
“Probably, because they weren’t expecting it, but then I think age, it’s got a little 
bit different as I’ve worked here for years, that people now who are 39, 40 don’t 
consider themselves old and we know that for fertility they are. So, I think even for 
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them, when it’s lower than what it should be for their age they’re still a bit shocked 
and for them, they know their chance ... I think having a very poor AMH at 40, you 
probably don’t do as well as a little bit lower younger.” (IVF Nurse 09). 
Many also commented on cultural differences in how the diagnosis of low ovarian reserve was perceived, 
with people from some ethnic backgrounds placing great emphasis on being fertile. 
“Asian culture tends to, erm, be a lot of denial, it’s not, can’t be a problem, because 
you hit the devastation then of, erm, the, the wider impact because it doesn’t only 
affect their fertility, it can affect their marriage, their family relationships; it’s a 
very wide reaching thing” (IVF Nurse 04). 
Egg	Donation	as	an	alternative	
IVF with donated eggs is a potential option to help women with low ovarian reserve conceive. However 
many couples do not find this acceptable. 
“The women’s expectations are to go through IVF treatment even if they have 
diminished ovarian reserve and to take home a baby that they are the genetic 
mother and father of.” (Doctor 04) 
According to clinicians, couples found the option of egg donation more acceptable only after going 
through multiple cycles of IVF attempting to retrieve and use their own eggs, even if they knew it was 
futile from the outset. 
“For our other patients having erm, the, the concept of egg donation, if they’ve 
been in treatment several cycles and it’s gradually this concept of egg donation is, 
is brought to their attention, they gradually accept it because they know that they’re 
not getting anywhere with their own eggs and that’s been introduced to them at an 
early time and, erm, gradually over time, they become accustomed to the fact that 
this is their way forward.” (IVF nurse 09) 
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Cultural differences were again noted, with many of the clinicians experiencing that women from certain 
ethnicities and religious grouping finding egg donation unacceptable. 
“So, to give an example a lot of Asian Muslim patients tend not to even consider 
donor egg IVF, but I’ve always been surprised by a small number of patients who 
would.” (Doctor 05) 
Even for ethnic minority women for whom donor eggs are acceptable, they were often specific about the 
characteristics of the donor they would find acceptable, and in general finding a suitable donor for an 
ethnic minority often proved to be more challenging. 
“there is still the I don’t want a donor from here, from here, from here, this type of  
donor, that type of donor and religion as well comes into it. So it can be very, very 
difficult,  there’s very long waiting lists and particularly as now going abroad is 
not as easy” (IVF Nurse 01) 
Counselling	and	support	
Many of the interviewees felt that their local NHS hospital clinics were not designed to deliver the news 
of low ovarian reserve to women and they did not receive adequate support and counselling after the 
news was delivered. 
“I think the doctor’s appointments where they discuss results with them are too 
short, they’re too rushed, when they tell them the bad news you know they got, 
maybe they don’t go into it in enough detail because they haven’t got the time” 
(Nurse 02) 
Qualities	of	an	ideal	research	study	
Participants seem to value research as important. Participants placed high emphasis on research that led 
to directly answering a clinically relevant question. 
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“Honestly, I like research that I think, "Gosh, I wish I'd thought of that". So, 
something that's novel, something that will change the way we practice. And, 
generally something that's relatively simple to do so it comes with a nice clear 
outcome. So sometimes you go to conferences and someone presents you with an 
idea and you think, "Oh my God, that would be great. If we only knew the answer 
to that then it would change what I would do for every patient I see". That's the sort 
of research that excites me. Yeah” (Doctor 03). 
IVF nurses and embryologists placed considerable emphasis on being able to understand rationale behind 
research before they can sign up to it.  They reported that they would struggle to support and recruit if 
they do not understand the study fully or are able to explain it. 
“When you’re not entirely sure of the benefits of the trial, it’s like trying to sell  
something you’re not, you don’t know, you know, here, here’s a glass, I can’t tell 
you whether it’s made of plastic or glass or china” (Embryologist 02). 
“It’s very difficult to encourage people to, to join a trial when it’s not easy to talk 
to them about it” (IVF Nurse 05). 
Clinicians also placed significant emphasis on the opinion of their peers and trusting clinical trials that 
have been talked about in their professional circles. 
“Erm, if the trial looked as though it, it’s, if, if it’s say multi centre trial and I have 
a lot of, of contacts outside of this unit and other fertility centres and obviously we 
talk erm, so trial, trials that are multicentred tend to be the ones that are, are more, 
erm, widely talked about because there’s lots of people talking about them which 
makes it easier to  discuss it with the patients because you get more, erm, more 
reviews.”  (IVF Nurse 07). 
Participants also expressed preference for research studies that were simple in design and not onerous 
with regards to additional burdens such as follow up after the trial that it places on clinicians. 
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“Simplicity of the treatment, or the intervention certainly comes into play, so the 
more complex the intervention and follow up the less likely I think trials would be, 
would be taken up” (Doctor 05) 
There was also the view that research studies that have clinicians recruiting, rather than dedicated 
research staff such as a research nurse, was preferable because the woman has a prior relationship with 
the clinician and trusts the information from them. However there was a recognition that once the initial 
recruitment had taken place, the support was needed from research staff to do the necessary paperwork 
and free up clinicians’ time. 
“I think it's better if you already know the patient. I think so. Having been in both 
situations myself, I get the impression that patients are more likely to trust what you 
say and therefore are more likely to invest time in what you're offering to them. 
They almost have an investment in you as much as you have an investment in them. 
Whereas, if you are just coldly approaching someone, I think it's very difficult 
sometimes to get them to take in and trust you straight away.” (Doctor 04). 
Many participants felt that whilst women are motivated by altruism to participate in research, giving 
them something as an extra incentive often helped to offset the additional burden placed by research. 
“If there are any incentives in there for them, erm, to, to take part in a trial I think 
they’d bite your hand off, erm, but a lot of the trials there are no incentives and so 
people don’t feel the obligation to, to take part in it. You know, if they were getting 
a free cycle of treatment by waiting and having this, that and the other or if they’re 
having some kind of benefit on the, the drugs or what have you, I think you’d get a 
better uptake”  (IVF Nurse 07). 
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Acceptability	of	an	antral	follicle	count	based	IVF	protocol	study	
All clinicians, apart from one (one doctor), were positive about the concept of a study looking into 
identifying the optimum month to start treatment based on AFC and felt that patients would find this 
appealing. 
“ if you take time to explain the science, and take time to explain that you are 
personalising the treatment for them, I think most of these women will sign up to it. 
When your chances are low to start with, they want to give it the best shot” (Doctor 
07). 
“I like the concept of it, actually. It's quite a sensible thing. So you might, I suppose, 
see them in the first assessment. See that they've got a low ovarian reserve, maybe 
only got four antral follicles or something. And then they come round to start 
treatment. You scan them. They've only got two antral follicles. You might be like 
maybe should we just wait another month and see if you've got a few more next 
month? And then start stimulation then.” (Doctor 02). 
However the biggest limiting factor that was identified was the potential delay in starting treatment and 
how some women may find that unacceptable. The current long waiting lists in NHS results in women 
The ideal fertility research study 
Research question should be clinically relevant and likely to change practice. 
Rationale behind the study should be understood by all clinicians. 
Design should be simple and not resource intensive. 
Preferably multi-centred. 
Offer incentives for participants to take part 
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often taking more than a year from their initial consultation to starting treatment. Introducing further 
potential delays when they are about to start treatment could prove troublesome. 
“Whenever you go through a consent signing appointment, the patient feels that 
they want to start treatment now, if not yesterday and so having to continuously 
wait to be scanned in the early part of the cycle, am I gonna start, aren’t I gonna 
start, and to be told again second month, third month, no we’re not gonna go with 
this one, we’re gonna scan you again next month t could come up with some, erm, 
obstacles” (IVF Nurse 02). 
Participants felt that this could be partially offset by giving women clear timelines and a plan on the 
maximum time they may have to wait for to identify their optimum month to start treatment. 
“Have, having a timescale so it’s like, erm, five (follicles) might be your best but if we 
don’t see five (follicles) within four consecutive scanning cycles – we start treatment. 
Something like that would reassure” (IVF Nurse 02). 
One doctor felt that a small proportion of his patients with very busy life schedules, would place more 
importance on starting treatment when it fitted their lives rather than when it might be the optimum time 
to treat. 
“Yeah. And the other thing that makes it difficult to plan is a lot of people plan IVF 
around their life and their career, like if they're going on holiday. A typical example 
is teachers, isn't it, who would rather have it over their summer holidays or 
whatever rather than in term time. Things like that that you might not necessarily 
think about when you're just thinking purely medically about what's going to give 
them the best response. Sometimes people time their IVF to what suits the rest of 
their life, so those people will be harder to recruit or to put off.” (Doctor 08) 
Others identified practical issues that might be created by the study, such as their departments currently 
not routinely performing AFC and therefore not having the right people with the right skills. 
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“You have a variety of scanning skills. We’ve got new scanners that are, are 
learning, we’ve got some very experienced scanners. We’re just about to change 
the way that we’re doing our scan clinic so I, I’m not sure if you can always 
guarantee that you’re gonna have a, erm, a skilled practitioner able to do specific 
scans.” (IVF Nurse 04). 
Uncertainty of when a particular woman will be starting her treatment could also be problematic for 
departments, as often there are long waiting lists and decision on who starts treatment is made months in 
advance. 
“If you are talking about one or two women a month, in the trial idea you talked 
about, we can just about cope. Anything more than that will be difficult. At the 
moment we have a four month wait from signing consent to starting down reg and 
I can’t justify it” (Doctor 01). 
The one doctor who said they did not like the concept of this study, gave their previous 
negative experience, and their belief that varying the way women with low ovarian 
reserve are treated does not change outcome, as the reason for rejecting this study. 
“Personal experience, poor responders who do not want to give the time. You want 
to get on with it. Secondly, whatever follicle you use, whatever dose of medication 
you give, it doesn't seem to make much difference. Honestly, I think it will be a little 
bit negative consultation to start with because I'm wasting patients’ time. I am 
sceptical.” (Doctor 15) 
Discussion	
Principle	findings	
Our study shows that clinicians find consultations with women with low ovarian reserve difficult. They 
often compare those to consultations where they had to break bad news such as conveying a cancer 
diagnosis. Clinicians found these consultations particularly stressful because of the perceived high 
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expectations of the women. Ovarian reserve tests such as AMH and AFC are often performed at a later 
stage of the woman’s fertility treatment, which often meant unexpectedly low results needing change of 
treatment plans, causing distress to women. Clinicians find treating women with low ovarian reserve 
difficult because of the lack of acceptable alternative treatment options. Women often find the idea of 
using donor eggs unpalatable at the onset. However, after having then had few unsuccessful attempts to 
have IVF treatment with their own eggs, they become more accepting of donor eggs. Younger women 
and women from certain cultural and religious background tend to find the concept of donor eggs 
unacceptable.  
 Reproductive practitioners felt a strong affinity towards research. Their ideal research should be 
designed to centre around a clinically relevant research question, should be simple in its design, should 
not be resource intensive, should be multi-centred and should have the potential to make changes to 
clinical practice. They felt that research projects which were easier to understand and explain and offered 
some sort of additional incentive to the participant were the easiest to recruit to. It was universally felt 
that clinicians with an established prior relationship with the participant were better placed to recruit to 
studies in comparison to designated research staff who had never met the woman before. 
Clinicians found the concept of a research study based on scanning for consecutive months and 
identifying the optimum cycle for women with low ovarian reserve appealing and most were positive 
about wanting to be part of such study if offered. However they did have some issues for consideration, 
including the additional burden posed by delaying the onset of treatment, need for the availability of 
sonographers with the requisite training to perform AFC, and the uncertainty created by not knowing 
exactly when these women might start their treatment and the resource implications resulting from that. 
It was also expressed that some women would value knowing exactly when their treatment starts more 
than any potential clinical benefit brought by delaying treatment, and for these women this study might 
not be suitable. 
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Comparison	with	existing	literature	
There are very few published literature exploring how clinicians find treating women with fertility issues. 
There are no published papers to our knowledge exploring clinician’s experience of treating women with 
low ovarian reserve. Universally all clinicians interviewed considered their consultations with women 
with low ovarian reserve difficult, often due to having to break bad news and being unable to meet the 
high expectations of patients. This supports the findings of Boivin et al., whose study of IVF clinicians 
identified these two factors amongst some of the top stressors for the profession (249). The denial of the 
diagnosis of low ovarian reserve and the expectations of women for treatment to succeed even against 
the odds reported in our study, is similar to the findings of Peddie et al., who explored the decision 
making process of women with subfertility (250). The reluctance of acceptance of egg donation amongst 
some cultural backgrounds such as Muslim women has been reported in literature (251). Complex 
reasons have been cited for this reluctance, including interpretation of religious rulings and strong 
cultural emphasis on kinship and lineage (252). 
Our finding of clinicians preferring research studies with a simple design over complex designs resonates 
with the findings of Thoma et al., who studied the research preferences of practising surgeons (253). The 
Cochrane review by Mapstone et al., supports our finding that there is a higher recruitment rate for studies 
which incentivise participants (254). However such incentives should be deployed with care to avoid 
ethical pitfalls such as coercion and exploitation, as cautioned in the published review by Tishler et al., 
(255). The cultural difference in accepting the diagnosis of subfertility and the perceived stigma 
surrounding gamete donation has been previously reported by Culley et al., (256). 
Strengths	and	limitations	
This study has multiple strengths. This study followed a validated qualitative research methodology and 
with its purposive sampling design, it was set to capture a wide range of clinician views. Clinicians were 
sampled from multiple locations across the UK, and from a range of different professionals such as 
doctors, nurses and embryologists were included, ensuring adequate representation and generalisability 
of findings. Sampling was continued until saturation of data was reached, increasing the likelihood that 
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majority of the key themes were captured. All interviews were recorded and transcribed, with 10% of the 
interviews being coded by two researchers independently, ensuring reproducibility. 
The study is limited by the weaknesses of its chosen methodology. Whilst purposive sampling is 
considered best suited to reach saturation efficiently, it relies on the judgement of the investigator in 
selecting samples. Therefore the impact of conscious and unconscious bias on the selection of subjects 
cannot be excluded. Transcripts were not returned to interviewers to verify, which can pose some 
questions about the validity of data. All interviews were conducted by the same researcher. Thus any bias 
or assumptions introduced by the interviewer’s questions or questioning style could not be eliminated. 
Implications	of	findings	
Young women and women from certain ethnic and religious backgrounds can find both the diagnosis of 
low ovarian reserve and the concept of egg donation difficult to accept. Therefore fertility centres may 
benefit from commissioning counsellors with expertise in catering for the needs of this specific 
population. Working with community leaders and religious elders to eliminate the stigma attached to 
fertility problems may also prove to be beneficial. Clinicians reported that ovarian reserve tests are 
performed after the patient and the clinician had committed to a particular treatment option, with the 
consequent change of treatment plans causing patients distress. Therefore it will be prudent to perform 
these tests early in the patient journey to better manage expectations. Our study reported perceived 
difficulties in the diagnosis of low ovarian reserve being conveyed to patients at routine fertility clinics, 
where the clinicians had considerable time constraints. Seeing these women at a dedicated appointment 
with the support of staff trained in counselling could alleviate some of the distress expressed. Some of 
the difficulties in consultations arose from perceived unrealistic expectations from women, and particular 
poor awareness of age related decline in fertility. Further research into finding ways to successfully 
convey to the wider population the success rates of IVF and about how this might be impaired by age 
related decline in ovarian reserve may be warranted. 
Our study showed enthusiasm among IVF clinicians to participate in research. To increase engagement 
with clinicians, those planning research studies should make them simple in design, not very onerous and 
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multi-centred. Researchers should also place efforts to engage with not only the principle investigators, 
but all frontline clinical staff and ensure that they have a good understanding of the underlying rationale 
for the research project. A partnership model, with the clinician know to the patient taking the lead in 
recruitment, supported by dedicated research staff for administration and follow-up, is likely to enhance 
recruitment.  
With regards to a hypothetical study identifying the optimum month to start IVF based on AFC, efforts 
should be made to recruit women at an early stage of their patient journey, ideally at the very first 
outpatient clinic appointment, to offset any delay caused by serial scanning. Clear communication of the 
protocol, and deploying the shortest maximum duration for which a woman might have to wait for to 
identify the optimum month to start her IVF treatment, would also help to allay some of the clinician and 
participant anxiety. A multi-centred approach would also be recommended, so that the number of women 
who may potentially start their IVF treatment at any given month could be restricted to small numbers, 
reducing resource allocation concerns borne by the uncertainty of when a women might start her IVF 
treatment. Researchers should also either restrict the selection of centres to ones where most sonographers 
and clinicians  have the expertise in performing AFC, or make provisions to ensure adequate training is 
made available prior to commencing the study. 
Clinicians also identified the role of additional incentives for participating in research and how this might 
encourage participants to take part. This has ethical implications. There is a plethora of published 
literature of the pitfalls of actual or perceived  coercion in research(257,258). Care needs to be taken to 
ensure that research study designs are scrutinised to exclude intended or unintended coercion and 
research recruiters are trained to identify such coercive factors and ensure that they play no part in 
recruiting. 
Conclusion	
Clinicians find consultations treating women with low ovarian reserve difficult. The acceptability of 
donor egg IVF is low, particularly amongst young women and those from certain cultural and ethnic 
background. There is considerable enthusiasm to participate in research amongst IVF clinicians. 
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Participation in research could be encouraged further by ensuring the design of the study meets the 
recommendations made in this article. 
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Chapter	eight:	Conclusion	to	thesis	
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In chapter two of this thesis, I shared the results of a systematic review of published studies, studying the 
menstrual cycle to menstrual cycle variation in the ovarian reserve tests of AFC, AMH and FSH. The 
method of reporting inter-cycle variability in the constituent studies were heterogeneous in nature, leading 
to a narrative synthesis. This review demonstrated that there is an inter-cycle variation in ovarian reserve 
tests. 
In chapter three of this thesis, I shared the results of a systematic review and meta-analysis I carried out. 
In this study, I studied the relationship between AFC, AMH, FSH and pregnancy loss. This study showed 
a statistically significant association between reduced ovarian reserve (low AFC, low AMH and high FSH) 
and increased chance of pregnancy loss.  
In chapter four of this thesis, I shared the findings of a large cohort study I carried out, analysing the data 
set of a large IVF provider. I studied the relationship between AFC, and important reproductive outcomes 
such as live birth and pregnancy loss. This study showed a positive association between AFC and live 
birth rate and a negative association between AFC and pregnancy loss. 
Using chapters three and four, I have demonstrated a strong association between the ovarian reserve tests 
and reproductive outcomes. Chapter two showed the existence of inter-cycle variation in ovarian reserve 
tests, which may have clinical significance. This is because, as I described in my illustrative example 
(chapter one), a woman with a low ovarian reserve might have an AFC of four one month and seven in 
another. In such woman, the first month, where there was only an AFC of four, there could be a low 
ovarian response, resulting in fewer eggs (for example four eggs). This would result in fewer fertilised 
eggs (for example two eggs), further leading to only one embryo suitable for implantation. This could be 
contrasted with another month in the same woman, where there was an AFC of seven and therefore where 
she may have a better ovarian response. This would lead to more eggs (for example seven eggs), and more 
fertilised eggs (for example four fertilised eggs) resulting in two or three embryos which were suitable for 
implantation. The clinical impact of inter-cycle variation is only likely to be of importance in women with 
low ovarian reserve, as an increase from one embryo to three embryos to choose from has the potential to 
improve a woman’s reproductive outcome, whilst an increase from ten to 14 is unlikely result in a different 
clinical outcome. 
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The next logical question that therefore arises is whether there is cycle to cycle variation in ovarian reserve 
tests in women with low ovarian reserve.. There are no published research papers studying this subset of 
women. Thus, I carried out a prospective cohort study, recruiting women with at least one know risk factor 
for low ovarian reserve. The results of this study are conveyed in chapter five of this thesis. Over three 
consecutive menstrual cycles at the early follicular phase, I took blood tests for AFC and AMH and 
undertook transvaginal ultrasound scans for AFC.. The mean AFC Max variation, AMH Max variation 
and FSH Max variation were 3.87, 9.61 pmol/L and 6.48 IU/ml respectively. When analysis was restricted 
to women who we deemed to have low ovarian reserve (AFC of 10 or less, AMH of 5.5 pmol/L or less or 
FSH of 8.9 IU/ml or more for one or more measurements), the mean AFC Max variation, AMH Max 
variation and FSH Max variation were 2.4, 1.2 pmol/L and 3.8 IU/ml respectively. This establishes that in 
women with low ovarian reserve, there is variation in ovarian reserve tests between menstrual cycles. 
Amongst the three ovarian reserve tests, AFC emerged as the test with the most likely significant inter-
cycle variation, as even when the analyses was restricted to women with proven low ovarian reserve, there 
was a maximum inter-cycle variation of 2.4 follicles.  
The next step in the research journey to improve reproductive outcomes in women with low ovarian 
reserve would be to test the hypothesis that starting IVF treatment on the month with the highest AFC for 
a particular individual would result in better reproductive outcomes. However, before conducting such a 
study, one needs to assess the acceptability of such treatment and research amongst the key stakeholders. 
In chapter six, I describe a qualitative study with purposive sampling (maximum variation method), which 
I conducted to study women with low ovarian reserve. The thematic analysis showed that women with 
low ovarian reserve have a strong desire to take part in research, even when it may not be of direct benefit 
to them. They found the concept of an antral follicle count based IVF treatment intuitively appealing and 
if offered would be keen to have it. They also found the concept of taking part in a research study to 
establish that choosing the optimum month to start IVF treatment based on AFC agreeable. However they 
had some reservations about taking part in a randomised controlled trial, as they felt uncomfortable with 
the role chance plays in determining their treatment. They also had concerns about any increase in the time 
it might take to receive treatment as a result of taking part in the study. This study offered further insight 
into women with low ovarian reserve. It highlighted their lack of awareness of age related decline in 
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fertility in the early part of their lives, the perceived impact of negative discrimination towards women 
who become pregnant at workplace has on delaying conception and the need for awareness of age related 
fertility decline in the general population. 
In chapter seven of this thesis, I shared the results of a qualitative study with purposive expert sampling 
of fertility clinicians, including doctors, nurses and embryologists. The thematic analysis shows a strong 
desire to support and participate in clinical research. Clinicians found the concept of using serial 
measurements of AFC to identify the best month to start IVF treatment agreeable. They also expressed 
interest in recruiting for such study and felt that the population they treat would find it acceptable. They 
expressed preference for a study which is multi-centred, not very resource intensive and offered some sort 
of incentive for women to take part in. They cautioned that any delay to start of the treatment should be 
kept to a minimum for it to be acceptable to participants and clinicians. Practical considerations were also 
mentioned, such as training of people with the expertise to conduct AFC and keeping number of women 
who were undergoing ultrasound scans to a minimum.   
This study of clinicians also provides a number of interesting observations, including that IVF clinicians 
found the consultations with women with low ovarian reserve difficult, due to the limited acceptable 
alternatives available and the low success rate of IVF in this cohort. They observed cultural differences in 
women, with a high prevalence of stigma attached to being infertile in certain ethnic groups and low 
acceptability of egg donation in some cultural and religious groups. It was also noted that some women 
were unaware of the scale of age related fertility decline. For some women, it was observed that there was 
an incorrect assessment of their fertility potential and unrealistic expectation of the ability of IVF to 
achieve conception. Some clinicians called for a public campaign to increase awareness. 
Implications	for	future	practice	
There are a number of clinical observations that can be made from the findings of my thesis. Firstly, my 
work establishes cycle to cycle variation in ovarian reserve tests, in both the overall population of women 
with subfertility and in women with low ovarian reserve. Therefore, clinicians should exercise caution 
when using ovarian reserve test measurements in a single menstrual cycle to make a clinical diagnosis and 
decisions about whether to proceed with IVF treatment or not. Our study shows ovarian reserve tests are 
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often performed at a late stage of the patient journey, after both the patient and clinician have committed 
to proceed with treatment. At this stage, clinicians find it difficult to discuss abandoning treatment or 
considering alternatives such as egg donation. As such, clinicians should consider requesting these 
investigations as early as feasible.  
My thesis also establishes the relationship between ovarian reserve tests and pregnancy loss in women 
having IVF treatments. As pregnancy loss is associated with significant psychological morbidity for both 
partners, women with low ovarian reserve should be thoroughly counselled about their higher risk of 
pregnancy loss prior to commencing IVF treatment. Our qualitative study also showed that many clinicians 
felt that they were supporting women with low ovarian reserve in suboptimal conditions. Therefore care 
providers should make every effort to ensure that women with low ovarian reserve can be seen at a clinic 
with longer appointment windows and by staff with training on counselling. 
Implication	for	public	policy	
This thesis shows that there is a strong lack of awareness of age related decline in ovarian reserve amongst 
women. There was a sense of being let down by society amongst many of the women interviewed. 
Therefore it may be important for policy makers to look at addressing this, perhaps by introducing this as 
part of the national curriculum of education.  
Cultural and religious stigma of being infertile and accepting egg donation was reported by participants. 
Clinicians had also reported a shortage of eggs donated by ethnic minority women. Whilst some 
assumptions have been made about why some cultural and religious groups may have negative attitudes 
to certain aspects of fertility treatments, in general this area is poorly understood. Policy makers need to 
carry out further qualitative research involving participants from these communities to gain further 
understanding in this issue. Policy makers should consider suitable strategies to engage with community 
leaders and identify solutions to eradicate stigma and improve the community support for women. 
Gender discrimination and pressures in workplace to not conceive were reported as reasons for delaying 
conception. This issue needs addressing to stop women having to choose between a career and starting a 
family. This fits in with the wider gender pay gap research which is taking place in the UK. 
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In the introduction of this thesis I shared some of the evidence showing the psychological, emotional and 
social costs of infertility. The qualitative research I carried out also demonstrated the wddwctof infertility 
on women’s wellbeing. The single biggest barrier for accessing fertility treatment in the UK is it’s 
prohibitive cost. There is also variation in what is funded in the UK, with some healthcare authorities 
funding multiple IVF treatment cycles whilst others have stopped funding entirely. This is often described 
as ‘postcode lottery’. Such healthcare inequalities, especially within the same country, is inherently unfair. 
Policy makers should engage with relevant stakeholders including political leaders to end such postcode 
lottery. 
Implications	for	research	
My thesis establishes the relationship between low ovarian reserve and pregnancy loss in women who 
have assisted conception. Further research is needed to see if such a relationship exists in women who 
conceive naturally. 
In my thesis, I have shown that inter-cycle variation exists between ovarian reserve tests. I have shown 
that this variation is preserved in women with low ovarian reserve, best demonstrated with AFC. I have 
shown that from cohort data, incremental increases in AFC results in higher live birth rate and lower 
pregnancy loss rate. I have shown that an IVF treatment protocol based on serial ultrasound scans being 
performed to establish the optimal month to start IVF treatment, is acceptable to most clinicians and 
women with low ovarian reserve. I recommend a study of women who have serial AFC measurements to 
identify and start treatment on an optimum month, and establish whether such an intervention results in 
better IVF outcomes. If such treatment protocol is proven to yield better reproductive outcomes, a cost-
benefit analysis should be conducted. Currently in the UK, many clinical commissioning groups fund more 
than one cycle of IVF treatment. If it can be shown that the additional cost of serial ultrasound scans could 
be recuperated from the money saved from funding additional cycles, an AFC based treatment protocol 
could be introduced universally. 
An extended longitudinal study of serial ultrasound scans and blood tests over many consecutive menstrual 
cycles could help to identify the intercycle variation better. Such a study could be used to develop 
algorithms which could predict a woman’s reproductive potential. For instance, it is conceivable where a 
173 
 
woman undergoes repeated ovarian reserve testing over a defined period of time, an algorithm could be 
created to estimate her reproductive lifespan. This could enable couples to make informed choices about 
starting a family. This could be particularly helpful for those with a family history of early menopause. 
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Appendix 1 
 
 
Prof Arri Coomarasamy  
Professor of Gynaecology Email: hra.approval@nhs.net  
University of Birmingham  
Academic Unit, 3rd Floor Birmingham Women's Hospital  
Foundation Trust  
Mindelsohn Way  
Edgbaston  
B15 2TG 
 
22 November 2016 
 
Dear Professor Coomarasamy,  
  Letter of HRA Approval  
    
Study title: Intercycle variation in AFC, AMH and FSH in predicted poor 
 Responders 
IRAS project ID: 204528  
REC reference: 16/NS/0104 
Sponsor University of Birmingham  
 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the 
basis described in the application form, protocol, supporting documentation and any clarifications 
noted in this letter. 
 
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS organisations in England. 
 
 
Appendix B provides important information for sponsors and participating NHS organisations in 
England for arranging and confirming capacity and capability. Please read Appendix B carefully, in 
particular the following sections:  
• Participating NHS organisations in England – this clarifies the types of participating organisations in 
the study and whether or not all organisations will be undertaking the same activities  
• Confirmation of capacity and capability - this confirms whether or not each type of participating NHS 
organisation in England is expected to give formal confirmation of capacity and capability. Where 
formal confirmation is not expected, the section also provides details on the time limit given to 
participating organisations to opt out of the study, or request additional time, before their participation is 
assumed.  
• Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment  
criteria) - this provides detail on the form of agreement to be used in the study to confirm 
capacity and capability, where applicable.  
Further information on funding, HR processes, and compliance with HRA criteria and standards is also 
provided. 
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IRAS project ID 204528 
  
It is critical that you involve both the research management function (e.g. R&D office) supporting each 
organisation and the local research team (where there is one) in setting up your study. Contact details 
and further information about working with the research management function for each organisation 
can be accessed from www.hra.nhs.uk/hra-approval. 
 
 
Appendices  
The HRA Approval letter contains the following appendices:  
• A – List of documents reviewed during HRA assessment  
• B – Summary of HRA assessment 
 
After HRA Approval 
 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your 
REC favourable opinion, gives detailed guidance on reporting expectations for studies, including:  
• Registration of research  
• Notifying amendments  
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, and is updated in the light of changes 
in reporting expectations or procedures. 
 
 
In addition to the guidance in the above, please note the following: 
 
• HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA.  
  Substantial amendments should be submitted directly to the Research Ethics Committee, as detailed 
in the After Ethical Review document. Non-substantial amendments should be submitted for review 
by the HRA using the form provided on the HRA website, and emailed to hra.amendments@nhs.net.  
  The HRA will categorise amendments (substantial and non-substantial) and issue confirmation of 
continued HRA Approval. Further details can be found on the HRA website. 
 
 
Scope  
HRA Approval provides an approval for research involving patients or staff in NHS organisations in 
England. 
 
 
If your study involves NHS organisations in other countries in the UK, please contact the relevant 
national coordinating functions for support and advice. Further information can be found at 
http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/. 
 
 
If there are participating non-NHS organisations, local agreement should be obtained in accordance 
with the procedures of the local participating non-NHS organisation. 
 
 
User Feedback 
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The Health Research Authority is continually striving to provide a high quality service to all applicants and 
sponsors. You are invited to give your view of the service you have received and the application 
procedure. If you wish to make your views known please email the HRA at hra.approval@nhs.net. 
Additionally, one of our staff would be happy to call and discuss your experience of HRA Approval. 
 
HRA Training 
 
We are pleased to welcome researchers and research management staff at our training days – see 
details at http://www.hra.nhs.uk/hra-training/ 
 
 
Your IRAS project ID is 204528. Please quote this on all correspondence. 
 
 
Yours sincerely, 
 
Steph Blacklock  
Senior Assessor 
 
Email: hra.approval@nhs.net 
 
 
 
 
 
Copy to: Dr Sean Jennings, Sponsor contact 
 Mrs Kelly Hard, Birmingham Women's Hospital, Lead R&D Contact 
 Dr Bala Karunakaran, Student 
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Appendix A - List of Documents 
 
 
The final document set assessed and approved by HRA Approval is listed below. 
 
 
Document Version Date 
Covering letter on headed paper [Response to Provisional Opinion]  22 September 2016 
    
GP/consultant information sheets or letters [GP letter] 1.0 01 September 2016 
    
Interview schedules or topic guides for participants [INCA interview] 1.1 22 September 2016 
    
IRAS Application Form 204528/1003 01 September 2016 
 284/37/747   
Letter from sponsor  31 August 2016 
    
Other [Insurance Certificate]  28 July 2016 
    
Other [University Peer Review] * date 05 September 2016 
 received   
Other [Dr Chu Peer Review]  01 July 2016 
    
Other [HRA schedule event] 1.1 22 November 206 
    
Other [statement of activities] 1.0 22 November 2016 
    
Participant consent form 1.1 09 August 2016 
    
Participant information sheet (PIS) 1.2 22 September 2016 
    
Research protocol or project proposal [INCA protocol] 1.3 20 November 2016 
    
Summary CV for Chief Investigator (CI) [Arri Coomarasamy]  01 September 2016 
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Appendix B - Summary of HRA Assessment 
 
 
This appendix provides assurance to you, the sponsor and the NHS in England that the study, as 
reviewed for HRA Approval, is compliant with relevant standards. It also provides information and 
clarification, where appropriate, to participating NHS organisations in England to assist in assessing 
and arranging capacity and capability. 
 
For information on how the sponsor should be working with participating NHS organisations in 
England, please refer to the, participating NHS organisations, capacity and capability and 
Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) sections in this appendix. 
 
The following person is the sponsor contact for the purpose of addressing participating 
organisation questions relating to the study: 
 
Dr Bala Karunakaran  
  
 
HRA assessment criteria 
 
Section HRA Assessment Criteria Compliant with Comments 
  Standards  
    
1.1 IRAS application completed Yes No comments 
 correctly   
    
    
2.1 Participant information/consent Yes No comments 
 documents and consent   
 process   
    
    
3.1 Protocol assessment Yes Protocol has been updated to V1.3 in 
   order to comply with HRA standards. 
    
    
4.1 Allocation of responsibilities Yes Statement of Activities and Schedule of 
 and rights are agreed and  Events have been provided by sponsor 
 documented  for use with the participating 
   organisation. 
    
4.2 Insurance/indemnity Yes Where applicable, independent 
 arrangements assessed  contractors (e.g. General Practitioners) 
   should ensure that the professional 
   indemnity provided by their medical 
   defence organisation covers the 
   activities expected of them for this 
   research study 
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Section HRA Assessment Criteria Compliant with  Comments 
  Standards    
    
4.3 Financial arrangements Yes There is no external funding acquired 
 assessed  for the study and as per the Statement 
   of Activities there are no funds available 
   for the participating organisation. 
     
      
5.1 Compliance with the Data Yes No comments  
 Protection Act and data     
 security issues assessed     
     
5.2 CTIMPS – Arrangements for Not Applicable Not Applicable  
 compliance with the Clinical     
 Trials Regulations assessed     
    
5.3 Compliance with any Yes Study complies with the Human Tissue 
 applicable laws or regulations  Act.  
     
     
6.1 NHS Research Ethics Yes No comments  
 Committee favourable opinion     
 received for applicable studies     
     
6.2 CTIMPS – Clinical Trials Not Applicable Not Applicable  
 Authorisation (CTA) letter     
 received     
     
6.3 Devices – MHRA notice of no Not Applicable Not Applicable  
 objection received     
     
6.4 Other regulatory approvals Not Applicable Not Applicable  
 and authorisations received     
      
 
 
Participating NHS Organisations in England  
 
This provides detail on the types of participating NHS organisations in the study and a statement as to 
whether the activities at all organisations are the same or different.   
This is a single site, basic science, student study with one site type. The aim of the study is to see 
whether variability in the number of follicles in the ovary exists and if so whether this can be exploited 
to improve fertility treatment for women. Study also aims to look at how acceptable such treatment 
will be for women and the cost effectiveness. Participants will undergo blood tests and interview. 
 
The Chief Investigator or sponsor should share relevant study documents with participating NHS 
organisations in England in order to put arrangements in place to deliver the study. The documents 
should be sent to both the local study team, where applicable, and the office providing the research 
management function at the participating organisation. For NIHR CRN Portfolio studies, the Local 
LCRN contact should also be copied into this correspondence. For further guidance on working with   
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participating NHS organisations please see the HRA website. 
 
If chief investigators, sponsors or principal investigators are asked to complete site level forms for 
participating NHS organisations in England which are not provided in IRAS or on the HRA website, 
the chief investigator, sponsor or principal investigator should notify the HRA immediately at 
hra.approval@nhs.net. The HRA will work with these organisations to achieve a consistent 
approach to information provision.  
 
 
Confirmation of Capacity and Capability  
 
This describes whether formal confirmation of capacity and capability is expected from participating 
NHS organisations in England. 
 
Participating NHS organisations in England that are recruiting participants and taking blood samples will 
be expected to formally confirm their capacity and capability to host this research. 
 
• Following issue of this letter, participating NHS organisations in England may now confirm to the 
sponsor their capacity and capability to host this research, when ready to do so. How capacity 
and capacity will be confirmed is detailed in the Allocation of responsibilities and rights are 
agreed and documented (4.1 of HRA assessment criteria) section of this appendix.  
  The Assessing, Arranging, and Confirming document on the HRA website provides further 
information for the sponsor and NHS organisations on assessing, arranging and 
confirming capacity and capability.  
 
 
 
Principal Investigator Suitability  
 
This confirms whether the sponsor position on whether a PI, LC or neither should be in place is correct for each 
type of participating NHS organisation in England and the minimum expectations for education, training and 
experience that PIs should meet (where applicable).  
Principal Investigator identified and listed in IRAS Part C. 
 
GCP training is not a generic training expectation, in line with the HRA statement on training 
expectations. 
 
 
HR Good Practice Resource Pack Expectations  
 
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement 
checks that should and should not be undertaken 
 
All staff have either full or honorary contracts with the participating organisation and therefore 
no further HR accesses are required. 
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Other Information to Aid Study Set-up   
This details any other information that may be helpful to sponsors and participating NHS 
organisations in England to aid study set-up. 
 
• The applicant has indicated that they do not intend to apply for inclusion on the 
NIHR CRN Portfolio.  
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PATIENT INFORMATION SHEET 
Inter Cycle Variation in Antral Follicle Count (INCA1) Study  
 
Thank you for reading this leaflet. 
 
We would like to invite you to take part in a study to investigate the monthly difference in 
fertility markers. We will be looking at the Antral Follicle Count (AFC), which looks at the 
structures in your ovary that can potentially release eggs. In addition we will be looking at 
two different hormones in your blood. These hormones are linked to fertility and are known 
as Anti-mullerian Hormone (AMH) and Follicle Stimulating Hormone.  
 Before you decide whether to take part we would like you to understand why the research is 
being done and what it will involve. Please take time to read this information leaflet. .One of 
our team will go through the information sheet with you and answer any questions that you 
have. 
 
What is the purpose of the study? 
 
The aim of the study is to improve fertility treatments by looking at monthly changes in 
fertility markers. The information obtained from this study will be useful to determine how 
we can personalise treatments to benefit women trying to get pregnant. The information 
gathered will help us understand your perspective better and help us to tailor treatments to 
meet your needs. 
 
Why have I been invited? 
 
Understanding how ovaries and hormones vary between monthly cycles may give us the 
crucial information to provide more targeted and personalised treatments to women who are 
trying to get pregnant. You have been invited to take part as you have been referred to our 
clinic with difficulties in trying to conceive and we have identified you to have one of the risk 
factors for infertility that we are studying. 
 
Do I have to take part? 
 
It is up to you to decide if you want to participate in this study. If you agree to take part we 
will request you to sign a written consent form. You are entitled to withdraw from the study 
at any time, without having to give a reason. Your choice will not affect the standard of your 
medical care in any way. 
 
 
 
 
 
Appendix 2 
184 
 
What will happen if I choose to take part? 
 
You will be asked to sign a consent form. With your consent we will inform your GP that you 
are participating in this study. You will be given a dedicated telephone number to contact the 
research team on. You will need to contact us on the first day of your menstrual cycle (first 
day of bleeding). We will then arrange to see you in the clinic between the first and fourth 
day of your menstrual cycle. At this appointment we will perform an internal vaginal 
ultrasound scan. During this visit, we will also take approximately 10ml or 2 tablespoon of 
blood to check your hormone levels. The above explained procedure will be repeated for 
three consecutive menstrual cycles. We will share the information with you and at your 
request we will be happy to share these with your GP or any other healthcare provider. 
During these investigations if we discover something that needs urgent attention, such as a 
large ovarian cyst, we will pass the information on to the relevant healthcare team, only with 
your permission. We plan to also conduct a interview to better understand  your views about 
the study and cater your treatment plan to your needs. If you proceed to have fertility 
treatment at Birmingham Women’s and Children’s NHS Foundation Trust, we would also 
review your patient notes at a later date to collect information. 
Please be ensured that we will always maintain all information collected in the study will 
remain strictly confidential in the same way as your other medical records  
 
What are the disadvantages of participating in the study? 
 
Apart the inconvenience of having blood tests and internal ultrasound scans, there is no 
disadvantage of participating in this study. Your fertility treatment will not be delayed by you 
taking part in this study. 
 
 
What benefits can come from participating in the study? 
 
If you choose to participate in this study, you will receive extra scans and blood tests 
(normally patients would have only had one set of these). These may help you and your 
clinicians to better understand and plan the treatment you require . 
 
Who has reviewed this study? 
 
This study has been peer reviewed for scientific validity by the University of Birmingham. 
The North of Scotland (1) Research Ethics Committee has reviewed this study. 
 
 
For further information 
 
You can discuss the details of this study with: 
 
Prof. Arri Coomarasamy (Consultant Obstetrician and Gynaecologist),  
Dr. Bala Karunakaran (Clinical Research Fellow) 
 
Contact:   
Email:  
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Alternatively you can discuss participation with: 
PALS (Patient advice and liaison service) 
You can talk to PALS who provide confidential advice and support to patients, families and 
their carers, and can provide information on the NHS and health related matters. 
PALS is a "confidential, friendly listening service" for people who would like to comment on 
any aspect of their treatment. 
PALS is sited in the Front of House area of the hospital, you can leave a message in one of 
our suggestion boxes. 
Tel:  0121 627 2747 
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In Cycle Antral Follicle Count (INCA) Study 
Participant Consent Form 
 
 
I confirm that I have read and understand the information sheet (v1.0, 25/07/2016) 
for the above study.  I have had the opportunity to consider the information, ask 
questions and these have been answered satisfactorily.     
    
I understand that my participation is voluntary and that if I take part, I am free to 
withdraw at any time, without giving a reason, and without my treatment being 
affected.       
 
I understand what is involved in the study and will be happy have extra blood tests 
and transvaginal ultrasound scans. 
 
 
I understand that my results as well as my patient records will be viewed by the 
research team, who are outside of my direct care team as well as my direct care 
team and that all clinical information will be kept confidential.		
 
I understand that my General Practitioner or any other healthcare providers will only 
be notified of my participation and results with my consent. 
 
I understand that the research team may wish to contact me in order to gather further 
information if required. 
 
 
I understand that relevant data collected during the study, may be looked at by 
individuals from the Birmingham Women’s and Children’s NHS Foundation Trust, the 
University of Birmingham, from regulatory authorities or from the NHS Trust, where it 
is relevant to my taking part in this research. I give permission for these individuals to 
have access to this data.	 
 
I agree to participate in the study.   
 
…………………………………. ……………  ………………………….. 
Name of Patient   Date   Signature 
 
…………………………………. ……………  ………………………….. 
Name of Person taking consent Date   Signature 
 
Trial Number ………………….
Please initial each 
box to confirm 
consent 
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INCA Interview Guide 
Experiences of women 
 
 
 
1. (i) How do you 
feel about subfertility? 
 
(ii) How does it affect your day to day life? 
             (iii)Awareness of age related decline in ovarian reserve and their views about it? 
(iv)Views of decisions around family planning and decision on when to conceive? 
(v) Other views and observations 
      2. Views on Medical Trials [General] 
          (2a) What do you think about medical trials… 
               (i)for individuals? 
              (ii) for medical science?  
         (2b) What do you think about randomisation?  
             (i)Understandings of randomisation/ how treatment is allocated  
            (ii)Is randomisation acceptable to you? 
            (iii) Is the possibility of not getting treatment acceptable? 
 Check 
Informed Consent Obtained  
Participant’s Questions Answered  
Consent to Record Obtained  
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      3. Views on Participation in a future RCT 
 (3a) How do you feel about the trial? Is it a necessary/worthy trial? Why? Why not?  
• NB: Expand into an open-ended discussion about the trial 
            (i)Hopes for the trial 
            (ii) Concerns about the trial 
(3b) What would motivate/motivated you to take part in the trial?  
         (i) What would you hope to get out of participating in the trial?  
(3d) Trial factors? 
        (i) Concerns about treatment availability  
        (ii)Concerns about treatment choice and randomisation 
4. Experiences of INCA study 
(4a) How did you feel about having serial ultrasound scans and blood tests? 
(4b) What were the positive experiences? 
(4c) What were the negative experiences? 
5. Concluding Questions 
(5a) Is there anything else we didn’t discuss that you would like to talk about?  
(5b) Do you have questions for me? 
Thank participant 
• Reinforce how valuable their participation has been 
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Interview Guide 
Clinicians 
 
-  
Check  
Consent for interview  
Consent to be recorded  
 Record gender, profession, and 
sector 
 
 
 
 
1. (i) How do you feel treating patients with low ovarian reserve? 
2.  
(ii) How do you feel about consultations with women with low ovarian reserve? 
             (iii)What do you think about the awareness of age related decline in ovarian resrve    
                  amongst women? 
(iv)  Are there currently enough treatment options for women with low ovarian reserve? 
(v) Are women with low ovarian reserve have their needs catered for where you work? 
      2. Views on Medical Trials [General] 
          (2a) What do you think about medical trials… 
               (i)for individuals? 
              (ii) for medical science?  
         (2b) What do you think about randomisation?  
             (i)Understandings of randomisation/ how treatment is allocated  
            (ii)Is randomisation acceptable to you? 
            (iii) Is the possibility of not getting treatment acceptable? 
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      3. Views on Participation in a future RCT 
 (3a) How do you feel about the proposed study? Is it a necessary/worthy trial? Why? Why 
not?  
• NB: Expand into an open-ended discussion about the trial 
            (i)Hopes for the trial 
            (ii) Concerns about the trial 
(3b) What would motivate/motivated you to take part in the trial?  
         (i)What would you hope to get out of participating in the trial?  
(3d) Trial factors? 
        (i) Concerns about treatment availability  
        (ii)Concerns about treatment choice and randomisation 
4..Concluding Questions 
(5a) Is there anything else we didn’t discuss that you would like to talk about?  
(5b) Do you have questions for me? 
Thank participant 
• Reinforce how valuable their participation has been 
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Analysis using binomial regression and a generalised linear model 
 
 
AFC Thresholds  
0 =≤5  
1= 6-10 
2= 11-15 
3=16-20 
4=21-25 
5 =>/25 
 
Unadjusted live birth by AFC categories expressed as odds ratio. 
Calculated using binomial regression and generalised linear model. 
------------------------------------------------------------------------------ 
             |                
             | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        afc3 | 
          0  |   .4015642    .045656    -8.02   0.000     .3213492    .5018024 
          1  |   .5331628   .0398011    -8.42   0.000     .4605925    .6171671 
          2  |    .725376   .0501389    -4.64   0.000     .6334714    .8306141 
          3  |          1  (base) 
          4  |   .9595529   .0766739    -0.52   0.605     .8204516    1.122238 
          5  |   1.119551    .075853     1.67   0.096     .9803306    1.278544 
------------------------------------------------------------------------------ 
 
             | 
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Adjusted live birth by AFC categories expressed as odds ratio. 
Calculated using binomial regression and generalised linear model. 
------------------------------------------------------------------------------ 
             |                
                Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        | 
          0  |   .3661979   .0556958    -6.61   0.000     .2718034    .4933746 
          1  |     .65628   .0572456    -4.83   0.000     .5531476    .7786411 
          2  |   .7991591   .0646871    -2.77   0.006     .6819203    .9365541 
          3  |          1  (base) 
          4  |   .9006357   .0829536    -1.14   0.256     .7518804    1.078821 
          5  |   1.022202   .0806618     0.28   0.781     .8757267    1.193177 
             | 
         age |   .9140756   .0052646   -15.60   0.000     .9038153    .9244525 
         BMI |   1.006336   .0067396     0.94   0.346     .9932131    1.019633 
      ethnic |   .9589892   .0257223    -1.56   0.118     .9098767    1.010753 
       _cons |   11.67237   2.977057     9.63   0.000     7.080419    19.24241 
 
Unadjusted pregnancy loss by AFC categories expressed as odds ratio. 
Calculated using binomial regression and generalised linear model. 
-----------------------------------------------------------------------------|                
                Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        | 
          0  |   2.452394   .4005442     5.49   0.000     1.780596    3.377654 
          1  |   1.655043   .1942103     4.29   0.000     1.314999    2.083019 
          2  |   1.393445   .1531507     3.02   0.003     1.123404    1.728398 
          3  |          1  (base) 
          4  |   1.263697    .158512     1.87   0.062     .9882626    1.615896 
          5  |   1.033236   .1128486     0.30   0.765     .8341271    1.279872 
             | 
       _cons |   .2917342   .0247165   -14.54   0.000     .2470992    .3444318 
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Unadjusted early pregnancy loss by AFC categories expressed as odds ratio. 
Calculated using binomial regression and generalised linear model              
            | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        | 
          0  |     2.0588   .3672437     4.05   0.000     1.451373    2.920447 
          1  |   1.190305   .1607268     1.29   0.197     .9135255    1.550944 
          2  |    1.18598   .1473253     1.37   0.170     .9296921    1.512919 
          3  |          1  (base) 
          4  |   1.187876   .1669747     1.22   0.221     .9018229    1.564663 
          5  |   .9230527   .1143758    -0.65   0.518     .7240255    1.176791 
             | 
       _cons |   .2021116   .0191452   -16.88   0.000     .1678651    .2433448 
 
Adjusted early pregnancy loss by AFC categories expressed as odds ratio. 
Calculated using binomial regression and generalised linear model 
------------------------------------------------------------------------------ 
             |               Robust 
                Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         
          0  |   2.294793   .5198625     3.67   0.000     1.472016     3.57746 
          1  |   1.175154   .1829813     1.04   0.300     .8660755    1.594535 
          2  |   1.187467    .172063     1.19   0.236      .893888    1.577466 
          3  |          1  (base) 
          4  |   1.319734   .2149253     1.70   0.088     .9591003    1.815971 
          5  |   1.069305   .1538504     0.47   0.641      .806551    1.417659 
             | 
         age |   1.074915   .0122651     6.33   0.000     1.051143    1.099225 
         BMI |   1.005619   .0117067     0.48   0.630     .9829344    1.028828 
      ethnic |    .968652   .0488965    -0.63   0.528     .8774049    1.069389 
       _cons |   .0138957   .0068258    -8.71   0.000     .0053058     .036392 
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Unadjusted late pregnancy loss by AFC categories expressed as odds ratio. 
Calculated using binomial regression and generalised linear model. 
------------------------------------------------------------------------------ 
             |                
                Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         
          0  |   2.294477   .5937006     3.21   0.001     1.381763    3.810078 
          1  |   2.476123   .4680748     4.80   0.000     1.709484    3.586571 
          2  |   1.727147    .321817     2.93   0.003     1.198743    2.488471 
          3  |          1  (base) 
          4  |   1.338204   .2905011     1.34   0.180     .8744622    2.047875 
          5  |   1.312051   .2467056     1.44   0.149      .907609    1.896717 
             | 
       _cons |   .0612517   .0093046   -18.38   0.000     .0454793    .0824939 
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Adjusted late pregnancy loss by AFC categories expressed as odds ratio. 
Calculated using binomial regression and generalised linear model. 
------------------------------------------------------------------------------ 
             |               Robust 
                Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         
          0  |   2.247793   .6651205     2.74   0.006     1.258596    4.014453 
          1  |   1.840694   .3897261     2.88   0.004      1.21551    2.787434 
          2  |    1.43828   .2981768     1.75   0.080     .9580246    2.159286 
          3  |          1  (base) 
          4  |   1.326771   .3173754     1.18   0.237      .830197    2.120367 
          5  |   1.275684    .268463     1.16   0.247     .8445219    1.926972 
             | 
         age |   1.108315   .0186872     6.10   0.000     1.072287    1.145553 
         BMI |   .9729895   .0153547    -1.74   0.083     .9433556    1.003554 
      ethnic |   1.028827   .0643815     0.45   0.650     .9100731    1.163077 
       _cons |   .0038042   .0026584    -7.97   0.000     .0009671    .0149653 
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Unadjusted early pregnancy loss by AFC categories expressed as risk ratio. 
Calculated using binomial regression and generalised linear model. 
--------------------------------------------------------------------------- 
               | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         
          0  |   1.747683    .231867     4.21   0.000     1.347513    2.266692 
          1  |   1.153401   .1275341     1.29   0.197     .9286691    1.432516 
          2  |    1.15002   .1173449     1.37   0.171     .9415671    1.404623 
          3  |          1  (base) 
          4  |   1.151503   .1324132     1.23   0.220     .9191445      1.4426 
          5  |    .935151   .0969198    -0.65   0.518     .7632424    1.145779 
             | 
       _cons |   .1681305   .0132486   -22.63   0.000     .1440695    .1962098 
------------------------------------------------------------------------------\ 
Unadjusted late pregnancy loss by AFC categories expressed as risk ratio. 
Calculated using binomial regression and generalised linear model. 
------------------------------------------------------------------------------ 
             |                
               | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         
          0  |   2.134968   .4971256     3.26   0.001     1.352663    3.369714 
          1  |   2.281728    .395424     4.76   0.000     1.624615    3.204625 
          2  |   1.657581   .2871513     2.92   0.004     1.180366    2.327731 
          3  |          1  (base) 
          4  |   1.312582   .2658824     1.34   0.179     .8824771    1.952314 
          5  |   1.288838   .2269589     1.44   0.150     .9126526    1.820084 
             | 
       _cons |   .0577164   .0082615   -19.93   0.000     .0435972    .0764083 
------------------------------------------------------------------------
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Appendix 6 
Plans for dissemination 
Chapter 3: Proposal accepted by Human Reproduction Update. Manuscript with wider 
authorship for comments and edits. 
Chapter 4: Manuscript prepared for RBM Online and awaiting comments and edits from the 
wider authorship 
Chapter 5: Manuscript being prepared by this author for  Human Reproduction. 
Chapter 6 and 7: Accepted for presentation at RCOG world congress in June. No decisions 
taken yet on intended journal for submission. 
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